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Summary
Titanium dental implants have become an integral part of modem dentistry. Implant 
surfaces may be modified in a number of ways which influence the rate of implant 
osseointegration. It is therefore desirable to characterise a surface with characteristics 
which are optimal for osseointegration.
Three commercially available surfaces: machined (M), grit blasted and acid etched 
(GB) and TCP coated (TCP), were characterised in terms of surface topography, 
chemistry and hydrophobicity. Osseointegrative potential was evaluated either (1) in 
vitro, by characterising the attachment, morphology and cellular behaviour of bone 
marrow stromal cells (BMSCs) cultured on the titanium surfaces or (2) using an in 
vivo model whereby aspects of the process of osseointegration were monitored over 
time following placement of implants into excised incisor sockets of rat mandibles. 
Additionally this in vivo model was used to compare the bone repair process in both 
normal and GK rats, which represent a model of type II diabetes mellitus (DM).
In vitro, BMSCs cultured in osteogenic media on M appeared more rounded, while 
they were more elongated on GB and TCP. BMSCs attached to all surfaces and 
produced matrix material. The matrix formed appeared as a thin layer covering M, 
while matrix was thicker on the GB and TCP surfaces, infilling topographical 
features. Surface modification appeared to have little effect on the osteogenic activity 
of BMSCs. However, titanium was found to suppress differentiation down the 
adipogenic pathway and expression of IL-lp compared to plastic. Surface 
modification appeared to have little effect on osteoblast activity or osseointegration, 
although roughened surfaces may provide better mechanical interlocking with bone. 
In vivo, no differences in the progression of osseointegration around any of the 
modified surfaces were observed. In DM, osteoblast activity was altered and bone 
healing was delayed. There is therefore clearly scope to investigate surface 
modifications such as biomimetic coatings for use in compromised clinical 
situations.
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Chapter 1: Introduction
1.1 Introduction
Titanium dental implants have established themselves as a critically 
important part of modem dentistry, with an estimated one million implantations 
performed annually (Le Guehennec et al. 2007). The advent of what can 
effectively be described as a ‘screw in tooth’ has opened a broad range of new 
treatment options to dentists confronted by tooth loss. Consequently, implants 
can be employed to act as stable anchors to which artificial crowns can be affixed 
as replacement teeth, or can be used to stabilize a denture, providing a full or 
partially edentulous individual with a new, well anchored replacement dentition 
(Davies 2003; Ellingsen et al. 2006; Le Guehennec et al. 2007). The use of 
titanium prosthetics, when successful, can result in dental restorations which 
closely approximate the look and feel of the original teeth, which is beneficial to 
the patients from both aesthetic and oral health perspectives.
The success or failure of titanium implants is directly related to how 
quickly and completely the surrounding tissues attach to the implant, integrating 
it, a process known as osseointegration. Osseointegration can be defined as the 
attachment of bone directly to the surface of the implant, anchoring and 
integrating it into the surrounding tissues (Ellingsen et al. 2006; Le Guehennec et 
al. 2007; Puleo and Thomas 2006). Briefly, this occurs through the infiltration, 
proliferation and differentiation of mesenchymal stem cells into osteogenic cells 
on the surface of an implant (Davies 2003; Ellingsen et al. 2006; Le Guehennec 
et al. 2007). These cells secrete the components of a collagenous extracellular 
matrix which mineralises (Davies 2003; Ellingsen et al. 2006). This newly 
formed mineralised tissue is then remodelled, resulting in the formation of 
mature bone around the implant, which secures it to the surrounding bone 
(Davies 2003; Ellingsen et al. 2006). The stability given to the implant as a result 
of this process is a critical determinate of the long term success of dental
implants, due to the relatively intense loading they are subjected to in routine 
use.
Titanium is generally considered to be an excellent material for dental 
implants and is in widespread use clinically (Ellingsen et al. 2006; Le Guehennec 
et al. 2007; Puleo and Thomas 2006). Titanium surfaces can and have been 
widely modified in attempt to improve their osseointegrative potential. Surface 
characteristics of titanium implants, particularly their topography and chemical 
properties, play a major role in the interactions between the implant surface and 
the tissue around the implant site and thus influence the extent and rate of 
osseointegration (Ellingsen et al. 2006; Joos et al. 2006; Hata et al. 2007; 
Tsukimura et al. 2008; Shibli et al. 2007; Sul et al. 2006; Zhao et al. 2005).
Ultimately, the clinical ‘holy grail’ of implantology is the design of 
titanium implants which osseointegrate quickly and efficiently with a minimal 
number of additional procedures required to ensure long term success of the 
implant (Davies 2003). In practice, this would mean that a patient could have an 
implant capped with an artificial tooth immediately placed after only one clinical 
procedure, significantly reducing chair-time and thereby reducing the currently 
substantial cost of dental implants. In addition, there are certain patient groups, 
for example those with Diabetes Mellitus (DM), severe periodontitis or 
osteoporosis which have a significantly reduced capability for osseointegration 
(Lemer 2006; Taubman and Kawai 2001; Valero et al. 2007). These are public 
health concerns which will only become more prevalent due to an aging 
population in the UK (Lemer 2006; Valero et al. 2007). Titanium surfaces which 
improve the chances of efficient osseointegration would widen the access of 
implants to these potentially large patient groups, allowing them to benefit 
> significantly.
This thesis will take a systematic approach to analyzing the effects of 
modified titanium surfaces on the process of osseointegration, using both in vitro 
and in vivo models. By investigating the interactions of cells and tissues with 
well characterised titanium surfaces, individual surface modifications favourable
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to osseointegration will be identified. Additionally, the in vivo model system will 
be employed to investigate the effects of Type II DM on osseointegration, which 
will allow the effects of a disease state with direct implications for the process of 
bone formation to be examined. Improving the understanding of how the process 
of osseointegration is influenced by alterations in the surface characteristics of 
titanium implants will hopefully contribute to improvements in implant design, 
ultimately producing implants which will osseointegrate quickly and efficiently 
in both routine use and in more challenging clinical situations.
1.2 Organization of Bone
In order to understand the wider interactions between bone and titanium 
implants, it is crucial to understand the basic composition of bone and its 
influence on the process of osseointegration. Ostensibly, the main functions of 
bone are to provide a rigid structure for the support of the body and to provide 
points of attachment for muscles and tendons, although it also has a myriad of 
other roles such as providing a reservoir for minerals and the production of many 
humoral cell types (Waugh and Grant 2002). Constituency, the components of 
bone tissue may be broadly divided into two major categories which together 
facilitate the function of the tissue: cellular and acellular. Bone contains various 
cell types which carry out a wide range of functions, from the anabolic 
osteoblasts and catabolic osteoclasts to pluripotent progenitor cells which are 
ultimately capable of developing into a number of different cell types. 
Essentially, the cellular component of bone forms the living part of the tissue and 
is responsible for maintaining the tissue structure and function in addition to 
providing physiological connections with other tissues (Waugh and Grant 2002). 
The acellular component of bone is the mineralised tissue, formed from the 
deposition of minerals onto an organic matrix secreted by cells of an osteoblastic 
lineage (Waugh and Grant 2002).
The mineralised matrix of bone provides the structural properties of the 
tissue and acts as the mineral reservoir of the body where ions critical to a variety
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of functions can be stored and accessed as needed. Understanding the way in 
which the mineralised matrix is formed, shaped and maintained by the cellular 
component is central to the topic of osseointegration. The extracellular matrix of 
bone is comprised of around 90% type I collagen, with the remainder comprised 
of a yariety of non-collagenous proteins like osteopontin, osteocalcin, 
osteonectin and bone sialoprotein to name several examples (Hughes et al. 2006; 
Nanci 1999; Waugh and Grant 2002). Type I collagen is the primary secretory 
product of osteoblasts and forms the framework for the mineralised matrix, 
providing much of the strength and flexibility of bone tissue. The non- 
collagenous proteins combine with type I collagen, forming a matrix which is a 
favourable environment for the collection of calcium and phosphate ions. These 
ions mineralise this protein matrix formed in a manner which forms a regular 
crystal structure, hydroxy apatite, ultimately resulting in an organic framework 
produced by cells overlaid with a mineralised deposit which provides many of 
the overall structural properties of bone (MacDonald and Go wen 1993; Nanci 
1999; Ng et al. 1997; Roberts and Hartsfield 2004).
There are several different types of bone, depending on the conditions 
under which is synthesized and its level of maturity. Woven bone consists of a 
web-like arrangement of intertwined and mineralised collagen fibres, oriented in 
many different directions and can be laid down quickly, although due to its 
irregular structure, woven bone is not an optimal for structural strength (Davies 
2003; Nanci 1999; Waugh and Grant 2002). In general, woven bone is typical of 
the initial period of fracture repair, when bone must be synthesized rapidly in 
order to fill the defect resulting from an injury. This is a similar situation to the 
creation of a socket for the placement of an implant, which occurs in some cases 
via tooth extraction and in others by surgical means (Davies 2003; Ellingsen et 
al. 2006; Le Guehennec et al. 2007; Nanci 1999; Puleo and Thomas 2006). After 
the rapid deposition and mineralization of woven bone, it is gradually remodelled 
into lamellar bone, characterised by layered sheets of collagen fibres, which run 
parallel to one another (Nanci 1999). This arrangement is much stronger than 
woven bone due to its more regular structure and can be considered as ‘mature’ 
bone which provides the greatest level of structural strength. Finally, cancellous
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bone is very low density bone generally found in the marrow cavities and is 
characterised by trabeculae separated by marrow spaces (Ng et al. 1997). The 
outer layer of cancellous bone is where progenitor or stem cells, ultimately 
responsible for the formation of cells in both mesenchymal and hematopoietic 
lineages, reside. Cancellous bone also has a very high surface to volume ratio 
and therefore lends itself to easy storage and release of calcium and phosphate 
ions (Ng et al. 1997). Although cancellous bone is a key component of bone 
physiology, it does not have a direct structural role.
1.3 Cellular Components of Bone, Their Function and Their Role in Bone 
Formation and Remodelling
The cellular component of bone is comprised of those cells mainly 
responsible for the maintenance of the mineralised tissue and those cells which 
contribute to formation of humoral cells. Within the marrow space is the 
hemopoietic stem cell niche, containing progenitor cells which produce 
erythrocytes, leukocytes and osteoclasts (Kartsogiannis and Ng 2004; Taichman
2005). Also present within the marrow space and in the periosteum are 
mesenchymal stem or progenitor cells from which are derived many connective 
tissue cells including adipocytes, fibroblasts, chondrocytes, osteoblasts and 
osteocytes (Kartsogiannis and Ng 2004; Taichman 2005). Bone formation results 
from the coordinated action of osteoblasts, which synthesize new bone matrix 
and osteoclasts, which strategically break down bone matrix. This interaction 
largely determines bone morphology and serves to remodel matrix from its 
initially deposited form into a more mature form (Boyle et al. 2003; Hughes et al. 
2006; Kartsogiannis and Ng 2004; Katagiri and Takahashi 2002). Osteocytes, 
meanwhile, provide communication and coordination between the two 
interrelated processes (Franz-Odendaal et al. 2006).
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1.3.1 Osteoblasts
The first phase of bone repair is one of recruitment, migration and 
proliferation. Osteoblasts arise from mesenchymal stem cells which are recruited 
from connective tissues to the surface of a bone (Owen 1967) and are also 
present in the bone marrow (Friedenstein 1976). Mesenchymal stem cells are 
undifferentiated, self renewing cells that have the potential to differentiate into 
diverse connective tissue cell types, including chondrocytes, myocytes, 
adipocytes, fibroblasts and osteoblasts (Beyer Nardi and da Silva Meirelles
2006). They arise from the embryonic mesenchyme, and are ultimately 
responsible for the formation of the connective tissues of the mammalian body 
(Beyer Nardi and da Silva Meirelles 2006). While they are commonly found in 
the bone marrow, it is currently unclear if they occupy a physical location, or 
‘niche’, or if they are simply distributed in a decentralised way around the bone 
marrow (Beyer Nardi and da Silva Meirelles 2006; Stewart et al. 1999). 
Although there are currently no definitive cell markers which are specific for 
mesenchymal stem cells, Stro-1, a cell surface protein with an unknown function, 
is thought to be associated with the early phases of osteoblast differentiation and 
is currently used as a marker to indicated the presence of osteoblast progenitor 
cells (Stewart et al. 1999).
Mesenchymal stem cell recruitment is mediated by a wide variety of 
chemotactic signals, and results in mesenchymal cells migrating from the 
periosteum and bone marrow to a site of bone repair (Davies 1996; Hughes et al. 
2006; Kartsogiannis and Ng 2004; Katagiri and Takahashi 2002; MacDonald and 
Gowen 1993; Ng et al. 1997). Upon arrival at this site, the mesenchymal cells 
begin a series of proliferative cycles, which serve to increase their number 
(Hughes et al. 1995; Katagiri and Takahashi 2002). Subsequently, they begin to 
progress down the osteoblast lineage under the direction of a complex signalling 
cascade and become osteoblast progenitor cells, an immature cell-type with a 
high proliferative potential firmly committed to the osteoblast differentiation 
pathway (Chaudhary et al. 2004; Hughes et al. 2006; Katagiri and Takahashi 
2002). Osteoblast progenitor cells undergo a number of proliferation and
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differentiation cycles before becoming pre-osteoblasts. Pre-osteoblasts have the 
cuboidal shape characteristic of mature osteoblasts and begin to express a 
number of markers associated with osteoblasts, for example Osteopontin (OP), 
Osteocalcin (OC), Osteonectin (ON), Bone Sialoprotein (BSP), Type I&III 
Collagen, and Alkaline Phosphatase (AP), although they retain their ability to 
proliferate (Katagiri and Takahashi 2002; Mackie 2003). Ultimately, pre­
osteoblasts mature into post mitotic osteoblasts, which represent the pinnacle of 
bone forming capability. A diagram from the review by Hughes and colleagues 
(2006) shows the simplified osteoblast differentiation pathway, including some 
of the growth factors which are known to act on mesenchymal stem cells to 
initiate osteoblast differentiation, although due to its complexity, current 
understanding of the process is far from complete (Figure 1.1).
Mesenchymal stem ceils osteoprogenito rce I is Pre Osteoblast Osteoblast
BMPs
FGFs
PDGFShh TGF[1
IGFs
Figure 1.1: A diagram which shows the main stages o f  the osteoblast lineage and where various 
growth factors are thought to exert their primary effects. BMP, bone morphogenetic protein; IGF, 
insulin-like growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; 
Shh, Sonic hedgehog; TGF-|3, transforming growth factor-P; Wnts, a group o f  >15 related 
extracellular signalling molecules (Taken from Hughes et al, 2006).
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Upon reaching the final stages of their differentiation pathway, 
osteoblasts begin to synthesize and secrete non-collagenous proteins, which have 
a variety of functions, including the induction of mineralisation, and type I 
collagen from their apical membranes, which together form an extracellular 
matrix (Davies 1996, 2003; MacDonald and Gowen 1993; Ng et al. 1997; 
Robling et al. 2006). This matrix is referred to as the osteoid prior to 
mineralization and forms a template for the formation of bone. Osteoblasts also 
secrete a number of osteogenic growth factors into the osteoid, sequestering 
them. When bone resorption occurs, these growth factors are released creating a 
feedback mechanism which balances bone resorption with bone formation 
(MacDonald and Gowen 1993; Ng et al. 1997; Roberts and Hartsfield 2004). The 
osteoid then undergoes mineralisation, which subsequently forms the mineralised 
extracellular matrix of bone tissue (MacDonald and Gowen 1993; Ng et al. 1997; 
Roberts and Hartsfield 2004).
Bone tissue is constantly in a series of metabolic resorption and repair 
cycles, with an estimated 25% of cancellous bone and 3% of cortical bone being 
turned over each year (Martin and Seeman 2008; Parfitt 1994; Seeman 2009). 
These cycles serve to renew, repair and reshape the mineralised matrix in 
addition to releasing calcium and other ions to maintain serum ion concentration 
homeostasis (MacDonald and Gowen 1993; Ng et al. 1997; Roberts and 
Hartsfield 2004; Seeman 2009; Waugh and Grant 2002). This process, termed 
remodelling, is critical in the repair of bone and comprises the final stage of bone 
formation. Bone remodelling is necessary for biomechanical adaptation, which 
allows bone tissue to be strengthened in response to increases in mechanical 
load. Remodelling is the means by which sections of mineralised matrix, which 
suffer damage while in routine use, are renewed with fresh depositions. It is also 
the means by which woven bone is laid down rapidly in response to bone injury 
is converted into stronger, mature cortical bone. Finally, bone remodelling 
moulds the matrix secreted by osteoblasts into the correct anatomical shape to 
form bones, specifically in foetal development (Roberts and Hartsfield 2004; 
Waugh and Grant 2002). In order to facilitate this process, osteoblasts must work
11
directly in concert with their osteoclast counterparts in order to ensure that bone 
is laid down, strategically resorbed and synthesized again in the correct location 
and format.
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1.3.2 Osteoclasts
Osteoclasts are large, multinucleated cells which are specialized to resorb 
the mineralised matrix of bone by adhering tightly to the bone surface via the 
apical membrane and secreting protons and osteolytic enzymes, forming a 
structure known as a resorption pit (Boyle et al. 2003; Chambers 2000; Katagiri 
and Takahashi 2002; Kollet et al. 2007). In contrast to osteoblasts and osteocytes, 
they are descended from hemopoietic progenitor cells found in the bone marrow. 
Monocyte precursor cells are recruited from either the bone marrow or possibly 
from the circulation, to the surface of the bone where they differentiate into 
mature osteoclasts, capable of bone resorption on an impressive scale (Boyle et 
al. 2003; Chambers 2000; Katagiri and Takahashi 2002; Kollet et al. 2007). The 
process of osteoclast differentiation is tightly regulated both directly and 
indirectly by a number of local and systemic factors including hormones, growth 
factors, inflammatory cytokines and other signalling molecules (Figure 1.2) 
(Calvi et al. 2003; Kollet et al. 2007; Takahashi et al. 1988).
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Figure 1.2: The osteoclast differentiation pathway, from bone marrow precursor cells to mature, 
active osteoclasts. (Boyle et al. 2003)
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Local signalling molecules produced by osteoblasts play a central role in 
regulating the process of osteoclast differentiation. It has long been known that 
stromal cells contain factors which are necessary for osteoclast formation in vivo. 
Takahashi and colleagues (1988) observed osteoclast formation in mouse bone 
marrow stromal cell cultures upon exposure to parathyroid hormone and, 
interestingly, that they tended to form around clusters of osteoblasts, implicating 
these cells in locally mediating a systemic differentiation signal. The specific 
signalling molecule expressed by osteoblasts which is directly responsible for the 
regulation of osteoclast differentiation is the tumour necrosis factor (TNF) 
related type II transmembrane protein receptor activator of nuclear factor k  p 
ligand (RANKL) (Hsu et al. 1999; Yasuda et al. 1998). RANKL acts through the 
receptor activator of nuclear factor k  P (RANK), which is expressed by 
hemopoietic monocyte precursor cells, initiating a complex intracellular 
signalling cascade which ultimately results in the phenotypic changes associated 
with the osteoclast lineage (Burgess et al. 1999; Hsu et al. 1999; Nakagawa et al. 
1998). RANK expression has been repeatedly shown to be required for the 
formation of osteoclasts in variety of studies in both in vivo and in vitro models 
(Burgess et al. 1999; Hsu et al. 1999; Lacey et al. 1998; Nakagawa et al. 1998; 
Yasuda et al. 1998). The growth factor colony stimulating factor-1 (CSF-1) is 
also involved in osteoclast differentiation and although it does not seem to be an 
absolute requirement for osteoclast formation, it seems to be necessary for 
inducing the proliferation of osteoclast progenitors (Boyle et al. 2003; Chambers 
2000). The osteopetrotic op/op knockout mouse, which lacks CSF-1, has a 
severely reduced osteoclast population, although a functional population is still 
present (Lagasse and Weissman 1997; Wiktor-Jedrzejczak et al. 1990; Yoshida 
et al. 1990). CSF-1 and RANK work in tandem to induce osteoclast 
differentiation, with CSF-1 driving progenitor cell proliferation and RANK 
serving to initiate differentiation. Osteoclast differentiation is thus induced by 
osteoblasts as the creation of new, mature and fully remodelled bone tissue 
requires the actions of both osteoblasts to synthesize new bone matrix and 
osteoclasts to shape and renew that bone matrix, allowing it to reach the required 
final structure.
14
Due to the severity of the pathologies which result from the unregulated 
resorption of bone, it is fortunate that the differentiation of osteoclasts is tightly 
regulated. Osteoprotegerin (OPG) is an extracellular signalling peptide in the 
TNF (Tumour Necrosis Factor) receptor superfamily and has been shown to 
induce marked osteopetrosis when over-expressed in transgenic mice and when 
applied to rats (Simonet et al. 1997; Yasuda et al. 1998). OPG blocks the 
formation of osteoclasts by acting as a decoy receptor for RANKL, preventing its 
binding to RANK, thereby inhibiting osteoclast differentiation and leading to 
osteoclast apoptosis (Schoppet et al. 2002; Simonet et al. 1997; Udagawa et al. 
2000). Osteoblasts secrete OPG in response to various osteogenic signals, 
curtailing bone resorption as required by the physiological situation (Schoppet et 
al. 2002; Udagawa et al. 2000). The activation and inhibition of osteoclast 
differentiation is therefore regulated by the receptor RANK, via its interactions 
with either RANKL or OPG produced by osteoblasts. Osteoblasts are in turn 
induced to express OPG by both systemic osteogenic signals and by local growth 
factors sequestered in the matrix by osteoblasts and released via osteoclast 
resorption. This results in a return to new bone formation after a period of 
resorption, completing a remodelling cycle and creating a complex physiological 
feedback system which balances bone resorption with formation.
Bone remodelling therefore, is the net result of initial deposition of 
osteoid by osteoblasts, its subsequent mineralization and the remodelling of the 
newly formed bone by osteoclasts. The resorption of the quickly synthesized 
woven bone results in increased osteoblast activity via the action of sequestered 
osteogenic growth factors released by either bone injury or osteoclast resorption, 
which culminate in the formation of the stronger cortical bone. Localized groups 
of osteoblasts and osteoclasts which coordinate their activities are referred to as 
bone multi-cellular units. This creates a system whereby woven bone can be laid 
down initially and rapidly by osteoblasts, creating a temporary structure which 
can then be resorbed incrementally by osteoblasts, and then reformed into a 
stronger, more permanent structure. Osteocytes play a role in modulating this
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system, serving to coordinate the activities of osteoblasts and osteoclasts, and 
providing a link to mechanical stimuli applied to the bone tissue.
1.3.3 Osteocytes
Osteoblasts have a lifespan of around 3 months, after which they undergo 
apoptosis, become inactive bone lining cells or become embedded in the secreted 
matrix where they differentiate into osteocytes (Bonewald 2007). Osteocytes are 
terminally differentiated, non-secretory cells responsible for overall control of 
bone maintenance and communication with surrounding tissues (Franz-Odendaal 
et al. 2006; Owen 1967). They are the most numerous cells found in bone tissue, 
comprising around 95% of the total and are 10 times more prevalent than 
osteoblasts (Franz-Odendaal et al. 2006). It is not currently clear what specific 
events lead to certain osteoblasts being selected for terminal differentiation to 
osteocytes and effectively becoming encased in newly formed bone, although it 
is probably influenced by a variety of factors, for example cell position and the 
presence of local cellular signalling (Bonewald 2007; Franz-Odendaal et al. 
2006; Manolagas 2000). Osteoblasts fated to become osteocytes, once embedded 
in the matrix, cease all secretory activity and undergo a series of radical 
phenotypic changes, including a loss of cell body size and a reduction in 
secretory organelles, for example Golgi bodies and endoplasmic reticula. Most 
notably however, osteocytes develop a web of dendritic extensions into the 
surrounding extracellular matrix which extend along the bone canaliculi, minute 
channels running through the compact bone tissue, connecting osteocytes to each 
other and to osteoblast and osteoclasts (Burger et al. 2003; Franz-Odendaal et al. 
2006; Manolagas 2000; Palumbo et al. 1990).
The dendritic extensions formed by osteocytes are central to their 
function, as they are the avenues of communication by which osteocytes exert 
overall regulation of bone mass. Osteocytes act as mechanoreceptor cells which 
detect changes in loading and bone micro-damage, and subsequently transmit 
signals for resorption or bone formation to the appropriate cell type, i.e.
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osteoblasts or osteoclasts (Burger et al. 2003; Manolagas 2000; Rodan 1997). It 
is thought that osteocytes detect changes in mechanical loading through 
sensitivity to alterations in sheer stress caused by the passage of bone interstitial 
fluid. As mechanical load is applied to or removed from bone, it causes 
alterations in the flow of interstitial fluid, which leads to deformation of 
osteocytes within their lacunae and mechanical signal transduction (Bonewald 
2007; Weinbaum et al. 1994). It is also a possibility that mechanical forces 
applied to the matrix surrounding osteocytes may directly cause deformation of 
either osteocyte cell bodies or their dendritic extensions, resulting in signal 
transduction (Bonewald 2006; Nicolella et al. 2006). Osteocytes are thought to 
communicate with and influence the activity of both osteoblasts and osteoclasts 
via gap junctions formed at the end of their dendritic extensions (Bonewald
2007). Supernatants from osteocyte cell line cultures have been reported to 
increase the expression of AP and OC in mouse bone marrow stromal cell 
cultures, suggesting that osteocytes may play a direct role in stimulating 
osteoblast differentiation (Heino et al. 2004). Osteocytes have also been shown 
to stimulate osteoclast formation in response to bone micro-damage (Heino et al. 
2009), and osteocyte death has been shown increase osteoclast activity in vitro 
(Gu et al. 2005).
Physiologically, it is well known that bone mass density (BMD) 
decreases due to an increase in resorption when bones are not mechanically 
loaded (Turner et al. 1995; Van der Meulen et al. 1995; Van der Wiel et al. 1995) 
and that the mechanical loading of bone increases bone formation (Bourrin et al. 
1995; Hillam and Skerry 1995). Osteoclasts have been shown to resorb 
mechanically inactive bone with the application mechanical stimulation having 
the opposite effect (Gross and Rubin 1995). There is some evidence to indicate 
that osteocytes are responsible for inducing these changes in activity in response 
to stress, for example increased levels of osteocyte apoptosis is linked to 
increased bone fragility, presumably due to the loss of central control over bone 
formation and resorption, and thus tissue renewal (Tomkinson et al. 1997; 
Weinstein et al. 1998). As they may have a role in increasing the amount of bone 
tissue under a mechanical load, such as those seen by dental implants in routine
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use, osteocytes may a key player in the osseointegration of implants, but the 
process by which they transduce mechanical signals is not currently well 
understood.
1.4 Control of the Synthetic Activity of Osteoblasts
As mentioned previously, the differentiation of osteoblasts, and by 
extension bone formation, is controlled by a plethora of systemic signals, which 
act through a number of local signalling molecules and growth factors. These all 
act synergistically to produce mature osteoblasts from the early progenitor cells 
which migrate to the site of bone formation. The interactions between all of these 
factors are highly complex and many different molecules have been implicated in 
the process of osteoblast differentiation. It simplifies the situation to consider 
each factor and its individual role in the osteoblast lineage, but it must be 
remembered that in vivo, they act in concert. It may be somewhat erroneous to 
attribute functions such as the induction of proliferation or the phenotypic 
changes associated with a particular phase of the osteoblast differentiation 
pathway to the action of a single signal working individually; the reality is that 
osteoblast differentiation is the product of a ‘cocktail’ of factors each impacting 
the functions of the others.
From the standpoint of titanium dental implants and the process of 
osseointegration, the osteoblast differentiation factors described here serve as 
useful markers for different stages of the osteoblast differentiation pathway. By 
visualizing and confirming the presence of these molecules, the presence of cells 
in the osteoblast lineage around a site of interest can be confirmed and their stage 
of differentiation identified. This makes understanding the role of these factors 
critically important to the study of osseointegration, as they provide a window 
into the cellular processes underway during interactions with a given titanium 
surface.
18
1.4.1 Bone Morphogenetic Proteins
Bone morphogenetic proteins (BMPs) are generally considered a 
principle factor for inducing osteoblast differentiation, although it is clear that 
they act synergistically with other growth factors (Canalis and Gabbitas 1994; 
Centrella et al. 1992). Members of the transforming growth factor P (TGFp) 
superfamily, BMPs were discovered as the result of a study by Urist and 
colleagues (1971) where decalcified bone matrix explants in muscle induced 
ectopic bone formation. BMPs act through serine/threonine kinase receptors at 
the cell surface and initiate complex intracellular signalling cascades resulting in 
a wide range of effects on the transcriptional and translation activity of the cell 
(Yamaguchi et al. 2000). There are type I and II BMP receptors and the 
activation of both receptor types is required for signal transduction, which is 
mainly carried out by the SMADs (Derynck et al. 2001; Heldin et al. 1997; 
Massague et al. 2005). SMADs are a group of intracellular signalling proteins 
which modulate the activity of all of the members of the TGFp superfamily 
members. There are currently eight SMADs. SMADs 1, 2, 3, 5 and 8 transduce 
signals from membrane receptors, SMAD 4 acts as a co-factor to the signalling 
SMADs and SMADs 6 and 7 act as inhibitors to the other SMADs (Massague et 
al. 2005). SMADs 1, 5, and 8 are the primary substrates for the BMP receptor 
(Massague et al. 2005).
Osteoblasts produce BMPs and sequester them in the bone matrix, to be 
released during periods of bone resorption, providing a physiological feedback 
response in order to maintain bone mass homeostasis (Mackie 2003). Genes for 
more than 20 different BMPs have been identified in vertebrates, several of 
which have been shown to independently induce ectopic bone formation, an 
ability unique among growth factors, and it is often claimed that they are the 
most important growth factor for initiating osteoblast differentiation (Katagiri 
and Takahashi 2002; Miyazono et al. 2005). There has been much evidence 
reported in the literature of BMPs being directly connected to skeletal formation 
and therefore osteoblast differentiation. BMP-2, BMP-4, BMP-6 have been 
reported to increase the formation of bone nodules in rat calvarial cell cultures,
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implicating these proteins in the recruitment of progenitor cells to the osteoblast 
lineage (Hughes et al. 1995). Similarly, BMP-2 has been shown to induce 
osteoblast formation in several pluripotent cell lines (Katagiri et al. 1990; Rosen 
et al. 1994; Yamaguchi et al. 1991). When treated with BMP-7, mesenchymal 
stem cells have been shown to differentiate into osteoblasts (Gerstenfeld et al. 
2002). Transfection with an adenovirus containing a BMP-7 cDNA construct has 
also been shown to induce an osteogenic response under both in vitro and in vivo 
models (Franceschi et al. 2000). Knockout mice for BMP-5, BMP-7 and BMP-11 
demonstrate localized skeletal abnormalities, indicating different positional roles 
for the various BMPs, in addition to other defects like abnormal kidney and eye 
development (Kingsley et al. 1992; Luo et al. 1995; McPherron et al. 1999). 
Many other BMP knockouts are not viable due to catastrophic disruption of their 
skeletal development, as is the case with both BMP-2 and BMP-4 knockout mice 
(Yamaguchi et al. 2000). BMPs are generally thought to act via a cascade of 
transcription factors, most notably Runx-2, reported to be the major driver of 
osteoblast differentiation (Ducy et al. 1997; Katagiri and Takahashi 2002; 
Yamaguchi et al. 2000). The extracellular signalling molecules Wnts and sonic 
hedgehog have been implicated in the regulation of BMP activity in osteoblasts 
(Baron et al. 2006; Kawai and Sugiura 2001). At the cellular level, BMPs are an 
indicator that there are cells present which are in the later stages of osteoblast 
development, especially if mature osteoblast markers such as osteopontin and 
osteocalcin are concurrently expressed.
1.4.2 Wnts
A group of over 19 different extracellular glycoprotein signalling 
molecules known as Wnts has been implicated in the initial recruitment of 
mesenchymal stem cells into the osteoblast lineage (Westendorf et al. 2004). 
Wnts bind to the extracellular receptor fizzled and to the co-receptors LRP5/6, 
whereupon they initiate a complex cascade of intracellular signalling events 
involving P-catenin (termed the canonical pathway) and other p-catenin 
independent pathways (non-canonical) (Westendorf et al. 2004). Wnt signalling
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seems to be involved in the early stages of osteoblast differentiation, as Wnt 
addition to precursor cell cultures induced alkaline phosphatase expression, an 
early marker of osteoblast differentiation present at the osteoprogenitor cell 
stage, but did not induce the osteocalcin or type one collagen production, which 
is generally associated with pre-osteoblasts and mature osteoblasts (Rawadi et 
al. 2003). The Wnt-p-catenin signalling pathway has been shown to be required 
for skeletogenesis, and acts specifically by promoting osteoblast differentiation at 
the expense of chondrocyte differentiation (Day et al. 2005). In the absence of 
this signalling pathway mesenchymal progenitor cells turn into chondrocytes 
(Hill et al. 2005). It has also been reported that over-expression of Wnts in a 
transgenic mouse model results in high bone mass and increased expression of 
both Runx-2 and osteocalcin, suggesting Wnt signalling is involved in regulating 
the differentiation of osteoblasts (Gaur et al. 2005). It has also been proposed that 
Wnt signalling is the one of the key mechanisms by which osteocytes regulate 
osteoblast activity, linking it to the osteogenic response stimulated by bone 
loading (Bonewald and Johnson 2008). Currently, the interaction of Wnts and 
other osteogenic factors is not completely understood. BMP-2 for iexample has 
been variously reported to both induce (Bain et al. 2003) and to be induced by 
(Winkler et al. 2005) the actions of Wnts. It appears that the regulatory actions of 
the Wnts are related to those of the BMPs, although the exact nature of this 
interaction is not currently clear.
1.4.3 Sonic Hedgehog
Sonic hedgehog is a polypeptide signalling molecule which acts through 
the cell surface receptor ‘patched’ and are involved in the regulation of BMP 
action (Hughes et al. 2006). In vitro, sonic hedgehog induces osteoblast 
formation in osteoblast and fibroblast cell lines, in addition to causing ectopic 
bone formation in mice by inducing BMP (Kinto et al. 1997; Yuasa et al. 2002). 
It has also been reported that sonic hedgehog enhances the induction of 
osteoblast differentiation by BMP-2 in vitro and inhibits adipocyte formation 
(Spinella-Jaegle et al. 2001). The actions of sonic hedgehog have been shown to
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be upstream of the BMPs; Kawai and Sugiura (2001) have demonstrated that the 
sonic hedgehog mediators, Gli proteins, directly enhance the expression of BMP- 
4 and BMP-7 when transfected into a COS-7 cell model. Like the Wnts, the 
presence of sonic hedgehog around an implant site may be a good indication that 
cells have migrated to the area and entered the osteoblasts differentiation 
pathway via the actions of BMPs.
1.4.4 Transforming Growth Factor B
Transforming growth factor p (TGFp) belong to the same superfamily of 
proteins as the BMPs and also play a major role in osteoblast differentiation. 
TGFp, specifically TGFpl, is found in many tissues of the body, but is 
particularly prevalent in bone tissue and platelets (Hughes et al. 2006; Janssens et 
al. 2005). Like the BMPs, TGFps act through serine/threonine kinase receptors, 
which in turn transduce signals into the cell via the SMADs (Heldin et al. 1997; 
Janssens et al. 2005). SMADs 2 and 3 are the primary substrates for the TGFP 
receptors (Massague et al. 2005). In addition TGFpl is known to signal through 
MAP Kinase pathways and thus also has SMAD-independent activity (Janssens 
et al. 2005; Miyazono et al. 2007). It has been shown in vitro that TGFpl 
reduces the expression of both Runx-2 and osteocalcin, which is reversed by 
treatment with TGFpl receptor blockers (Alliston et al. 2001; Maeda et al. 2004). 
This rules out their participation in the later stages of osteoblast differentiation, 
but there have been many descriptions of their mitogenic properties and 
stimulation of matrix synthesis earlier in the pathway. It has long been known 
that TGFpi increases the proliferation rate of osteoblasts in vitro in addition to 
increasing the levels of type I collagen synthesis, indicating its importance in 
bone matrix production (Centrella et al. 1992; Centrella et al. 1986). Essentially 
this has the effect of producing a large pool of matrix producing cells ready to be 
moved on into the later stages of osteoblast development by other growth factors 
such as the BMPs (Centrella et al. 1992; Hughes et al. 2006; Janssens et al. 
2005). TGFpi has a complex and synergistic relationship with the BMPs in 
producing mature osteoblasts that is currently not fully understood, but it seems
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that TGFpl effectively increase osteoprogenitor cell numbers which the BMPs 
then induce into the later stages of the osteoblast lineage while simultaneously 
suppressing the inhibitory effects of TGFpl on differentiation. As a marker of 
cell activity, the presence of TGFpl around an implant site would be a strong 
indicator of osseointegrative activity.
1.4.5 Fibroblast Growth Factors
The fibroblast growth factors (FGFs) are another family of signalling 
polypeptides implicated in the osteoblast differentiation pathway which act 
through tyrosine kinase receptors (Duchesne et al. 2006). FGFs have long been 
implicated in the development of osteoblasts, particularly in the early stages of 
differentiation, although the extent of their role in the osteoblast differentiation 
pathway is not completely clear. FGF-2 knockout mice show decreased bone 
mass compared to normal mice (Naganawa et al. 2006). Naganawa and 
colleagues (2006) also demonstrated that cultures of bone marrow stromal cells 
from these mice appear to have lower expression levels of Runx-2 and decreased 
bone nodule formation. Determining the exact function of FGFs in osteoblast 
differentiation has proved more problematic however, although they seem to be 
mainly involved in inducing proliferation at the osteoprogenitor stage as opposed 
to driving differentiation. Canalis and colleagues (1988) demonstrated that basic 
FGF, when applied to rat calvarial cells, stimulated the proliferation of type I 
collagen producing cells (i.e. osteoblasts), while simultaneously and directly 
decreasing type I collagen synthesis. Interestingly, it has also been reported that 
FGFs, when applied to immature human calvarial cell cultures, increases the rate 
of proliferation but decreases the expression of mature osteoblast cell markers 
(Debiais et al. 1998). FGF-2 increases proliferation in immature osteoblasts from 
both rat calvarial cell culture and the OBI osteoblast cell line, while it induces 
apoptosis in more mature osteoblasts from those sources (Mansukhani et al.
2000). Transgenic mice over-expressing FGF-2 have an increased level of 
apoptosis in their calvariae (Mansukhani et al. 2000). Taken together, these 
paradoxical effects seem to suggest that the function of FGFs is differentiation 
phase dependent; FGFs drive the proliferation of cells in the osteoprogenitor
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phase of osteoblast development, while they seem to obstruct and actively 
prohibit their differentiation. While there is ample evidence that FGFs drive 
osteoprogenitor cell proliferation, their involvement in cell differentiation and the 
mechanisms by which this is regulated remain to be elucidated. The presence of 
FGF alone around an implant site may not be a useful indicator of 
osseointegration as it is also expressed at an early, pre-commitment stage in the 
osteoblast lineage, and could, depending on local conditions, stimulate the 
development of fibroblasts among other connective tissue cells.
1.4.6 Platelet Derived Growth Factor
As the name suggests, platelet derived growth factor (PDGF) is released 
by platelets when they are ruptured, but can also be found in a variety of tissue 
types. PDGF is composed of two polypeptide chains and acts through an ‘a’ 
receptor and a ‘b’ receptor (D'Andrea et al. 2009). PDGF has many functions and 
has been reported to induce osteoblast proliferation in primary human osteoblast 
cell cultures but decreases differentiation in a similar fashion to FGFs (Kim and 
Valentini 1997). It has been demonstrated that PDGF inhibits osteoblast 
differentiation; Yu et al (1997) report that PDGF decreases the expression of 
alkaline phosphatase, osteocalcin and type I collagen in addition to inhibiting the 
formation of mineralised nodules in vitro. PDGF has been shown to induce the 
migration of osteoblasts in rat calvarial cell cultures and is a major chemotactic 
factor for many other connective tissue cell types (Hughes et al. 1992), which is 
not surprising given that it is one of the first factors released around a wound site 
where cell migration is the first step to healing. The regulatory mechanisms 
which cont|ol PDGF production by osteoblasts are not fully understood; Rydziel 
and colleagues (1992; 1994) have reported that transforming growth factor pi is 
capable of inducing PDGF production, although they have subsequently reported 
that PDGF is capable of autoinduction. The overall functions of PDGF, as it 
relates to osteoblast differentiation, appear to be the stimulation of 
osteoprogenitor cell proliferation in a manner akin to FGFs and the recruitment 
of osteoprogenitor cells to wound sites in order to initiate repair. This last
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function is particularly interesting as the first step towards the osseointegration of 
a titanium implant is to recruit osteoprogenitor cells to the implant site, so PDGF 
may be therapeutically relevant. Clinically for example, Bio-Oss™ and other 
artificial bone matrices are commonly mixed with blood before being used to fill 
a defect, in  an attempt to impregnate them with PDGF amongst other factors 
thereby stimulating the recruitment and differentiation of osteoblast progenitor 
cells. Accordingly their presence at an implant site indicates early migration and 
proliferation, but would not be a useful indicator of osseointegration as it would 
be expressed at a wound site regardless of de novo bone synthesis occurring due 
to the disruption of platelets.
1.4.7 Insulin-Like Growth Factors
The insulin-like growth factors (IGFs) are systemic signalling peptides 
released by growth hormone acting on target cells in various tissues, including 
osteoblasts, depending on local conditions. There are two types of IGF, IGF-I 
and IGF-II, both of which display bone specific activity (Rosen et al. 1997). IGFs 
actually bind to a variety of receptors in vivo, including specific IGF receptors 
and insulin receptors. Due to the wide variety of systemic activity which the 
IGFs carry out, it has been difficult to localize specific effects to bone 
(Delafontaine et al. 2004; Hughes et al. 2006). IGFs have been reported to have 
synergistic effects with several other growth factors implicated in the osteoblast 
differentiation pathway. Treatment with BMP-2 substantially increases the 
expression of IGFI and IGFII in foetal rat calvarial cell cultures (Canalis and 
Gabbitas 1994). Okazaki and colleagues (1995) have reported that TGFpi 
increases the expression of IGF I and II in human osteoblast cell cultures, while 
it has also been reported in Gangji et al (1998) that TGFpi, along with FGF-2 
and PDGF suppresses the expression of IGF II across several in vitro models. 
Although the ways in which IGF is modulated by other growth factors in bone is 
currently unclear, it is associated with the later stages of osteoblast 
differentiation, specifically the final maturation from pre-osteoblast to 
osteoblasts. BMPs may induce the IGFs, which seem to be suppressed by many
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of the growth factors involved in the early stages of osteoblast differentiation, in 
order to begin the final phase of maturation before they reach the mature 
osteoblast phenotype. Although known to be involved with osteoblast 
differentiation, the specific actions of IGFs on bone as a tissue remain fairly 
enigmatic and due to their ubiquity, they may not in themselves be specific 
markers of osseointegration.
1.4.8 Major Transcription Factors in Osteoblast Differentiation
Growth factors exert transcriptional regulation through a wide range of 
molecules, initiating a wide range of intracellular signalling cascades which 
result in shifting progenitor cells away from certain differentiation pathways, for 
example the adipocyte or chondrocyte lineages, and towards the osteoblast 
differentiation pathway. Some of these signalling pathways are known, for 
example, BMP-2 has been reported to up-regulate the transcription factor TAZ, 
associated with the differentiation of mesenchymal stem cells into fully 
committed osteoprogenitor cells. Hong and colleagues (2005) have reported that 
in cell line, mouse embryonic fibroblast and primary mesenchymal cell model 
systems, the presence of BMP-2 upregulates TAZ expression, which in turn 
initiates the formation of osteoblasts and the suppression of adipocyte formation.
Runx-2 is a transcription factor that is reported to be the ‘switch’ 
responsible for moving osteoprogenitor cells to the pre-osteoblast phenotype. It 
has been shown to be up-regulated by both TAZ and thus is downstream of BMP 
signalling (Ducy et al. 1997; Gersbach et al. 2004; Hong et al. 2005). Wnt 
signalling has also been shown to directly upregulate Rux-2 via the p Catenin 
pathway (Gaur et al. 2005). Transfection of a fibroblast cell line with Runx-2 
cDNA induces expression of the osteoblast cell marker alkaline phosphatase 
(Harada et al. 1999). Similarly, transfection of a primary mouse myocyte cultures 
with Runx-2 cDNA results in the suppression of myogenesis and the expression 
of a variety of osteoblast markers (Gersbach et al. 2004). Komori and colleagues 
(1997) have also reported that Runx-2 expression is an absolute requirement for
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bone formation, as Runx-2 knockout mice fail to develop either osteoblasts or a 
skeletal system.
The transcription factor Msx-2 has also been reported to be induced by 
BMP-2 in primary aortic myofibroblasts, resulting in differentiation into the 
osteoblast phenotype via the induction of osterix, a transcription factor which, 
like Runx-2, is an absolute requirement for osteoblast development (Cheng et al. 
2003). Osterix was identified by Nakashima and colleagues (2002) in cultured 
osteoblast cells and subsequently they managed to create a knockout mouse 
which failed to develop a skeleton. Interestingly, Runx-2 is still expressed in 
these mice although osterix is not expressed in the Runx-2 knockout mouse, 
suggesting that osterix is activated downstream of Runx-2 (Nakashima et al.
2002). BMP-2 and IGF have been reported to synergistically act to increase 
osterix expression, moving osteoblasts into late stage differentiation (Celil and 
Campbell 2005). There are many other transcription factors involved in 
intracellular signalling which synergistically act to induce the differentiation of 
osteoblasts from mesenchymal stem cells, each being modulated by the 
combined effects of the growth factors previously described. Although the net 
result of bone formation is relatively well understood, it is clear that the majority 
of the fine detail regarding signalling and modulation remains obscure in its 
complexity.
The growth and transcription factors described here as being involved in 
the osteoblast differentiation pathway do not comprise an exhaustive list and 
there are no doubt many other factors involved in the process at both direct and 
regulatory levels. There is a significant amount of work implicating the 
signalling nfolecules described here in the osteoblast differentiation pathways 
however, even if the nature of their involvement is not totally understood. As 
they are established indicators of osteoblast development and in many cases are 
detectable qualitatively and quantitatively by various techniques, they provide 
the components from which a picture of cellular activity can be built when 
examining an implant site. Data collected from these markers could indicate the
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presence, quantity, and developmental phase of cells in the osteoblast lineage and 
how these factors are altered under various conditions.
1.5 Proteins Expressed During the Osteogenic Pathway
The protein products induced by the transcription and growth factors 
responsible for driving osteoblast differentiation can also represent important 
markers when considering the cellular events around a site of bone formation. 
Table 1.1 gives some of the many cellular markers and secretory products 
induced during different phases during osteoblast differentiation. Although the 
specific function of many proteins expressed by osteoblasts is unknown, they 
have been associated with particular phases in the osteoblast lineage and can 
therefore be visualized to give an indication of the osteogenic situation around a 
site of interest.
D ifferentiation
Stage
M esenchym al Stem  
Cells
O steoprogenitor
Cells
Pre-osteoblasts O steoblasts
M arkers
Expressed
*
-Stro-1 
(early progenitor cell 
marker) 
-Capable o f  collagen 
type I, II, III 
synthesis
-Stro-1 
-Alkaline 
Phosphatase 
-Capable o f  
collagen type I, 
II, III synthesis
-Alkaline 
Phosphatase 
-Stro-1 not 
expressed 
-Bone Sialoprotein 
-Parathyroid 
hormone related 
protein receptor 
-Only capable o f  
collagen type I 
synthesis
-Alkaline 
Phosphatase 
-Stro-1 not 
expressed  
-Bone Sialoprotein 
-Parathyroid 
hormone related 
protein receptor 
-Only capable o f  
collagen type I 
synthesis 
-Osteopontin 
-Osteocalcin  
-Osteonectin
Table 1.1: A table giving some o f  the markers o f  each phase in t le  osteoblast differentiation
pathway. Compiled from (Hughes et al. 2006; Katagiri and Takahashi 2002).
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1.5.1 Type I Collagen
Type I collagen is the primary secretary product of osteoblasts and by far 
the main component of the osteoid matrix. It constitutes approximately 90% of 
the bone matrix proteins produced by osteoblasts (Buckwalter et al. 1995; Kalfas
2001). Type III collagen is also a major component of bone tissue, but is 
typically found in initially deposited woven bone (Kalfas 2001). Type I collagen 
has a unique triple helical structure, with the three helices intertwining to form 
fibrils (Allori et al. 2008). These fibrils are then bundled together in larger fibres, 
an arrangement which is directly related to the structural properties of type I 
collagen and forms a framework for mineral deposition (Allori et al. 2008). As 
fibres of type I collagen are laid down, the gap zones formed between each triple 
helical subunit serve as nucleation sites for mineral deposition, resulting in a 
highly organised mineralised structure (Allori et al. 2008; Buckwalter et al. 
1995). The process of mineralisation is not directly facilitated by type I collagen, 
but it interacts with the other non-collagenous bone matrix proteins which act as 
nucleators, providing the scaffold for the formation of mineralised bone tissue 
(Boskey 1992). Type I collagen may also directly regulate cellular activity in 
relation to bone repair. It has been shown induce osteoblast differentiation via 
interaction with ci2 integrin (Xiao et al. 1998), and has been shown to be involved 
in the recruitment of osteoblast progenitor cells (Malone et al. 1982). Due to its 
central role in both the structural and cellular functions of bone, type I collagen is 
of critical importance in the process of osseointegration. Its expression around an 
implant site would be a clear indicator of osteoblast activity and therefore 
suggestive ofiosseointegrative activity.
1.5.2 Osteocalcin
Osteocalcin (OC) is a non-collagenous matrix protein which is generally 
held to be bone-specific due to its exclusive synthesis by osteoblasts, and is the 
most abundant non-collagenous protein in bone (Boivin et al. 1990; Ducy et al.
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1996; Weinreb et al. 1990). Normally, osteocalcin is tightly bound to the 
hydroxyapatite of the mineralised bone matrix due to the post-translational 
carboxylation of glutamic acid residues, which favour calcium binding (Hoang et 
al. 2003; Poser and Price 1979). Therefore, osteocalcin is primarily incorporated 
into the bone matrix, although the detection of osteocalcin in the plasma is used 
as an indicator of bone turnover in osteoporosis (Lateef et al. 2009). 
Interestingly, osteocalcin knockout mice have no initial skeletal defects and 
express normal levels of all other bone matrix non-collagenous proteins, but over 
time show increased bone formation rate and a higher overall BMD, indicating a 
currently undefined regulatory role in skeletal development (Ducy et al. 1996). 
Osteocalcin has also been reported to be involved in the recruitment of both 
osteoblast and osteoclast progenitors, indicating that it may have a role in the 
regulation of bone formation (Lucas et al. 1988; Malone et al. 1982). Although 
the exact function of osteocalcin is unknown, it is exclusively expressed in bone 
tissue by osteoblasts and is therefore a useful marker of osteoblast activity. 
Around an implant site, its presence would be strongly indicative of 
osseointegrative activity.
1.5.3 Osteopontin
Osteopontin (OP) is a non-collagenous matrix protein which serves as an 
early marker for osteoblast activity. It contains the cell adhesion amino acid 
sequence Gly-Asp-Ser, and has been found to act as a cell attachment protein 
(Oldberg et al. 1986; Sodek et al. 2000; Somerman et al. 1988; Young et al. 
1992). Like osteocalcin, it contains post-translational carboxylated glutamic acid 
residues, which enable calcium binding and resulting in an affinity to 
hydroxyapatite (Giachelli and Steitz 2000). Osteopontin has also been shown to 
bind both type I collagen and osteocalcin, which leads to its sequestration in the 
matrix and suggests a possible role in maintaining the structure of bone as a 
tissue (Giachelli and Steitz 2000). Expression of osteopontin is seen in bone 
tissue, particularly woven bone, where it has been detected in the cytoplasm of 
both osteoblast precursor cells and mature osteoblasts (Mark et al. 1987; Young 
et al. 1992). It is not exclusive to bone tissue however, and has also been
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localized in the proximal convoluted tubule of the kidney and also sensory 
epithelia of the ear (Young et al. 1992). There is also a possibility that 
osteopontin is involved in the mediation of the inflammatory process, as it been 
shown to act as a chemo-attractant and anti-apoptotic signal for macrophages, 
neutrophils, T-cells, fibroblasts and endothelial cells as well as osteoblast 
progenitors (Ashkar et al. 2000; Denhardt et al. 2001; Giachelli and Steitz 2000; 
O’Regan et al. 1999; Wang and Denhardt 2008). Osteopontin knock out mice 
display normal skeletal development, but have abnormal osteoclast function and 
are resistant to ovariectomy-induced bone resorption (Rittling et al. 1998; 
Yoshitake et al. 1999), indicating that it may also have a role in regulating 
osteoclast function. Osteopontin is a useful indicator of the process of bone 
formation around titanium implant sites, as its expression may be indicative of 
osteoblast progenitor attachment and differentiation into osteoblasts. Although it 
is not specific to bone, its expression alongside other bone markers in a bone 
healing context is indicative of osseointegrative activity.
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1.5.4 Bone Sialoprotein
Bone sialoprotein (BSP) is a non-collagenous matrix protein expressed by 
mature osteoblasts at a late stage in their differentiation and, like osteopontin, it 
contains the Gly-Asp-Ser cell adhesion sequence, despite having a markedly 
different structure (Oldberg et al. 1988; Young et al. 1992). BSP binds to type I 
collagen and a variety of other matrix proteins including various matrix 
metalloproteinases and integrins (Fisher et al. 2001; Wuttke et al. 2001) and has 
been shown to directly promote hydroxyapatite nucleation (Baht et al. 2008), 
suggesting a role in initiating the mineralisation of the osteoid matrix. 
Osteoclasts have also been reported to express BSP and it is a possibility that it, 
like many of the non-collagenous bone matrix proteins, plays either an indirect or 
a direct role in regulating bone resorption (Wuttke et al. 2001; Young et al. 
1992). Indeed, BSP has been associated with areas in which bone has been 
recently formed or remodelled (Hultenby et al. 1994). BSP knockout mice are 
smaller than normal counterparts and have under-mineralised skeletons (Malaval 
et al. 2008) and display impaired bone defect repair (Luc et al. 2009), indicating 
that BSP has important roles in bone formation and healing. Although the exact 
mechanisms by which BSP functions enigmatic, it is most probably directly 
involved in the formation and mineralisation of bone. As it is widely expressed 
by osteoblasts, particularly in areas of new bone formation, it is a useful indicator 
of osseointegrative activity.
1.5.5 Osteonectin
Osteonectin is a calcium binding glycoprotein expressed by many 
different cell types, including osteoblasts. It is thought to be involved in the 
formation of mineralised tissues by regulating the deposition and assembly of 
other osteoid matrix proteins (Brekken and Sage 2001; Lane and Sage 1994).
The expression of osteonectin is primarily associated with tissues undergoing
/
remodelling or healing (Brekken and Sage 2001; Lane and Sage. 1994). Although
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its specific role in bone formation is not fully understood, osteonectin does not 
appear to support cell attachment and inhibits cell spreading (Sage and Bornstein 
1991), and has also been shown to inhibit cellular proliferation and 
mineralisation in vitro (Brekken and Sage 2001; Kelm et al. 1994). Osteonectin 
knock-out mice display impaired bone formation and osteopenia, and have 
decreased numbers of both osteoblasts and osteoclasts (Delany et al. 2000). 
Stromal cells from these osteonectin knock-out mice display decreased osteoblast 
differentiation in vitro (Delany et al. 2003). It therefore appears that osteonectin 
has a role in the maintenance of bone tissue and in driving osteoblast 
differentiation, although not necessarily in osteoid mineralisation. Due to its 
association with healing tissues, particularly bone, and its involvement in 
regulating osteoblast differentiation, its presence around an implant site would be 
indicative of bone healing.
1.5.6 Alkaline Phosphatase
Alkaline Phosphatase is an enzyme which is widely expressed in various
tissues around the body. There are four different isoforms of alkaline
phosphatase, however the one associated with bone is the tissue non-specific
alkaline phosphatase (TNAP), although it is expressed ubiquitously (Moss 1992;
Young et al. 1992). This alkaline phosphatase has long been associated with bone
formation, and is directly involved in the mineralisation of the osteoid matrix by
removing pyrophosphates which inhibit hydroxyapatite formation (Whyte 1994).
It is known to be expressed on the surface of both osteoblasts and osteoblast
progenitor cells and is therefore commonly used as an indicator of osteoblast 
*differentiation and activity, (Katagiri and Takahashi 2002; Sharp and Magnusson 
2008). The ubiquity of alkaline phosphatase makes it fairly non-specific as an 
indicator of bone formation despite its wide acceptance as a marker. Its 
expression alongside other markers of osteoblast activity would however, serve 
as an indicator of osseointegrative activity around an implant site.
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1.6 The Process of Osseointegration of Titanium Dental Implants
The insertion of a dental implant into bone tissue results in an injury and 
therefore the process of osseointegration is also one of bone healing. Bone 
healing involves a complex cascade of events and is comprised of several stages 
(Davies 2003). Initially inflammation results from the injury and the 
subsequently both immune and mesenchymal progenitor cells infiltrate the site. 
These cells then undergo cycles of proliferation and differentiation, transforming 
the initial haematoma into more stable, vascularised granulation tissue. As the 
mesenchymal cells differentiate into osteoblasts, they begin to synthesize the 
osteoid matrix, which is composed of both type I and type III collagen and the 
various non-collagenous proteins. Together, the components of the osteoid form 
a matrix which then undergoes mineralisation as woven bone and is subsequently 
remodelled to form lamellar bone. An understanding of the bone repair process 
after implant placement is central to the study of the osseointegration of titanium 
implants, as it is during this process which the level of bone apposition to the 
implant surface is determined.
1.6.1 Initial Inflammatory Response
One of the first events after the placement of an implant which has a 
major influence on the subsequent rate of osseointegration is the resolution of the 
initial inflammatory response. This response is modulated by a cascade of 
signalling molecules released from cells in the damaged tissue and ruptured 
platelets, including many of the growth factors described (Bolander 1992; 
Einhom 1998). Inflammatory cytokines implicated in the early inflammatory 
process and also in the regulation of osteoblast differentiation and function 
include interleukin (IL)-l, IL- 6  and tumour necrosis factor (TNF) a (Bertolini et 
al. 1986; Einhom et al. 1995). While the inflammatory response is necessary to 
initiate the process of bone repair, it is critical that it is quickly resolved as many 
of the inflammatory cytokines released have a deleterious effect on 
osseointegration (Davies ,2003; Hughes et al. 2006). Sustained inflammation
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around an implant site can therefore ultimately lead to implant failure (Davies
2003). Implants modified in such a way as to improve the rate of bone synthesis 
in apposition to the implant surface can minimise the risk of sustained local 
inflammation (Le Guehennec et al. 2007).
1.6.1.1IL-1
IL-1 has two subtypes, IL-1 a and IL-1 p, which both act through the same 
receptor and appear to have similar biological activities (Hughes et al. 2006). A 
variety of functions have been attributed to IL-1, some of which are apparently 
contradictory. In different instances, IL-1 has been reported to inhibit osteoblast 
proliferation yet increase bone formation and also to enhance osteoblast 
proliferation but decrease bone formation (Ellies and Aubin 1990; Hanazawa et 
al. 1986; Rickard et al. 1993). IL-1 has also been shown to induce the synthesis 
of many other inflammatory cytokines and mediators, including IL-6 , TNFa, 
prostaglandin E2, and nitric oxide (Hughes et al. 1999; Hukkanen et al. 1995; 
Ishimi et al. 1990; Wei et al. 2005). IL-1 also induces bone resorption in vitro, 
although whether this is a direct action of IL-1 or an indirect effect through the 
induction of a variety of other cytokines is unknown (Lorenzo et al. 1987).
1.6.1.2 IL-6
Osteoblasts and stromal cells are the main source of IL- 6  in bone (Holt et 
al. 1996). IL- 6  forms a complex with a soluble form of its receptor, termed sIL- 
6 R, which has b£en shown to decrease the proliferation of osteoprogenitor cells
V. '
and drive osteoblast differentiation (Bellido et al. 1997). In addition to the direct 
action of IL- 6  on osteoblasts, via an intracellular signalling cascade mediated by 
the IL-6 /sIL6 R complex receptor subunit gpl30, IL- 6  has been shown to induce 
the expression of IGFs and BMPs which are potent drivers of osteoblast 
differentiation (Franchimont et al. 1997; Yeh et al. 2002). IL- 6  therefore appears 
to be an important step in initiating additional osteoblast differentiation, and 
thereby bone formation, in the aftermath of injury to bone tissue.
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1.6.13 TNFa
TNFa is a cytokine well known to be involved in the inflammatory 
response, and has been clearly shown to increase the rate bone resorption by the 
induction of osteoclast formation and to decrease bone formation through the 
inhibition of osteoblast differentiation, proliferation and secretory activity 
(Bertolini et al. 1986; Nanes 2003). The main producers of TNFa are the T-cells 
of the acquired immune system, which produce it response to IL-1 secretion by 
osteoblasts (Nanes 2003). TNFa is a major repressor of osteoblast activity at a 
number of levels and, as such, is a key mediator of the deleterious effects of 
inflammation on osseointegration.
The cumulative result of sustained secretion of inflammatory cytokines 
and mediators, not withstanding their ability to concurrently mediate certain 
osteogenic effects, is osteoclast activation and bone resorption (Hofbauer et al. 
1999; O'Brien et al. 2000; Wei et al. 2005).
1.6.2 Resolution of Inflammation
The inflammatory response is necessary for initiating wound healing and 
the elimination of infectious agents. If it is not contained and arrested promptly 
however, it can seriously hamper successful osseointegration by promoting the 
destruction of tissues adjacent to the implant site while simultaneously 
preventing bone repair.
Inflammation is generally resolved by a number of signalling molecules 
which suppress the infiltration and activation of inflammatory cells present at the 
site of injury. These include the glucocorticoids which decrease the infiltration of 
immune cells, the production of prostaglandins and a number of other well 
characterised anti-inflammatory actions (Adcock 2000; Lawrence et al. 2002). 
TGFpi has been shown to have a role in the resolution of inflammation by down-
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regulating macrophage production of various inflammatory cytokines, including 
IL-1 p, via Smad 3 activity (Werner et al. 2000). There are a number of anti­
inflammatory cytokines which have roles in suppressing immune cell 
inflammatory activity, a prominent example being IL-10. IL-10 is primarily 
produced by monocytes and has been shown inhibit the synthesis of a variety of 
inflammatory cytokines by leukocytes, including TNFa and IL-1 p (Cassatella et 
al. 1993; de Vries 1995). A variety of lipid signalling molecules, for example 
lipoxins, are also thought to have a variety of anti-inflammatory functions 
including reducing the infiltration of neutrophils and eosinophils (Lawrence et al. 
2002; Maddox et al. 1998; Soyombo et al. 1994). The relatively short half life of 
inflammatory cytokines means that switching off the cells which produce them 
quickly results in their clearance from the site of injury, thus resolving the 
inflammation (Lawrence et al. 2002).
In addition to suppressing the cells that produce inflammatory mediators, 
inflammatory mediators themselves are directly antagonized through the 
synthesis of anti-inflammatory molecules such as the soluble TNF receptor, 
which acts as a decoy for TNFa (Olsson et al. 1993) and IL-1 receptor 
antagonist, which occupies the IL-1 receptor without activating it (Dinarello 
2000). When these molecules act in concert with the suppression of immune cell 
activity, it leads to a rapid containment and resolution of inflammation, which is 
necessary for the progression of bone healing to occur.
1.6.3 Initiation of Bone Repair around the Implant Site 
¥
The disruption of tissue and the subsequent degranulation of platelets 
which occurs during the placement of an implant also results in the formation of 
a fibrin clot around the site which adheres to the implant surface (Davies 2003; 
Einhom 1998). During the initial injury and inflammatory response a wide range 
of chemical signals are released, initiating a whirlwind of growth factors, 
inflammatory mediators and cell chemotactic factors, major examples being 
PDGF and TGFp. These factors stimulate the infiltration of the fibrin clot
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surrounding the implant site by many different cell types, including various 
immune cell types and mesenchymal progenitor cells which ultimately 
differentiate into a variety of cell types including fibroblasts, chondrocytes and 
osteoblasts (Davies 2003; Einhom 1998). Invasion by these cell types and their 
subsequent activity results in the initial fibrin clot resolving into a more stable 
fibrous connective tissue composed of type III collagen secreted by fibroblasts 
(Davies 2003; Einhom 1998). This fibrous or granulation tissue is rapidly 
vascularised through the actions of angiogenic growth factors such as vascular 
endothelial growth factor (VEGF) in order to supply the repair site with a ready 
blood supply, which is absolutely required to support and sustain the healing 
process (Davies 2003; Einhom 1998). Although VEGF does not directly 
stimulate bone formation, it has been shown to be required for normal bone 
healing in mice (Street et al. 2002). Additionally, endothelial cells produce BMP- 
2 in response to VEGF (Bouletreau et al. 2002), indicating that the process of 
angiogenesis is directly linked to the initiation of bone healing.
Osteoblast progenitor cell migration to the site of the implant is 
stimulated by various growth factors, for example PDGF. As these cells reach the 
implant site, they adhere to either the bone tissue surrounding the site or move 
through the granulation tissue and onto the surface of the implant (Davies 2003; 
Einhom 1998). Upon reaching the final stage of differentiation, osteoblasts begin 
to rapidly synthesize osteoid matrix around the implant. Eventually, this process 
results in a layer of osteoblasts attached to bone tissue surrounding the implant 
site laying down osteoid, referred to as distance osteogenesis, and a layer of 
osteoblasts attached to the implant surface synthesizing osteoid matrix directly at 
the implant surfacj, or contact osteogenesis. Both distance and contact 
osteogenesis occur simultaneously, steadily replacing the granulation tissue from 
both ‘sides’ with osteoid matrix, which then becomes mineralised, creating 
woven bone around the implant and initially stabilizing it (Davies 2003; Einhom 
1998). Woven bone is then remodelled incrementally into stronger lamellar bone 
by the combined action of osteoblasts and osteoclasts, resulting in the 
osseointegration of the titanium implant. Titanium surfaces which maximize
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contact osteogenesis are clearly favourable as bone formation directly around the 
implant provides rapid stability and enhanced chances of osseointegration.
1.7 Titanium Surface Modifications and their Impact on Osseointegration
Although other materials have been put forward for use implant design, it 
is generally accepted that titanium is a highly effective material from which to 
make dental implants, due to several highly beneficial properties. Firstly, 
titanium and its alloys are highly resistant to corrosion. Corrosion is a major 
problem with other types of material in dental implants, as it can erode the 
mechanical strength of implants over time, leading ultimately to implant failure 
(Lacefield 1999). Titanium is also, critically, a structurally robust material, which 
is essential for implants to withstand the loading placed on them in the course of 
normal use, for example during mastication (Lacefield 1999; Le Guehennec et al. 
2007). The immunologically inert nature of titanium is also highly beneficial, as 
there are minimal complications with hypersensitivity reactions to implants, 
which can be problematic with other materials like nickel or cobalt (Rushing et 
al. 2007). Finally, both the surface chemistry and topography of titanium can be 
easily modified in a variety of ways to enhance its level of interaction with 
surrounding tissues, increasing contact osteogenesis and thus osseointegration 
(Ellingsen et al. 2006).
It has long been thought that the modification of titanium implant 
surfaces to optimize conditions for rapid osseointegration, which is critical for 
the long term clinical success of a dental implant (Albrektsson et al. 1981; 
Ellingsen et al. 2006; Le Guehennec et al. 2007; Puleo and Thomas 2006). 
Increasing the osseointegrative potential through the modification of titanium 
surfaces is a key focus of this thesis.
1.7.1 General Principles of Implant Design
There are several general characteristics of implants which are currently 
thought to enhance to potential for osseointegration to occur and minimize the
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chances of eventual failure. Titanium implants are usually made from titanium 
alloys, grade 5 titanium, consisting of titanium, aluminium, vanadium, iron, and 
oxygen, being a prime example. Titanium alloys are stronger and less prone to 
fatigue than pure titanium, and are therefore commonly used in dental implant 
design (Steinemann 1998). Alterations to the surface chemistry of the implant 
influence the level of interaction with surrounding tissues. Hydrophilic surfaces 
have also been reported to be more likely to experience tissue attachment then
hydrophobic ones (Buser et al. 2004; Zhao et al. 2005), although there are also
\
contradictory findings (Carlsson et al. 1989; Wennerberg et al. 1991). A key 
principle in the general design of titanium implants however, is that roughened 
surfaces have a greater osseointegrative potential than smooth, machined 
surfaces.
1.7.2 Rough versus Smooth Surfaces
It is a generally held and very widely supported principle that implants 
which have a roughened surface are much more likely to rapidly osseointegrate 
than implants with a smooth machined surface, with the optimal roughness being 
in the range of 1-1 OpM (Abrahamsson et al. 2004; Buser et al. 1998; Le 
Guehennec et al. 2007; Shibli et al. 2007; Trisi et al. 2003; Wennerberg et al. 
1995; Wennerberg et al. 1996b; Wennerberg et al. 1998; Zechner et al. 2004). 
This may be due to implants with smooth surfaces being more susceptible to 
fibrous encapsulation than implants with roughened surfaces (Abron et al. 2001; 
Ellingsen et al. 2006; Ronold and Ellingsen 2002).
Fibrous encapsulation is the formation of a poorly vascularised 
collagenous capsule around the implant, which results in the failure of 
osseointegration (Ellingsen et al. 2006). There are a number of factors which can 
cause fibrous encapsulation, including a sustained inflammatory response, lack 
of vascularisation at the implant site and low levels of osteoblast migration or 
attachment to the implant surface (Ellingsen et al. 2006; Kyriakides et al. 2001; 
Le. Guehennec et al. 2007; Shibli et al. 2007). The ultimate result of fibrous
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encapsulation is that tissue does not attach directly to the implant surface, leaving 
a space between the fibrous capsule and implant which fills with fluid. This 
fluid-filled space provides an ideal environment for bacterial infiltration and a 
subsequent infection which leads to bone resorption via a sustained inflammatory 
response (Ellingsen et al. 2006; Kyriakides et al. 2001; Le Guehennec et al. 
2007). Fibrous encapsulation may occur with less frequency around roughened 
implants due to the increased adherence of the initial fibrin clot to the implant 
surface, increased osteoblast progenitor migration and vascularisation or through 
increased rates of contact osteogenesis enhancing implant stability (Davies 2003; 
Ellingsen et al. 2006; Shibli et al. 2007). Roughened surfaces also have a thicker 
titanium oxide layer, which is a reactive layer of surface particles thought to have 
a dynamic effect on surrounding tissues, encouraging attachment (Ellingsen et al. 
2006; Mustafa et al. 2001; Sul et al. 2006; Zhao et al. 2005)
There is a broad consensus that rough implant surfaces have superior 
osseointegrative potential than smooth implant surfaces. There are however, a 
broad range of methods to create roughened titanium surfaces, and there has been 
much discussion in the literature about which of these methods creates surfaces 
optimized for osseointegration (Bagno and Di Bello 2004).
1.7.2.1 Grit Blasted Surfaces
Grit blasting is one of the most common methods by which titanium 
dental implants are roughened. They are manufactured by bombarding implants 
with particles composed of a variety of substances, for example alumina (AI2O3), 
titanium oxide, and calcium phosphates such as hydroxyapatite (Davies 2003; 
Ellingsen et al. 2006; Le Guehennec et al. 2007). It is interesting to note that 
residual alumina from the blasting process may have a deleterious effect on 
osseointegration and may increase the chances of implant corrosion (Aparicio et 
al. 2003). The use of hydroxyapatite to roughen implant surfaces has been 
reported to result in similar rates of bone apposition around implants as other
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techniques, but hydroxyapatite has the advantage of being resorbable in situ 
(Mueller et al. 2003/
In vitro studies have suggested that grit blasted titanium surfaces 
encourage osteoblast differentiation and, by extension, osseointegration. Cells 
from both osteoblast cell lines and primary mandibular bone from various 
species grown on grit blasted titanium surfaces have been reported increase 
expression of osteoblast specific mRNA and proteins as well as increased 
mineralization compared to cell grown on smooth surfaces (Marinucci et al. 
2006; Martin et al. 1995; Mustafa et al. 2001; Schneider et al. 2003). These 
results have been corroborated in a number of in vivo studies which reported that 
implants with grit blasted surfaces have superior bone to implant contact 
compared to machined implants with smooth surfaces in rabbits, with 
corresponding increases in the torsional strength of the implants (Gotfredsen et 
al. 1995; Wennerberg et al. 1996a; Wennerberg et al. 1996b; Wennerberg et al. 
1996c). Similarly, grit blasted microimplants in humans have been shown to 
shown increase bone apposition compared to smooth machined edges (Ivanoff et 
al. 2001). Grit blasting has been shown in a number of both in vitro and in vivo 
studies to increase the amount of bone apposition around titanium dental 
implants.
1.7.2.2 Acid Etched Surfaces
Another titanium implant surface treatment which has been reported to 
increase the chances of osseointegration is acid etching. The process of acid 
etching involves the submersion of implants in a strong acid such as HC1, H2SO4, 
HNO3 and HF, which creates a topography that is moderately roughened (Le 
Guehennec et al. 2007). Acid etching is often used in conjunction with grit 
blasting in implant manufacture. Cells from osteoblast cell lines cultured on acid 
etched surfaces express higher levels of alkaline phosphatase than cells cultured 
on smooth surfaces (Martin et al. 1995). In vivo, acid etched surfaces improve 
bone apposition rates compared to implants with smooth and plasma sprayed
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surfaces (Cho and Park 2003; Cochran et al. 1998). Various clinical studies have 
shown acid etched implants to be successful in humans, with radiological 
evidence suggesting improved bone apposition rates compared to machined 
implants (Trisi et al. 2003; Zechner et al. 2004). The use of strong acids in the 
manufacture of these implants has however, led to some concerns over structural 
integrity. Exposure to these acids has been shown to cause hydrogen 
embrittlement of titanium, which can causes micro cracks on the surface, 
potentially undermining the structural integrity of the implant, and leading 
ultimately to implant failure (Yokoyama et al. 2002). Nevertheless, acid etched 
implants have a proven clinical track record and are still currently in use.
1.7.2.3 Calcium Phosphate Coated Surfaces
Tri-calcium phosphate (TCP) coatings have also been widely applied to 
titanium surfaces, with the intention of encouraging more rapid attachment of 
bone (de Groot et al. 1998; Lacefield 1999; Le Guehennec et al. 2007). It is 
thought that presence of calcium phosphate enhances the attachment of the 
coating to the surrounding bone due to its chemical similarity to hydroxyapatite 
(Daculsi et al. 2003; de Groot et al. 1998). TCP coating a titanium surface also 
increases its surface roughness and it is therefore thought that it encourages the 
deposition osteoid matrix in apposition to implants by promoting osteoblast 
progenitor attachment and differentiation (Daculsi et al. 2003; de Groot et al. 
1998). TCP coated implants have been reported to undergo more rapid 
osseointegration in goat femurs (Barrere et al. 2003), although it has been 
reported that there is no clinical advantage to using them (Morris et al. 2000). In 
vitro, osteoblast-like cells have been reported to adhere preferentially to titanium 
surfaces with a calcium phosphate coating compared to plastic or smooth 
titanium (Le Guehennec et al. 2008). Osteoblast-like cells have also been 
reported to have higher levels of alkaline phosphatase expression on TCP coated 
titanium surfaces compared to machined controls (Bigi et al. 2005; Montanaro et 
al. 2002). A possible disadvantage to this type of surface modification is that 
coating may detach from the implant surface once implanted, decreasing direct
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bone-implant contact over time, although there has so far been is little evidence 
of this occurring (Daculsi et al. 2003; de Groot et al. 1998).
In summary, there are a number of ways in which dental implants can be 
modified in order to increase their chances of osseointegration. Although there 
are studies comparing the efficacy of these various techniques, it has proven 
difficult to determine an optimum surface topography due the wide variety of 
different surface modifications in existence (Bagno and Di Bello 2004; Cooper 
2000).
1.8 Placement of Implants into Compromised Patients
In practice, dental implants currently have a very high clinical success 
rate, approaching 95% at 5 years post insertion (Lazzara et al. 1996; Le 
Guehennec et al. 2007). This high success rate is at least partially due to the fact 
that candidates for implants are chosen according to highly selective criteria, 
which may exclude many individuals for whom implants would normally be 
clinically contraindicated. Ideal candidates have large amounts of healthy 
mandibular and maxillary bone, which is well supplied by the vasculature. This 
can severely limit the number of patients who can actually benefit from implants, 
particularly from groups which demonstrate the largest clinical need for 
implants. Periodontitis for example, causes tooth loss through bone resorption 
around the tooth as the result of a sustained inflammatory response to bacterial 
invasion (Lemer 2006; Taubman and Kawai 2001). Patients with osteoporosis 
are similarly unlikely to meet the criteria for treatment. Individuals with low 
levels of maxillary and mandibular bone and are correspondingly poor candidates 
for treatment with dental implants, despite the fact that they would benefit from it 
as they have an elevated risk of tooth loss.
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1.8.1 Diabetes Mellitus
Diabetes Mellitus is a metabolic disease characterised by chronic 
hyperglycaemia. It is estimated that DM will affect 220 million individual 
worldwide by 2010, making it a significant and expanding public health concern 
(Zimmet et al. 2003). DM results from either a lack of insulin production, as in 
type I DM, or in the desensitisation of cells to insulin, as in type II DM (Graves 
et al. 2006; Zimmet et al. 2003). In the context of dental implants, DM has been 
shown to hamper both bone formation and osseointegration leading to a 
generally poorer outcome for diabetic individuals (Morris et al. 2000; Valero et 
al. 2007). Indeed, diabetes is normally a contraindication for dental implants, 
denying a potentially large patient group the chance to benefit from treatment 
(Morris et al. 2000; Valero et al. 2007). This is particularly unfortunate for DM 
patients, as they have a high clinical need for dental implants. Due to their 
chronic hyperglycaemia, diabetic individuals have an increased risk of severe 
periodontitis and therefore tooth loss (Loe 1993).
Delayed healing is probably the root cause of increased implant failure in 
DM, as slower attachment of tissue to the implant surface allows a greater chance 
for bacterial infiltration, infection and sustained inflammation leading to implant 
failure (Valero et al. 2007). In the literature, delayed bone healing has been 
extensively associated with DM. It has been repeatedly demonstrated that 
diabetic rats have impaired rates of bone formation around titanium implants 
compared to normal controls in models of both type I (Fiorellini et al. 1999; 
McCracken et al. 2006; Nevins et al. 1998; Shyng et al. 2006) and type II 
(Hasegawa et al. 2008; He et al. 2004) DM. Furthermore, this delay in bone 
healing has been shown to be reversible by treatment with insulin (Fiorellini et 
al. 1999; Kwon et al. 2005; Siqueira et al. 2003). These findings suggest that the 
delayed bone formation in DM is a direct result of the hyperglycaemia associated 
with the disease. Indeed, diabetic pathologies are thought to be the direct result 
of raised intracellular glucose levels, where sustained systemic hyperglycaemia 
results in cells losing the ability to regulate their internal glucose levels (Heilig et
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al. 1995; Kaiser et al. 1993). Hyperglycaemia, therefore, has a broad range of 
complex effects relating to bone healing and interferes with cellular processes at 
a number of different levels.
One of the main systemic effects of DM is a deleterious effect on 
angiogenesis, which has clear implications for diabetic bone healing (Martin et 
al. 2003; Valero et al. 2007). In order for rapid and complete bone healing to 
occur, the injury site must be well vascularised to allow for the transit of a wide 
array of cell types and growth factors which are critical for stimulating of the 
bone repair process in addition to providing metabolic support to the site (Davies 
2003; Martin et al. 2003). Hyperglycaemic conditions have been shown to impair 
angiogenesis, indicating that it is probably the central cause of the relatively poor 
vascularisation associated with DM (Kim et al. 2002; Larger et al. 2004; Martin 
et al. 2003). A lower level of vascularisation around an implant site is likely to be 
a significant contributing factor to a delay in bone healing.
It has been demonstrated that the inflammatory response is altered in DM, 
which is another systemic effect of the disease likely to contribute to a delay in 
bone healing. Diabetic mice have been shown to have a greater rates of both 
osteoblast and fibroblast apoptosis in response to bacterial challenge, possibly 
indicating a reduced capacity to respond to and resolve infection (He et al. 2004; 
Liu et al. 2004). TNFa expression has been reported to be prolonged in wounds 
on diabetic mice after bacterial challenge (Naguib et al. 2003). It has also been 
reported that diabetic rats have a prolonged inflammatory response, enhanced 
bone resorption and inhibited bone formation (Liu et al. 2006). DM therefore 
appears to inhibit the immune response to infectious agents in addition to the 
resolution of the inflammatory process, both of which directly contribute to an 
impaired bone healing response.
Hyperglycaemia also directly interferes with cellular metabolism and has 
been shown to directly inhibit osteoblast differentiation and function. Rat 
mesenchymal progenitor cells have increased rates of apoptosis in response to 
elevated glucose levels, indicating that the pool of cells from which osteoblasts
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arise may be suppressed in DM (Stolzing et al. 2006). Osteoblasts cultured in 
hyperglycaemic conditions have a decreased capacity to produce mineralised 
bone nodules (Balint et al. 2001), and hyperglycaemia has been reported to 
decrease the expression of type I collagen, osteocalcin and Runx-2 in diabetic 
mice (Lu et al. 2003). Likewise, rat bone marrow stromal cells cultured under 
hyperglycaemic conditions show decreased rates of proliferation, decreased 
expression of alkaline phosphatase and type I collagen, and decreased 
mineralised nodule formation (Gopalakrishnan et al. 2006). Although there is not 
currently a unified understanding of the cellular processes affected by DM, the 
formation of advanced glycation end products and the generation of reactive 
oxygen species are thought be important mechanisms in the impairment of bone 
healing.
Advanced glycation end products (AGEs) result from sugars which have 
been nonenzymatically reduced by the amino groups of proteins and 
subsequently irreversibly cross-link, forming molecules which accumulate in 
various tissue around the body (Brownlee et al. 1988). They are particularly 
prevalent in diabetic individuals due to routine hyperglycaemia and can build up 
to substantial levels, particularly in the absence of treatment with insulin 
(Brownlee et al. 1988; Valero et al. 2007). AGEs have been shown to induce 
apoptosis in human mesenchymal progenitor cells and also to inhibit their 
differentiation of into osteoblasts (Kume et al. 2005). Using a fracturing healing 
model in diabetic and normal mice, Santana and colleagues (2003) demonstrated 
that the accumulation of AGEs leads to decreased osteoblast function and 
differentiation and also significantly alters osteoblast response to parathyroid 
hormone. AGEs exert their anti-osteogenic effects through a specific receptor for
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advanced glycation end products or RAGE, a transmembrane receptor in the 
immunoglobulin superfamily (Bucciarelli et al. 2002; Neeper et al. 1992). It has 
been shown that increased osteoblast apoptosis in the presence of AGEs is 
directly caused by RAGE activation (Alikhani et al. 2007). The accumulation of 
AGEs in bone tissues is therefore likely to be one of the primary underlying 
causes of the deleterious effects of DM on osteoblast function and, by extension, 
bone formation.
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Reactive oxygen species (ROS) are also thought to play a key role in the 
cellular pathologies associated with DM. ROS are generated when the increased 
intracellular glucose levels resulting from systemic hyperglycaemia lead to 
increased numbers glucose molecules being oxidised by the tricarboxylic acid 
cycle in the cellular mitochondria, generating a large number of electrons to be 
transported through electron transport chain, causing in effect a saturation of the 
chain (Brownlee 2005). As electrons accumulate in the mitochondria, coenzyme 
Q donates them to oxygen atoms, resulting in oxygen free radicals or superoxides 
(Brownlee 2005). Increased production of ROS in cells results in the condition 
known as oxidative stress, which causes a variety of changes within the cell, 
including the activation of the transcription factor NF-kP (Hoogeboom and 
Burgering 2009). Oxidative stress and the subsequent activation of NF-Kp have 
been associated with a variety of effects, including the inhibition of osteoblast 
differentiation in vitro (Almeida et al. 2007; Bai et al. 2004; Mody et al. 2001). 
NF-kappaP also induces a number of inflammatory cytokines, including IL-ip 
and TNFa (Baeuerle and Henkel 1994) Therefore, increased numbers of ROS 
may directly contribute to decreased bone formation and increased production of 
inflammatory mediators. Increased ROS production has also been shown to 
damage endothelial cells by inhibiting normal GAPDH activity, and is therefore 
linked to the impairment of angiogenesis which directly contributes to the 
impaired bone healing (Du et al. 2003). Effectively, ROS are a cellular 
mechanism which may heavily contribute to the impairment of bone healing 
observed in DM.
Diabetic patients can attempt to manage their glucose levels through 
insulin therapy (type I DM) or through dietary regulation (type II DM). They can 
therefore, in theory, successfully receive implants. The fact remains however that 
the failure rate for implants is still significantly higher in diabetic individuals, 
possibly due to the unpredictable nature of their control over blood glucose 
levels, particularly in type II DM (Valero et al. 2007). Although the exact 
mechanisms by which osseointegration is delayed in DM are not totally 
understood, it has been associated with both a diminished capacity for
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angiogenesis, possibly resulting in poor vascularisation of the implant site, and 
an impaired ability to resolve both infection and inflammation. Due to the high 
cost of the implant procedures, individuals with DM rarely receive implants, 
despite being a patient group with an increased need for dental implant treatment. 
Therefore, investigation of the exact effects of DM on osseointegration is of 
interest, as it may provide information which will be useful in implant design, 
possibly allowing more of these patients to benefit from treatment with dental 
implants.
1.8.2 Other Challenging Clinical Conditions
Unsurprisingly, individuals with osteoporosis may have higher rates of 
implant failure than normal, although comprehensive clinical data is lacking, 
probably because of the expense of implants is prohibitive in cases which may 
have complicating conditions (Mombelli and Cionca 2006). The osseointegration 
of implants with various surface treatments has been shown to be significantly 
decreased in osteoporotic models of sheep (Borsari et al. 2007a; Borsari et al. 
2007b). There have been clinical reports of implants being successfully placed 
and retained in patients with osteoporosis and that implants can be successfully 
placed even in severely atrophied mandibles, although it is not possible to draw 
definitive conclusions as substantial clinical studies have not been performed 
(Friberg et al. 2001; Friberg et al. 2000; Mombelli and Cionca 2006). In theory, 
immuno-compromised individuals would also have a higher risk of implant 
failure, due to their increased chances of infection at the implant site, although 
there have not been any significant clinical studies to indicate this.
By better understanding the ways in which systemic conditions influence 
the process of osteogenesis and by extension osseointegration, advances can be 
made which place dental implants within the reach of individuals who would 
otherwise not be able to benefit from them. The utility of future research into the 
osseointegration of titanium implants is not improvement of an already excellent
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routine clinical outcome, but rather the expansion of access in cases where 
implants are generally unavailable.
1.9 Aims
The overall aim of this thesis is to investigate the ways in which modified 
titanium surfaces influence the osseointegration of titanium dental implants. To 
this end, three commercially available modified titanium surfaces will be 
systematically characterised in terms of their topography, surface chemistry and 
hydrophobicity, variations in all of which are known to influence 
osseointegrative potential. The influence of these surfaces on the process of 
osseointegration will be investigated using both an in vitro and an in vivo model. 
Titanium implant osseointegration will also be investigated in the context of type 
II DM using a variation of the in vivo model system.
Osteoblasts are central to the investigation of the influence of modified 
titanium surfaces on osseointegration, as they are the cells which directly drive 
bone formation. The impairment of bone formation healing in DM is also 
mediated in a large part through osteoblast dysfunction. Osteoblasts also play a 
central regulatory role in bone tissue as a whole, both through their eventual 
differentiation into osteocytes and their involvement in regulating bone 
resorption through the control of osteoclast differentiation. Therefore, bone 
marrow derived mesenchymal progenitor cells cultured on modified titanium 
surfaces will be used to model the effects of surface modification on osteoblasts 
in vitro. In addition to investigating differences in the morphology and adherence 
of these cells on the different experimental titanium surfaces, the mRNA 
expression of a variety of osteoblast and bone specific markers will be examined 
in order to evaluate the influence of surface modification on the process of 
osteoblast differentiation. Inflammatory cytokine and growth factor mRNA 
expression profiles will also be compared across the different experimental 
titanium surfaces, as both of these have obvious implications for both osteoblast 
differentiation and the process of osseointegration. Expression of RANKL and
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OPG mRNA will be examined in bone marrow derived osteoblast progenitors 
cultured on each of the experimental surfaces, in order to investigate the potential 
role of modified surfaces in the regulation of bone resorption. The protein 
composition of extracellular matrices produced by osteoblast progenitors 
cultured on the different experimental surfaces will also be examined, as this 
may have an impact on the ultimate rate of osseointegration.
Modelling the effects of modified titanium surfaces on osteoblast cellular 
behaviour will give an insight into which surface modifications stimulate 
osteoblasts to more rapidly synthesize bone in apposition to implant surfaces. By 
characterising the implant surfaces, specific parameters which affect this process 
can be identified. Also, by examining those factors which impair the process of 
bone repair, such as increased production of inflammatory cytokines or signals 
for bone resorption, potentially counter-productive effects of surface 
modification will be identified. The information generated by this model could 
therefore be directly applied to improve implant design and manufacture, 
hopefully improving patient outcomes, even in difficult clinical situations or 
disease states such as DM or osteoporosis.
It would be fallacious, however, to assume that osteoblasts are the only 
cells involved in the osseointegration of dental implants, as this process takes 
place in a tissue with a variety of cell types which interact in complex ways. 
Therefore an in vivo rat model of bone healing will be used in order to examine 
the interactions between bone tissue and implants with characterised 
experimental surfaces. Differences in the progression of bone healing around 
different implant sites over time will be investigated using histological methods, 
and immunolocalisation of bone markers will be used to gauge the corresponding 
activity of surrounding cells.
In addition, this model will also be used to investigate the 
osseointegration of dental implants in type II DM, a relatively common clinical 
condition with direct implications for dental implant treatment. This will provide 
an excellent opportunity fo investigate the temporal effects of this disease on
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bone as a living tissue, and will also provide direct information about alterations 
in cellular activity, such as the expression of bone markers, inflammatory 
cytokines and growth factors pertinent to bone formation. Investigating the 
specific effects of type II DM on the process of implant osseointegration may 
ultimately provide information which will improve the outcome of dental implant 
treatments in diabetic individuals.
The data presented in this thesis will be directly applicable to the design 
and manufacture of titanium dental implants. Any specific influences of surface 
modification on the differentiation of osteoblasts, bone formation, the 
inflammatory response and bone resorption will hopefully be elucidated and 
described. If surfaces which are optimal for rapid osseointegration can be 
identified, it would increase the applicability of implants in difficult clinical 
situations, increasing the level of access for patients who have a number of 
relatively common diseases. Additionally rapidly integrating implants would 
allow for one-stage implants, which would reduce the overall chair-time 
currently necessary for treatment, effectively reducing the cost of dental 
implants. Essentially, this would serve to broaden access to a treatment regime 
which has been consistently proven to be highly effective in improving the 
quality of life and overall oral health for a vast number of individuals. This 
project therefore has a high degree of relevance to not only bone biology, but 
also the practice of modem dentistry, the wider public health, and commercial 
and social medicine interests.
52
Chapter 2^Xj>aracterisation of Modified Titanium Surfaces
2.1 Introduction
The surfa^s of titanium dental implants are frequently modified in an 
attempt to enhan£§ their potential for osseointegration. Clinically, implants with 
surfaces which j^ ld ly  and efficiently osseointegrate bring a lower risk of 
complications aftrf therefore a better outcome for patients (Davies 2003), 
resulting in a larg® amount of interest in defining the ideal implant surface. Many 
investigations into fhe osseointegrative potential of various modified surfaces 
have been carried ofitin both in vitro (Annunziata et al. 2008; Le Guehennec et 
al. 2008; Marinu^i ctal. 2006; Martin et al. 1996; Postiglione et al. 2003; Qu et 
al. 2007; Tsukimt1^  et al. 2008) and in vivo (Bemd et al. 2008; Buser et al. 2004; 
Cho and Park 200$; Cochran et al. 1998; Franchi et al. 2007; Schwarz et al. 
2007) model systems. These surface modifications generally consist of 
alterations in surface topography, which may also lead to alterations in the 
surface chemistry (Tsukimura et al. 2008; Zhao et al. 2005). The ultimate goal of 
any modification titanium implant surfaces is to create an environment which 
is optimally suites for the adhesion, differentiation and osteogenic activity of 
osteoblasts.
Surface ^^graphy  can be altered in a number of ways. For example, a 
surface can be smooth through machining, which results in a generally 
more uniform afld flat surface. It can also be roughed through a variety of 
methods, which result in a more varied surface populated by peaks and valleys. 
In the literature, it is often stated that rougher surfaces are superior in dental 
implants, as a rougfrened surface enhances cell attachment, stimulates osteoblast 
differentiation, increases the amount of bone apposition to dental implants 
(Cooper et al. 1§99; Masaki et al. 2005; Mustafa et al. 2001). The exact 
mechanisms fot  the increased affinity of osteoblasts and roughened titanium 
surfaces are ciuf^tly unclear, but are probably multi-factorial and may include 
increased interaction with the initial fibrin clot, increased surface energy and
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hydrophilicity, and provision of an optimal scaffold for the initial deposition and 
organisation of bone proteins (Bagno and Di Bello 2004; Deligianni et al. 2001; 
Le Guehennec et al. 2007; Zhao et al. 2005).
As noted previously, it is virtually impossible to alter the topography of a 
titanium surface without also altering its physiochemical properties in some way. 
For example, grit blasting, etching with an acid or the application of a 
biomimetic coating to a titanium surface would result in both changes to the 
topography and the surface chemistry. Consequently, the interaction between 
cells and titanium surfaces is also influenced by the surface chemistry of those 
surfaces, specifically in terms of the elemental composition of the surface, 
formation of a titanium oxide layer, surface energy and hydrophobicity (Buser et 
al. 2004; Schwarz et al. 2009; Tsukimura et al. 2008; Zhao et al. 2005). Titanium 
surfaces spontaneously form an oxide layer in both atmospheric and aqueous 
environments (Tengvall and Lundstrom 1992; Tsukimura et al. 2008; Zhao et al. 
2005). This oxide layer increases both the surface energy and hydrophilicity of 
titanium, which has been shown to increase the absorption of serum proteins and 
enhance osteoblast cell attachment and activity (Tsukimura et al. 2008; Zhao et 
al. 2005). When placed in contact with physiologically relevant fluids, oxide 
layers on titanium surfaces have also been shown to play a role in the induction 
of hydroxyapatite formation, indicating an important role in the process of 
osseointegration (Li et al. 1994; Zhao et al. 2005). Various surface modifications, 
for example acid etching or grit blasting alter the thickness of this oxide layer, 
thus affecting the interaction of cells with the surface (Tengvall and Lundstrom 
1992; Tsukimura et al. 2008; Zhao et al. 2005).
There is an extensive range of techniques which have been used to alter 
the surface characteristics of titanium (Annunziata et al. 2008; Bagno and Di 
Bello 2004; Bemd et al. 2008; Buser et al. 2004; Cho and Park 2003; Cochran et 
al. 2002; Cochran et al. 1998; Mueller et al. 2003). Unfortunately, with this 
nearly infinite range of possibilities for surface alteration, it remains unclear 
which factors constitute optimal conditions for osseointegration, despite many 
studies into the .area, as each study is almost invariably carried out under a
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different set of conditions with regard to both surface type and model system, 
making direct comparison difficult (Bagno and Di Bello 2004; Le Guehennec et 
al. 2007). It is therefore difficult to determine with certainty which roughened 
surface is the ‘ideally roughened’ surface, in terms of osteoblast interaction under 
either in vitro or in vivo conditions.
Within this study, three differently modified commercially available 
titanium surfaces representing a range of surface types were examined for their 
effects on the process of osteoblast like cell differentiation, adhesion and activity. 
A machined surface provided a relatively smooth and homogenous environment, 
while an alumina grit blasted and hydrofluoric acid etched surface provided a 
rougher heterogeneous one. The third surface was also grit blasted and acid 
etched, but was then coated with a layer of tri-calcium phosphate, providing a 
surface with possible bioactivity. Due to the difficulties presented by the wide 
range of possible surface modifications and the subsequent difficulty comparing 
surface properties and drawing conclusions over their impact on the process of 
osseointegration, it is clearly important that these surfaces be thoroughly 
analyzed in terms of their surface topography, surface chemistry and 
hydrophobicity. This will enable correlations to be drawn between surface 
characteristics and the impact these have in both in vitro and in vivo models of 
osseointegration. In addition, bone marrow stromal cells extracted from rat 
femurs will be cultured on the surface to demonstrate that all surfaces are capable 
of supporting progenitor cells attachment.
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2.2 Materials and Methods
2.2.1Manufacture and Surface Treatment of Titanium Discs
Titanium discs were prepared and supplied by Osteo-Ti (Guernsey). A 
brief description of their preparation was provided by the company, although a 
more detailed description was unavailable. The discs with a diameter of 1.5 cm 
were manufactured from grade 5 titanium bar stock (Titanium International Ltd, 
Birmingham, UK) by a combined lathe and mill machine (Star CNC Machine 
Tool Corp., New York, USA ) in a one step process using Vasomill 10 vegetable 
based metal working oil (Blaser Swisslube, Switzerland). All discs were cleaned 
and passivated in 17.5% nitric acid. Machined surfaces were then polished. Both 
the surfaces to be grit blasted/acid etched and TCP coated surfaces were blasted 
with alumina grit and then etched in 2% hydrofluoric acid and 17.5% nitric acid 
for 30 seconds. TCP coated surfaces were then thermally coated with a TCP 
coating 75-100pm thick. All discs were UV treated for the purposes of 
sterilisation.
The titanium discs were delivered in two separate batches over the course 
of this project. Therefore both the first and second batches were both investigated 
and characterised in terms of their surface characteristics. As some differences 
were found between the two sets of discs, particularly in terms of their surface 
topography, it is important to note that the first batch of discs were used for the 
work presented in this chapter, while the work in all following chapters of this 
thesis was carried out using discs from the second batch.
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2.2.2 Characterisation of Titanium Surfaces
2.2.2.1 Scanning Electron Microscopy (SEM)
Samples were mounted on stubs using double sided adhesive tape before 
being sputter coated with a thin 7-10nm layer of gold using an EMScope SC 
5000 Sputter Coater (Thermo Electron Company, Berkshire, UK). Subsequently, 
images were captured using an EBT1 scanning electron microscope (SEMTech 
Ltd, Derbyshire, UK). All images were taken from random sites on each sample 
in order to visualize the general topographical features of each titanium surface.
2.2.2.2 Profilometrv
The surface roughness of the three titanium surfaces was measured using 
a Precision Talysurf C LI 2000 profilometer (Taylor Hobson, Leicester, UK) 
running in contact mode. To measure the topography of a surface, the Talysurf 
passes a diamond edged stylus with a diameter of 2pm over a designated sample 
area on a surface. As it passes over the topographical features of a surface, the 
stylus is displaced and moves up or down. This movement creates a series of 
traces, from which the average roughness, or Ra, of the surface was calculated by 
the Talymap software package (Taylor Hobson). Ra is defined as the arithmetic 
mean deviation from a line representing a totally flat surface plane. The Talysurf 
is capable of measuring very small head displacements, with resolutions of up to 
0.1pm possible.
The sample area was designated as a 2mm by 2mm square section of each 
disc, which the stylus passed over 1001 times, at a velocity of 14mm/min, with a 
distance of 2pm between each pass. These individual traces were compiled and 
the average deviation in microns from a zero point was calculated as the Ra 
value. A three dimensional image of the sample area was generated by the
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Talymap software package based on a compilation of all 1001 traces. All 
samples were run in triplicate, with Ra values averaged and the standard error of 
the mean calculated using Minitab statistical software (Minitab Inc., Coventry, 
UK).
2.223  X-Rav-Photoelectron Spectroscopy (XPS)
In order to analyse the specific elemental composition of the titanium 
surfaces X-Ray Photoelectron Spectroscopy (XPS) was used. XPS works on the 
principle that electrons in the atoms of different elements have different binding 
energies and therefore, when excited by bombardment with X-rays, are released 
with varying levels of kinetic energy, depending on which type of atom they are 
contained in. In order to detect the elemental composition of a given sample, the 
surface is bombarded with x-rays of a known intensity, causing electrons to be 
freed from the atoms present on the surface of the sample. The number and 
kinetic energy of the electrons released from the surface are measured, which 
produces a series of peaks used to determine which elements are present in the 
first lOnm of the surface and in what relative quantity, with accuracy possible 
into the parts per thousand range. XPS is capable of detecting elements with an 
atomic number 3 or greater.
Titanium discs were mounted using double sided adhesive tape and 
scanned using a Kratos Axis Ultra DLD Spectrometer (Kratos Analytical Ltd, 
Manchester, UK) which has a monochromatic A1K« X-Ray source (75-150W). 
Survey XPS scans, which give a broad view of the elements present on a surface, 
were acquired at an analyser pass energy of 160eV, while more detailed scans 
were made with an analyser pass energy of 40eV.
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2.2.2.4 Contact Angle Analysis
The hydrophobicity of each titanium surface was analysed using dynamic 
contact angle analysis. To generate the dynamic contract angle, a sample is 
submerged and withdrawn in liquid, commonly water, by a force transducer at a 
constant speed. By measuring the force on the transducer during both submersion 
and withdrawal from the liquid, a buoyancy graph can be plotted, from which the 
surface tension forces active on the sample surface can be calculated. These 
forces can be used to determine the spread, or contact angle, of water on the 
surface. The contact angle is indicative of the degree of surface wetability and 
therefore the relative hydrophobicity of a surface. If a surface is highly 
hydrophilic, water will spread widely on the surface, resulting in low contact 
angle of less than 90°. Conversely, a contact angle of between 90° and 180° 
indicates a hydrophobic surface, as the spread of water is much reduced.
To measure the contact angle of each titanium surface, a Dynamic 
Contact Angle Analyzer 312 (Cahn Instruments Inc., Thermo Electron 
Corporation) was used. Each disc was suspended at the same distance above 
double distilled water, at room temperature, before being submerged and 
withdrawn at a rate of 30pm/s. A buoyancy graph based on the force applied to 
the disc at each position during submersion and withdrawal was generated by 
Cahn Application Software (Thermo Electron Corporation). The advancing 
contact angle was calculated using the least squares analysis provided in the 
software package. Six discs of each surface were examined, with the contact 
angles averaged and standard error of the mean calculated using Minitab 
statistical software (Minitab Inc).
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2.2.2.5 Stability of TCP Coated Surfaces
In order to investigate if immersion during culture of cells causes the dissolution 
of the TCP coating, discs were placed into mineralising media and left at 37°C, 
5% CO2 for a period of 1, 2 and 5 days. Profilometry was used to measure the Ra 
values of surfaces from all three time points as described in section 2.2.2.2, while 
XPS broad spectrum analysis was carried out as described in section 2.2.2.3 on 
surfaces from the 5 day time point. Triplicate specimens were used in all 
experiments. Significance between Ra values from soaked TCP coated surfaces 
and un-soaked TCP coated surfaces was determined using Student’s T test. P 
values below .05 at a 95% confidence interval were held to be statistically 
significant.
2.2.3 Morphological Characterisation of Adherent Bone Marrow Stromal 
Cells on Titanium Surfaces
As a proof of principal that bone marrow stromal cells could be 
successfully cultured and differentiated on all three experimental titanium 
surfaces, BMSCs were isolated and cultured on each surface. Growth media was 
supplemented such that BMSCs would differentiate down the osteoblast lineage.
2.2.3.1 BMSC Isolation and Culture
BMSCs were isolated from the femurs of 28 day old male Wistar rats. Rats 
were sacrificed via CO2 asphyxiation and dipped in 70% ethanol to sterilize 
the outer skin. Femurs were then dissected from the rats and placed into lOx 
antibiotic media, consisting of a-MEM (Gibco, Invitrogen, Paisley, UK) 
supplemented with 10% v/v penicillin/streptomycin (Sigma-Aldrich, Dorset, 
UK). In a sterile environment, the both ends of the femur were removed and
the bone marrow flushed out into a 50ml falcon tube using 15ml of culture
/
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media for each femur. Culture media consisted of a-MEM (Gibco) 
supplemented with 10% foetal calf serum (FCS) (Sigma-Aldrich), 1% 
penicillin/streptomycin (Sigma-Aldrich), 1% 10‘8M Dexamethasone (Sigma- 
Aldrich), 1% lOmM p-Glycerophosphate (Sigma-Aldrich), and 1% 50ug/ml 
Ascorbic acid (Sigma-Aldrich). After centrifugation at 1000 RPM for 5 mins, 
the pellet was dispersed into 500pls of collagenase/dispase (Sigma-Aldrich) 
and incubated for 20 mins at 37°C. Following incubation, 5ml of culture 
media was added to the tube and it was centrifuged at lOOOg for 5 mins, and 
the supernatant decanted. The pellet was then resuspended in 10ml of alpha 
MEM and passed through a 40pm filter (Falcon) to generate a single cell 
suspension. Cells were counted using a hematocytometer. Cell concentration 
was adjusted to 36x105 cells/ml by the addition of culture media, and 50pl 
droplets were seeded onto titanium discs in 24 well plates, resulting in a 
seeding density of 1x10s cells/cm2. The plate was then incubated at 37°C and 
5% CO2 for 2 hrs before the wells were filled with 2ml of culture media. 
BMSCs were cultured for 7 days prior to fixation and visualisation, with 
media changes every two days.
2.2.3.2 SEM Imaging of BMSCs
In order to view cell morphology on the three titanium surfaces, cells were 
visualised using scanning electron microscopy. Following 7 days of culture, discs 
containing BMSCs were placed in a fresh 24 well plate, washed once with tris- 
buffered solution (TBS) and fixed for 1 hr with a 2% paraformaldehyde (Sigma- 
Aldrich) solution. The discs were air dried for 24 hrs before being prepared for 
SEM and visualised in the same manner as for the titanium surfaces, described 
previously in section 2.2.2.1.
61
2.2.3.3 Fluorescent Imaging of BMSC
In order to visualize the actin cytoskeleton and vinculin focal adhesion sites of 
the BMSCs cultured on the titanium surfaces, phalloidin-FITC and anti-vinculin 
antibodies, visualised with a Texas Red conjugated secondary antibody were 
used. Following 7 days of culture, titanium discs were placed in a fresh 24 well 
plate, washed once for 5 mins with TBS and fixed as described above in section 
2.2.3.2. Cells were permeabilized with a 0.3% Triton-X 100 (Sigma-Aldrich) 
solution for 15 mins, washed in TBS and blocked with 1% bovine serum albumin 
(BSA) (Sigma-Aldrich) for 30 mins at room temperature. Cells were then stained 
with a 1 pg/ml Phalloidin-FITC (Sigma-Aldrich) solution diluted 1:16 with TBS 
for 1 hr at 4°C, washed three times in TBS for 5 mins each time prior to addition 
of a goat anti-rat IgG vinculin antibody (Sigma-Aldrich), diluted 1:50 in TBS 
and 1% BSA, for 1 hr. For two separate negative controls, one disc was 
incubated for an hr 1% BSA with the primary antibody excluded, while another 
was incubated with a non immunogenic isotype IgG (Sigma-Aldrich) substituted 
for the primary antibody. After a 3x 5 mins washes in TBS, a solution containing 
both bisbenzaminde (Sigma-Aldrich) diluted 1:100 in TBS as a nuclear counter 
stain and an anti-goat IgG-Texas Red conjugated secondary antibody (Sigma- 
Aldrich) diluted 1:100 in TBS and 1% BSA was added for 1 hr. Finally after a 
series of 3x 5 mins washes, the discs were removed from their wells, mounted 
with cover-slips on glass slides using Fluorosave mounting media (Calbiochem, 
San Diego, USA) and visualized using a Zeiss Axiovert 200M microscope with a 
mercury lamp.
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2.3 Results
2.3.1 SEM of Titanium Surfaces
Figure 2.1a showed the relatively smooth topography of the machined 
surface, albeit with machining lines visible. In Figure 2.1b, the grit blasted/acid 
etched surface was shown to have a much rougher topography, with visible 
‘impact craters’ and debris from the alumina grit. The visible peaks resulting 
from the grit blasting had relatively smooth faces from the acid etching, yet still 
rose to form fairly jagged points. In contrast, the TCP coated surface, shown in 
Figure 2.1c, showed a series of raised rounded protrusions, due to the TCP 
coating, which appeared to totally cover the titanium surface.
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Figure 2.1: Typical images obtained by SEM of a titanium surfaces (a) machined, (b) 
grit blasted and acid etched, and (c) TCP coated.
2.3.2 Characterisation of Surface Roughness by Profilometrv
The three dimensional image of the machined surface produced following 
profilometry, shown in Figure 2.2a, showed a largely smooth topography, 
although machining lines formed depressed regions, causing some variation in 
the topography. In the centre of each machined disc, there was one raised peak, 
located in the centre of each disc as a consequence of the machining process. 
With a replicated average Ra value of only .09pm (Table 2.1), the machined 
surface possessed a relatively smooth surface. The second batch of titanium discs 
had a replicated average Ra of .26pm (Table 2.1), which although higher than the 
first batch average, is still relatively smooth. In terms of topographical 
appearance, both batches were similar.
In contrast, the three dimensional image showed that the grit blasted/acid 
etched surface, shown in Figure 2.2b, was significantly rougher, with a series of 
‘peaks’ and ‘valleys’ distributed over the sample area. These appeared to be 
random in their distribution, as they were created by the impact of alumna grit 
particles and the action of hydrofluoric acid across the titanium surface. A 
replicated average Ra of 1.51pm (Table 2.1) denotes this surface as being much 
rougher than the machined surface. In the second batch of grit blasted/acid 
etched discs, a replicated average Ra of 2.71pm (Table 2.1) was observed. This is 
substantially rougher than the first batch of discs, despite having a similar 
topographical appearance to the surfaces in the first batch.
Finally, the three dimensional image of the TCP coated surface in Figure 
2.2c showed a roughened surface with higher and more densely packed ‘peaks’ 
than the grit blasted/acid etched surface. Deeper ‘valleys’, compared to the grit 
blasted/acid etched surface were also evident from the compiled and single 
traces. The rounded protrusions visible in the SEM of the TCP coated surface 
were not as evident from the three dimensional image from profilometry, 
possibly due to the probe recording them as sharper peaks. TCP coating resulted
64
in the roughest of the three surfaces with a replicated average Ra of 2.09pm 
(Table 2.1) for the first batch. The second batch of TCP coated surfaces was 
found to be substantially rougher with a replicated average Ra of 6.08pm (Table 
2.1), although their overall topographical appearance was similar to that of the 
first batch, albeit with relatively deeper ‘valleys’ and higher ‘peaks.’
There were some differences observed in the second batch of discs in 
terms of the surface roughness values. While the machined surfaces from both 
batches had similar Ra values, the roughness values for the grit blast/acid etched 
surface were, much lower than in the first batch, while the TCP coated surfaces 
were seen to be much rougher than those in the first batch. In a similar sequence 
to the first batch of titanium discs, the machined was the smoothest surface, 
followed by the grit blasted/acid etched surface and finally the TCP coated 
surface was by far the roughest.
Soaking TCP coated surfaces from the second batch of discs in 
mineralizing culture media did not reveal any significant changes in the Ra 
values observed over time (Table 2.2). P Values resulting from Students T test 
comparison between soaked and un-soaked Ra values were as follows: 1 day: 
p=0.40, 2 day: p= 0.26, and 5 day: p= 0.14.
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Figure 2.2(a)
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Figure 2.2: Typical examples of the 3 dimensional images (upper box) and traces 
(lower box) of the machined (a), grit blast/acid etched (b) and TCP coated (c) surfaces 
generated by the Talysurf. In the traces, the grey area is composed of 1001 individual 
traces made over the sample area of 2mm by 2mm. Each trace has a space of 2pm in 
between them, due to the diameter of the stylus head. After all 1001 traces are 
compiled, a mean line is drawn (shown at 0 on the y axis) and the arithmetic mean of 
the deviations from this line are calculated, indicated by the blue line, giving a value for 
average roughness, or Ra.
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Figure 2.2(c)
2.0001 mm
Profile # 1 1 1001 Pt = 84.843 trm Scale = 200 pm
Surface Average Roughness 
(Ra) Batch 1
Average Roughness 
(Ra) Batch 2
Machined
(n=3)
0.09pm SD+/-0.02 0.26pm SD+/- 0.05
Alumina Grit Blasted, 
HF Acid Etched 
(n=3)
1.51pm SD+/-0.17 2.71pm SD+/- 0.24
Alumina Grit Blasted, 
Acid Etched, Tri- 
Calcium Phosphate 
(TCP) Coated
(n=3)
2.09pm SD+/-0.14 6.08pm SD+/- .64
Table 2.1: Average roughness values from all three surfaces in both batches of 
discs supplied.
Surface Average Average Average
Roughness Roughness Roughness
(Ra) 1 Day (R*) 2 Day (Ra) 5 Day
Alumina Grit 6.22pm SD+/-.1 6.05pm SD+/-.06 6.32pm SD+/-.2
Blasted, Acid
Etched, Tri-Calcium
Phosphate (TCP)
Coated and Soaked
(n=3)
Table 2.2: Profilometry data showing Ra values for 2nd batch TCP coated surfaces 
soaked in mineralizing culture media for 1,2 and 5 days.
2.3.3 Surface Chemical Analysis of Titanium Surfaces
2.3.3.1 Broad Spectrum X-Ray Photoelectron Spectroscopy (XPS)
Broad spectrum XPS scans for the machined surface shown in Figure 
2.3(a) had substantial peaks for both oxygen and titanium, which indicated the 
presence of a titanium oxide layer. A nitrogen peak was also present, which was 
probably the result of residual nitrogen from the passivation process. Carbon was 
also shown to be present in relatively high levels, probably due to carbon 
contamination of the surface. There were also a number of other elements present 
in trace amounts: Al, Pb, P, Ca, Zn, Na, and Mg, as shown in Table 2.3.
XPS data for the grit blasted/acid etched surface, shown in Figure 2.3(b) 
again showed substantial peaks for titanium and oxygen, which suggested the 
presence of a titanium oxide layer on the surface. Residual amounts of fluoride 
and aluminium were shown to be present as the result of the alumna grit blasting 
and hydrofluoric acid etching process. Carbon contamination was again seen at 
the surface, resulting in a substantial carbon peak. There were also several other 
trace elements present on the surface, but comprised a less diverse list that of the 
machined surface, specifically Na, Zn, and P, as shown in Table 2.3.
The broad spectrum scans of the TCP coated surface, shown in Figure 
2.3(c) showed no titanium peak, indicating that the titanium surface had been 
totally covered by the TCP coating. A large oxygen peak was present however, 
which may indicate an oxide layer on the TCP. As would be expected, calcium 
and phosphorous from the TCP coating were present on the surface. Carbon 
contamination was also seen, although it was less prevalent compared to the 
other two surfaces. Although there were some contaminants on the surface, 
namely Si and N, these are much fewer in number than on the other two surface 
types (Table 2.3).
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The XPS analysis of the second batch of discs showed that they had 
relatively similar surface chemistry to those of the first batch, with similar 
proportions of the main elements seen between both batches. There were, 
however, some differences in the trace elements present on the surfaces between 
the two batches.
Soaking TCP coated discs from the second batch in mineralizing culture 
media for 5 days did not reveal any substantial changes in the surface chemistry 
of the discs (Figure 2.5), with the only difference being the absence of trace 
amounts of N and Na from the soaked surfaces (Table 2.4). It does not therefore 
appear that the TCP coating was dissolved by soaking in culture media.
2.3.3.2 Narrow Spectrum XPS
In order to more closely examine the presence of fluoride, nitrogen and 
phosphorous, elements known to contribute to the bioactivity of a surface, 
narrow spectrum analyses were produced. The narrow spectrum scans shown for 
all surfaces in Figure 2.4, fluoride appeared to be present in the greatest amount 
on the girt blasted and acid etched surfaces, while nitrogen was only present in 
large amounts on the machined surfaces. Phosphorous was highly variable 
between replicates, with a large amount appearing on the TCP coated surfaces, 
but definite peaks were seen on the machined surfaces as well.
Narrow spectrum XPS revealed similar proportions of nitrogen, fluoride 
and phosphorous between the first and second batches of discs.
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Figure 2.3: Typical examples of the broad survey XPS traces obtained from 
Machined (a), Grit blasted/Acid Etched (b), and TCP coated surfaces (c). Peaks 
showing the electron counts on the y axis determine the relative proportion of 
electrons released, while their location on the X axis shows the binding energy of the 
electrons, which determines the element the peak represents. In the comer of each 
trace, a table gives the species, X-axis position, the full width at half maximum 
(FWHM) of each peak, the area of each peak and the percentage of the total electrons 
detected for each element. All experiments were performed in triplicate.
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Figure 2.4: Typical examples of the narrow spectrum scans for each surface for 
Fluoride (top), Nitrogen (middle) and Phosphorous (bottom). In all traces, and A2 
designate duplicate machined surfaces, B, and B2 grit blasted and acid etched surfaces 
and C, and C2 TCP coated surfaces.
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Figure 2.4
Surface Elements Present at 
Surface, Batch 1
Elements Present at 
Surface, Batch 2
Machined
(n=3)
Main: Ti, O, C
Trace: Al, Pb, P, Ca, 
Zn, Na, Mg, N
Main: Ti, O, C 
Trace: P, S, Ca, N
Alumina Grit Blasted, 
HF Acid Etched 
(n=3)
Main: Ti, O, C 
Trace: F, Na, Zn, Al, P
Main: Ti, O, C 
Trace: F, Al, P, N, Ca
Alumina Grit Blasted, 
Acid Etched, Tri- 
Calcium Phosphate 
(TCP) Coated 
(n=3)
Main: O, C, Ca, P 
Trace: Si, N
Main: 0, C, Ca, P 
Trace: Si, Na, N
Table 23: Elements found by XPS on all three surfaces for the two batches 
supplied. The distinction between trace or main elements is a subjective one, 
with the categorisation arrived at on the examination of the relative proportions 
present on each surface.
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Figure 2.5: A broad spectrum XPS trace from 2nd batch TCP surfaces soaked in 
mineralizing culture media for 5 days. Surface chemistry was only different in the 
absence of N and Na on the soaked surfaces. Ti is still not present on the surface and 
relatively high levels of Ca and P are seen. This suggests that immersion in media does 
not cause dissolution of the TCP coating.
Surface Elements Present at Surface
Alumina Grit Blasted, Acid 
Etched, Tri-Calcium Phosphate 
(TCP) Coated, Soaked for 5 Days 
(n=3)
Main: O, C, Ca, P 
Trace: Si
Table 2.4: Elements found on the surface of TCP coated discs after 
soaking for 5 days in culture media.
2.3.4 Hvdrophobicitv of Titanium Surfaces
The average values obtained following contact angle analysis are 
presented in Table 2.5. There were only relatively small differences between the 
advancing contact angles of the three surfaces, and all were under 90°, indicating 
that all three surfaces were hydrophilic, with the grit blasted/acid etched surface 
being the least hydrophilic and the TCP coated the most hydrophilic.
Hydrophobicity analysis showed similar contact angles between the first 
and second batches of discs (Table 2.5).
/
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Surface Average Advancing 
Contact Angle 
Batch 1
Average Advancing 
Contact Angle 
Batch 2
Machined
(n=6) 82.87°+/-1.62 80.32°+/-2.10
Alumina Grit Blasted, 
HF Acid Etched
(n=6)
87.17°+/-.308 86.3 °+/-.276
Alumina Grit Blasted, 
Acid Etched, Tri- 
Calcium Phosphate 
(TCP) Coated 
(n=6)
77.17°+/-.975 74.64 °+/-i .36
Table 2.5: Replicated average value s for the advancing contact angles of the 
three surfaces for the two batches supplied. Values are plus or minus the 
standard deviation.
2.3.5 Culture of Bone Marrow Stromal Cells (BMSCs) on Surfaces
To establish the potential for the cell adherence and differentiation of the 
three experimental surfaces, BMSCs were isolated and grown on the surfaces. 
Their morphology and distribution were analyzed using both SEM and 
fluorescent imaging.
2.3.5.1 SEM Imaging of BMSCs
When examined using SEM, cells were found to be attached to all three 
surfaces. On the machined surface, shown in Figure 2.6a, cells showed a rounded 
morphology. Images from the grit blasted/acid etched surface in Figure 2.6b 
show cells with a more elongated morphology. Cells attached to the TCP coated 
surface, shown in Figure 2.6c, were widely spread across the surface and were 
fewer in number than on the other two surfaces. The morphology of cells on the 
TCP and grit blasted/acid etched surfaces resembled each other more than those 
seen on the machined surface.
/
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Figure 2.6a
HT=20Kv, W D =6.1, MAG=1389
Figure 2.6: SEMs of BMSCs grown on the machined (a), grit blasted and 
acid etched (b), and TCP coated (c) surfaces. Cells are indicated by arrows.
Figure 2.6b
Figure 2.6c
2.3.5.2 Visualisation of the BMSC Cvtoskeleton and Focal Adhesion Points
Adherent cells were found on both the machined and grit blasted/acid 
etched surfaces. Some differences in terms of the cytoskeletal arrangement and 
the distribution of focal adhesion sites were observed between cells grown on 
each surface. On the machined surface, shown in Figure 2.7a, cells were 
relatively large with a rounded morphology and had a well developed 
cytoskeleton, with a number of focal adhesion sites located at the end of 
cytoskeletal projections. These cells also tended to be spread out widely across 
the surface. In contrast, cells grown on the grit blasted/acid etched surface, seen 
in Figure 2.7b, showed a more compact, elongated morphology and had a 
number of densely packed focal adhesion sites closely associated with the cell 
bodies, demonstrated by the intense red staining seen in this area. They were 
observed to be generally more densely packed than cells grown on the machined 
surface. All isotype and vinculin primary antibody excluded negative controls 
showed minimal immuno-staining, indicating that the staining observed was 
specific for vinculin focal adhesion points. Unfortunately, auto-fluorescence 
from the TCP coating prevented the fluorescent imaging of cells adherent on the 
TCP coated surface.
/
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Figure 2.7a
m m
Figure 2.7: Images of rat BMSCs grown on the three different titanium surfaces. In 
the fluorescent images from the machined (a) and grit blasted and acid etched surface 
(b), the actin cytoskeleton is stained green, with the nuclei stained blue and the focal 
adhesion sites stained red. Below each image are the negative controls with the isotype 
control on the left and the primary antibody excluded on the right.
Figure 2.7b
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2.4 Discussion
This chapter has been successful in providing a full characterisation of 
the three experimental surfaces, in terms of their topography and physiochemical 
properties. Furthermore, the studies presented have established that all of the 
surfaces are capable of supporting BSMC adhesion. The differences seen in the 
properties of all three surfaces have been shown to have some influence on the 
pattern of adhesion and morphology of attached BMSCs.
All of the experimental surfaces were shown to be hydrophilic. 
Hydrophilicity has been widely reported to be important for implant surfaces in 
terms of their ability to absorb plasma proteins during the initial formation of the 
fibrin clot and therefore for the initial adhesion and differentiation of osteoblast 
progenitor cells (Buser et al. 2004; Schwarz et al. 2009; Tsukimura et al. 2008; 
Zhao et al. 2005) Alterations to a titanium surface, for example roughening by 
grit blasting/acid etching, is known to increase surface hydrophobicity by 
enhancing the potential for carbon contamination (Rupp et al. 2006; Zhao et al. 
2005). This is because roughening a titanium surface generally leads to a thicker 
hydrophilic titanium oxide layer, which has a high surface energy, thus forming a 
favourable environment for the attachment of atmospheric carbon compounds 
(Rupp et al. 2006; Schwarz et al. 2009; Zhao et al. 2005). As these compounds 
accumulate, they decrease the overall surface energy and hydrophilicity of the 
surface (Rupp et al. 2006; Zhao et al. 2005). Within the present study, it was 
found that both the machined surface and the Grit blasted/acid etched surface 
have similar average contact angle values and also similar levels of carbon 
contamination. This may be the reason why these surfaces were found to be less 
hydrophilic, with an average advancing contact angle closer to 90°. The TCP 
coated surface had the lowest levels of carbon contamination, which may explain 
its relative hydrophilicity.
The full impact of hydrophilicity on the osseointegrative potential of each 
of these surfaces in an in vivo situation cannot be assessed here on the basis of
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the work contained in this chapter. Upon referring to the literature, however, it is 
widely held that hydrophilic surfaces are more desirable than hydrophobic ones 
(Buser et al. 2004; Schwarz et al. 2009; Zhao et al. 2005). There are however, 
implications for the surface hydrophobicity in terms of the cell seeding technique 
used in the in vitro model of BMSC attachment described. Cells were seeded in 
droplets, and the more hydrophobic the surface, the less these droplets tended to 
spread over the surface. This means that with increasing hydrophobicity, the 
initial distribution of BMSCs across the surface increased in density, which may 
affect the initial adhesion and distribution of cells, as BMSC activity and growth 
kinetics have been shown to be influenced by the initial seeding density (Kamalia 
et al. 1992). When droplets were placed on the TCP coated surface, it was 
apparent that the droplets spread significantly more than on the other two 
surfaces, resulting in a lower initial clustering of cells on the surface, which may 
be a factor in the relatively low density of cells observed on the surface after one 
week in culture. The hydrophilicity of each surface may therefore have an impact 
on the performance of the in vitro model used here.
The elemental composition of titanium surfaces is widely thought to 
influence both the behaviour of osteoblast progenitor cells and the 
osseointegration of titanium implants (Buser et al. 2004; Le Guehennec et al. 
2007; Tsukimura et al. 2008; Zhao et al. 2005). Specifically, one of the most 
important aspects of the surface chemistry is the titanium oxide layer, which 
occurs spontaneously in atmospheric conditions and has been shown to have 
significant biological activity both in vitro and in vivo (Buser et al. 2004; 
Tsukimura et al. 2008; Zhao et al. 2005). The thickness of this layer can be 
increased or decreased by various surface treatments and, as noted previously, is 
a major reason for the carbon contamination seen in the chemical analysis of the 
surfaces (Buser et al. 2004; Le Guehennec et al. 2007; Tsukimura et al. 2008; 
Zhao et al. 2005). From the broad spectrum XPS scans, it is clear that specific 
components of the oxide layer observed on the three experimental surfaces 
varied depending on the surface modification. On both the machined and grit 
blasted/acid etched surfaces, the presence of a titanium oxide layer was detected. 
There are, however, possible differences in the specific composition of these
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oxide layers, for example the oxide layer on the machined surface was shown to 
contain nitrogen from the passivation process. Fluoride, present on the grit 
blasted/acid etched surface, has been shown to affect osteoblast function 
(Waddington and Langley 1998, 2003), and it has been reported that alumina, 
also found: on this surface as a by-product of grit blasting, may do the same 
(Bellows et al. 1999; Le Guehennec et al. 2007; Malluche 2002). These elements 
along with the other surface contaminants observed, could alter the specific 
properties of the oxide layers. In contrast, there is no titanium oxide layer on the 
TCP surface as the titanium is completely covered by TCP. Therefore, the oxide 
layer seen on this surface was probably largely comprised of calcium or 
phosphorous. This difference in the composition of the reactive oxide layer may 
explain the reduced carbon contamination and thereby influences the relative 
hydrophilicity of this surface. Alterations in the composition and properties of 
the reactive oxide layer is likely to have implications for BMSCs grown on each 
surface and may be responsible for some of the differences in cell morphology 
and distribution observed between cells grown on the three experimental surfaces 
(Arys et al. 1998; Sittig et al. 1999; Zhao et al. 2005). It is also of note that 
profilometry and XPS results indicate that the TCP layer was stable under the 
culture conditions used, and did not dissolve off during the culture of adherent 
BMSCs.
In addition to altering the composition of the reactive oxide layer, grit 
blasting and acid etching and TCP coating were shown to decrease the overall 
number of surface contaminants compared to the machined surface. 
Contaminants found on surfaces in the current study, for example Zn, Pb, Na, 
and Si are relatively common contaminants in titanium implants, due to the 
reactive nature of titanium^ and may have a negative influence on cell-surface 
interaction and the process of osseointegration (Arys et al. 1998; Sittig et al. 
1999; Zhao et al. 2005). The decrease in the number of surface contaminants 
observed may be due to the ablation of the titanium surface, which may serve to 
remove some of these elements and is therefore a possible beneficial effect of 
roughening or coating implant surfaces.
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Each of the treatments produced a titanium surface which had a distinct 
topography, both in terms of the average roughness and general appearance. All 
surfaces had an average roughness value of less than 10 pm and are therefore 
classified as micro rough surfaces (Bagno and Di Bello 2004; Le Guehennec et 
al. 2007). The machined surface had a surface roughness which is comparable to 
other surfaces in the literature which are considered to be ‘smooth’ (Bagno and 
Di Bello 2004; Le Guehennec et al. 2007) while the grit blasted/acid etched 
surface and TCP coated surfaces had roughness profiles which are similar to 
many other blasted and etched surfaces, although are notably much lower than 
those of typical plasma sprayed surfaces (Bagno and Di Bello 2004; Le 
Guehennec et al. 2007). It has been suggested that surfaces with an average 
roughness of greater than 2pm are outside the range of optimal roughness (Le 
Guehennec et al. 2007) and only the TCP coated surface approaches this value in 
the first batch. The second batch surfaces, aside from the machined surface, 
tended to be rougher, particularly the TCP coated surface. It is a possibility that 
such high Ra values may have a deleterious effect on BMSC attachment and 
differentiation.
Generally, the 3D traces produced by profilometry reproduced with great 
fidelity the images obtained by SEM. A notable exception was the TCP coated 
surface. In the SEM, the TCP surface was shown to have much more rounded 
projections, while the image produced by profilometry shows much sharper 
peaks. This may be due to the fact that the profilometer probe is displaced 
sharply as it moves over a rounded surface and records it as a peak instead. The 
Ra values generated should not have been unduly affected however, as the probe 
would still have accurately recorded the height of the projections and the depths 
of the ‘valleys’ in between them. It is possible that the general profile of the 
roughened topography, i.e. sharp peaks as seen in the grit blasted/acid etched 
surface as opposed to rounded projections as seen in the TCP coated surface 
affect Cell behaviour in addition to the average roughness of the surface.
An important proof of concept for this work was to actually grow BMSCs 
on each surface in order to investigate any obvious cellular differences which
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might be brought on by alterations in surface conditions. Cells were shown to be 
capable of adhering to and differentiating on all of the surfaces. On the relatively 
flat machined surface, there was space available for cells to spread out, resulting 
in a flattened morphology and more widely distributed focal adhesion points. In 
contrast, on the rougher grit blasted/acid etched surface, the cells adhered onto 
irregular ‘peaks’, resulting in focal adhesion points which clustered around the 
cell body and adopted a more elongated appearance. There was also a tendency 
for cells to populate ‘valleys’ formed by the process of grit blasting/acid etching, 
resulting in a more tightly packed appearance across the surface. The low 
number and sparse distribution of cells seen in each field of view on the TCP 
coated surface may be due to its high roughness reducing cell adherence, or its 
higher hydrophilicity leading to a greater spreading of the cells during seeding. 
Some cells did adhere to the surface however, and the similarity of morphology 
compared to the cells observed on the grit blasted/acid etched surfaces indicates 
that this particular elongated shape may be the result of rougher topography.
In summary, all of the surface treatments produced surfaces with unique 
physiochemical properties. It has also been demonstrated that all surfaces support 
the attachment and viability of BMSCs, and each surface appears to influence 
cell morphology and distribution. The relative contribution of surface 
hydrophobicity, chemistry and topography to any cellular differences is unclear 
from the data presented within this chapter, although it is well supported by the 
literature that all three factors act in concert, forming a complex and dynamic 
environment for cell-surface interaction. Each facet of the surface environments 
characterised in this chapter no doubt has a bearing on the attachment, metabolic 
activity and behaviour of BMSCs grown on them, and also influences implant 
performance in an in vivo situation.
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Chapter 3: The Effects of Modified Titanium Surfaces on Bone
Marrow Stromal Cell Behaviour
3.1 Introduction
One of the most important aims of the modification of titanium dental 
implant surfaces is to increase the attachment, proliferation and osteoid matrix 
production of osteoblast progenitor cells around the implant site, promoting rapid 
healing and enhancing the process of osseointegration (Bagno and Di Bello 2004; 
Ellingsen et al. 2006; Le Guehennec et al. 2007). Dental implants which accomplish 
more rapid and complete bone healing and osseointegration, allowing ‘one step’ 
implants for example, would be advantageous clinically by decreasing ‘chair time’, 
thus decreasing the cost of placement. Rapid bone healing around the implant would 
also reduce the chances of infection and thus peri-implantitis, further improving 
patient outcomes (Davies 2003; Le Guehennec et al. 2007; Zhao et al. 2005). There 
are a number of factors however, like the sheer number of effects modifying a 
surface has on its characteristics, which complicates the process of defining the 
optimal surface characteristics for osseointegration.
The process of osseointegration begins with the initial placement of the 
implant, which results in an immediate trauma around the site of implantation, 
leading to the formation of a fibrin clot. Crucially, the elements found in the fibrin 
clot, for example TGF-p, PDGF, fibronectin and indeed fibrin itself, facilitate the 
attachment and differentiation of a variety of cell types, including osteoblast 
progenitor cells, forming a cell rich granulation tissue around the implant site 
(Davies 2003; Haga et af 2008; Hughes et al. 2006; Jobs et al. 2006). This 
granulation tissue, under the influence of a wide variety of local and systemic 
signals, provides an environment conducive to the formation and multiplication of 
osteoblast-like cells, which in turn produce an osteoid matrix consisting of mainly 
type I collagen and diverse of non-collagenous proteins such as osteopontin, 
osteonectin, osteocalcin, and bone sialoprotein among others, which then undergoes 
mineralisation. As this newly formed bone is remodelled by the combined activity of
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osteoblast and osteoclast cells, the implant is ultimately surrounded by dense cortical 
bone attached to the implant surface and thereby being fully osseointegrated (Davies 
2003; Haga et al. 2008; Hughes et al. 2006; Joos et al. 2006). Both the topography 
and the surface chemistry of the titanium surface influence this process, in terms of 
initial surface interaction with the fibrin clot, attachment and differentiation of 
osteoblast progenitor cells, and the pattern of osteoid matrix deposition and 
mineralisation (Abrahamsson et al. 2004; Chung et al. 2008; Le Guehennec et al. 
2007; Shibli et al. 2007; Sul et al. 2006; Trisi et al. 2003; Zhao et al. 2005).
It has been widely reported that roughened surfaces with a thick oxide layer 
induce osteoblast differentiation and the subsequent production of osteoid matrix in 
vitro (Deligianni et al. 2001; Qu et al. 2007; Salido et al. 2007; Schneider et al. 2003; 
Tsukimura et al. 2008; Zhao et al. 2005) and enhance osseointegration in vivo (Buser 
et al. 2004; Cho and Park 2003; Cochran et al. 1998; Franchi et al. 2007; Schwarz et 
al. 2007; Sul et al. 2005; Sul et al. 2001; Wennerberg et al. 1998). In the initial phase 
of osseointegration, such surfaces are proposed to increase the absorption of plasma 
proteins during the initial formation of the fibrin clot (Deligianni et al. 2001; Park 
and Davies 2000). As the initial fibrin clot gives way to a cell-rich granulation tissue, 
surfaces with these particular characteristics may also enhance the differentiation of 
osteoblast progenitor cells into mature osteoblasts, leading to a greater number of 
osteoid producing cells and thereby enhancing the potential for osseointegration (Qu 
et al. 2007; Salido et al. 2007; Schneider et al. 2003). Roughened surfaces with a 
thick oxide layer have been reported to enhance the production of osteoid matrix 
proteins, influence the pattern of matrix deposition and enhance mineralised tissue 
apposition, resulting in a stronger anchorage for dental implants (Bemd et al. 2008; 
Buser et al. 2004; Cho and Park 2003; Le Guehennec et al. 2007; Qu et al. 2007). 
Calcium phosphate coatings, introduced onto implant surfaces as osteogenic agents, 
have also been reported to influence the process of osteoblast differentiation to 
varying degrees and have and also directly influence the topography and surface 
chemistry (Bigi et al. 2005; Daculsi et al. 2003; Lacefield 1999; Le Guehennec et al. 
2008; Montanaro et al. 2002).
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Despite the widely reported influences of roughened surfaces on the process 
of osseointegration, the exact mechanisms by which surface topography influences 
the behaviour of osteoblast cells remain to be elucidated, as does the optimal 
topography and surface chemistry for the osseointegrating dental implants. Although 
much of the literature clearly suggests that various characteristics of different 
titanium surfaces directly influence osteoblast progenitor cell behaviour, it is difficult 
to determine the relative importance of each surface characteristic’s influence over 
the process of osseointegration (Le Guehennec et al. 2007; Tsukimura et al. 2008; 
Zhao et al. 2005). It is unclear if a roughened implant surface with a thick oxide layer 
owes its greater osseointegrative potential, compared to a smoother surface, to the 
enhanced attachment of mesenchymal progenitor cells, increased differentiation of 
these cells into osteoblasts, altered osteoblast secretory activity, provision a better 
scaffold for the deposition of osteoid matrix and mineralisation or some combination 
of the above factors. The plethora of methods currently used to modify the chemistry 
and topography of titanium surfaces (Bagno and Di Bello 2004; Le Guehennec et al. 
2007), and the wide range of both in vitro and in vivo models which have been used 
to examine the effects of surface modification on the process of osseointegration 
(Bachle and Kohal 2004; Davies 1996; Joos et al. 2006) further complicate defining 
optimal conditions. A surface may be roughened by two different methods which 
could result in the surface having the same Ra value; the nature of the roughness 
achieved however may be different in terms the distribution of the resulting 
topography. For example, the features can be regularly or irregularly distributed 
across a surface, which would also have an impact on the surface chemistry (Bagno 
and Di Bello 2004; Zhao et al. 2005). Thus, beyond the roughness of a surface, the 
pattern of surface roughness may influence the process of osseointegration, rendering 
direct comparisons even more difficult as each surface will have unique, individual 
characteristics.
In order to investigate the osseointegrative potential of modified titanium 
surfaces, it is critical to characterise them in terms of their topography and surface 
chemistry characteristics before examining their effect on osteoblast cells, as has 
been done in the previous chapter. In this chapter, an in vitro rat model which utilises 
bone marrow stromal cells was used to investigate the effects of modified titanium
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surfaces on the adhesion of BMSCs and their expression of osteoid matrix markers at 
both the mRNA and protein level. Examination of these factors determined which 
aspects of osteoblast cell activity are influenced by titanium surface characteristics 
and how these affect the overall process of bone formation. Ultimately, this will 
provide information about the suitability of each surface for supporting osteoblast 
progenitor cells and thereby allow inferences to be made about the osseointegrative 
potential of each surface in an in vivo situation.
/
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3.2 Materials and Methods
3.2.1 Bone Marrow Stromal Cell (BMSC) Isolation and Culture on Titanium 
Surfaces
In order to assess the influence of titanium surfaces on osteoblast like cells, 
BMSCs were extracted from rat femurs and cultured on the experimental surfaces as 
described in Chapter 2. Studies were then performed to determine the initial survival 
of BMSCs on each of the surfaces in addition to their mRNA and protein expression 
profiles. It was the aim of these experiments to establish the ability of each 
experimental surface to support the initial adhesion, survival and bone matrix 
synthesis of osteoblast progenitor cells.
3.2.1.1 BMSC Isolation and Culture
Rat femurs were obtained as described in section 2.2.3.1 and washed in media 
prepared as described in section 2.2.3.1. Due to the low cell numbers obtained 
through the method described in this section, alterations in the method of cell 
isolation and culture were made to select for a higher proportion of BMSCs to seed 
onto each of the titanium surfaces. Cells were also seeded directly onto the bottom of 
plastic wells to serve as controls. Ends of 4 femurs were removed in a sterile 
environment and the bone marrow flushed out into a single T-75 tissue culture flask 
using 15mL of the mineralising culture media, prepared as described in section 
2.2.3.1. Cells were incubated at 37°C and 5% CO2, allowing the BMSCs to adhere to 
the bottom of the flask, while the non-adherent cells remained in suspension and 
were removed when the culture media was changed after 24 hrs. This served to 
create a BMSC rich cell population which could be used for further experiments. 
Culture media was changed every 2 days during the culture period. After 5 days in 
culture, adherent BMSCs were incubated with 5mL of Accutase (Sigma Aldrich) for 
5 mins at 37°C in order to detach them from the flask, centrifuged, counted and
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seeded onto surfaces, as described in section 2.4.3. Seeded cells cultured for 5, 7, 9 
and 12 days prior to experimental use.
3.2.2 Scanning Electron Microscopy (SEM)
Visualization of cells on the titanium discs was carried out at the 7 day post 
seeding time point. Cells were fixed in 2% paraformaldehyde and examined using 
SEM as described in section 2.2.3.2.
3.2.3 Analysis of BMSC Survival over Time by Direct Counting
In order to investigate the number of BMSCs remaining on the four different 
surfaces over time, cells were recovered from the discs and counted in order to 
determine the proportion of initially seeded cells remaining attached to the surfaces 
at 1 hr, 1, 3 and 5 days after seeding. To recover cells, the discs were removed from 
their culture wells at the appropriate time point and placed into a fresh 24 well plate 
and washed twice with PBS. Each disc was incubated in 500pi of Accutase (Sigma 
Aldrich) for 5 mins at 37°C. After incubation, 500pi of PBS was added to each well 
and the entire lmL was recovered by pipetting up and down several times. 
Recovered cells were then counted using a hematocytometer and expressed as a 
proportion of the total number of cells originally seeded (1.8xl05 cells per disc). Cell 
counts were performed in triplicate generated from three replicates of each 
experimental surface and the experiment was repeated once in its entirety.
3.2.4 BMSC mRNA Expression Profiles on Experimental Surfaces
In order to investigate the capability of each experimental surface to support 
the production of osteoid matrix by BMSCs, RT-PCR was carried out on RNA 
extracted from cells grown on each surface at 5, 7, and 12 days post seeding. 
Specifically the presence of mRNA from a range of bone and osteoblast cell markers 
was examined. The presence of chondrocyte and adipocyte specific mRNA was also
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investigated in order to investigate BMSC differentiation on each surface under 
mineralising conditions. This work was repeated in its entirety, meaning that there 
was an experimental replicate, using a single biological sample each time.
3.2.4.1 RNA Extraction
At 5, 7 and 12 days post-seeding, discs were recovered, placed in a fresh 24 
well plate and washed twice with PBS. Cells grown on plastic as controls were 
simply washed twice in PBS. RNA extraction was carried out using the RNeasy™ 
mini kit (Qiagen, Crawley, UK). This kit consists of RLT lysis buffer, RW1 and RPE 
wash buffers and spin columns containing membranes which bind RNA. A volume 
of 350pl RLT buffer containing 0.1% 2-p-mercaptoethanol (Sigma Aldrich) was 
placed directly onto cells adherent to each experimental surface. Lysate from 5 discs 
of each surface type (and 5 wells containing cells grown directly on plastic) were 
pooled in order to ensure sufficient RNA was extracted for RT-PCR. The lysate was 
first placed into QIAshredder™ columns (Qiagen) and centrifuged at 13,600g for 2 
mins in order to homogenise them. An equal volume of ethanol (Sigma Aldrich) was 
added to each lysate prior to placing it into an RNeasy™ spin column, which served 
to increase the attachment of RNA to the column membranes. Columns were 
centrifuged at 12,000g, binding the RNA to their membranes. 350pl of RW1 wash 
buffer was added to each column prior to centrifugation at 12,000g for 30 sec. In 
order to reduce the chances of genomic DNA contamination, lOpl of DNase enzyme 
(Qiagen) was added to each column, which were then incubated at room temperature 
for 15 mins, prior to another RW1 buffer wash. Two washes with 500pi of RPE 
buffer were carried out by centrifugation at 12,000g for 30 sec each. Finally, the 
column was centrifuged at 12,000g for 1 min in order to dry the membrane and the 
RNA was then eluted by adding 40pl of sterile water and centrifuging at 12,000g for 
1 min.
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3.2.4.2 RNA Quantification
Total RNA quantification was carried out using the Nanovue™ 
spectrophotometer (GE Healthcare). The absorbance at 260:280nm ratio of all 
samples was between 1.7 and 2.1, indicating RNA purity.
3.2.4.3 Reverse Transcription
Reverse transcription (RT) reactions were set up by the addition of 500ng 
total RNA (final volume dependent on the concentration of RNA) to lOpl of 5x 1st 
Strand Buffer (Invitrogen), lpl of 200U/pl Superscript II reverse transcriptase 
(Invitrogen), lpl of 40U/mL RNase Inhibitor (Promega), lOpl lOmM PCR 
Nucleotide Mix (Promega), and 2.5pi Random Primers (Promega). All reaction 
volumes were made up to a total of 50pl with sterile water. For each RT reaction 
performed, a water negative control was established by substituting sterile water for 
RNA. RT-negative controls were set up excluding the reverse transcriptase RNA. For 
this control, 500ng RNA was used from each of the surfaces at the 7 day post seeding 
time point, all of which had sufficient RNA. All reactions were run on a G-storm™ 
GS1 thermal cycler (Genetic Research Instrumentation Ltd, Braintree, UK) with an 
initial denaturing step of 95°C for 5 mins, followed by an annealing step at 25°C for 
lOmins, elongation at 42°C for 60 mins and 95°C for 5 mins as a final denaturing 
step. All resulting cDNA was stored at -20°C for use in PCR reactions.
3.2.4.4 Polymerase Chain Reaction (PCR)
All PCR reactions were set up by the addition of 1 pi of cDNA/control generated by 
reverse transcription to lOpl 5x Green GoTaq™ Flexi Buffer (Promega), 4pl 25mM 
MgCl, lpl lOmM PCR Nucleotide Mix, .5pl 5U/pl GoTaq™ DNA Polymerase, 
2.5pl 0.04pg/pl Forward Primer (Table 3.1), and 2.5pl 0.04pg/pl Reverse Primer 
(Table 3.1). All reaction volumes were made up to 50pl with sterile water. Reactions 
were run on a G-storm™ GS1 thermal cycler (Genetic Research Instrumentation Ltd)
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with an initial denaturing step of 95°C for 5mins, followed by 30 cycles of a 1 min 
95°C denaturing step, a 1 min 56°C annealing step and a 1 min 72°C extension step. 
A final extension step at 72°C for 5 mins was run, ending the reaction. All PCR 
products were stored at 4°C until visualisation.
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Primer Sequences 5’-3’ Product Reference
Size
Osteocalcin F: ATGAGGACCCTCTCTCTGCTC 
R:GTGGTGCCATAGATGCGCTTG
293bp (Alvarez et al. 
1997)
Alkaline
Phosphatase
F: TGATCACTCCCACGTTTTCA 
R: CTGGGCCTGGTAGTTGTTGT
202bp (Kono et al. 2007)
Collagen 
Type I
F:GGTCTTCCTGGCTTAAAGGG
R:GCTGGTCAGCCCTGTAGAAG
313bp (Murphy et al. 
1999)
Runx2 F :CCAGATGGGACTGTGGTTACC 
R:ACTTGGTGCAGAGTTCAGGG
381bp (Gilbert et al. 
2002)
Osteonectin F :CTGCAGAAGAGATGGTGGCGG 
R:CAGGCAGGGGGCAATGTATTTG
395bp (Hack-Young 
• Maeng 2002)
Osteopontin F :GGAGTCCGATGAGGCTATCAA 
R:TCCGACTGCTCAGTGCTCTC
189bp (Fu et al. 2008)
BSP F :CTGCTTTAATCTTGCTCTG 
RiCCATCTCCATTTTCTTCC
21 lbp (Emi and Yorimasa 
2002)
Collagen 
Type II
F: ACTTTCCTCCGTCTACTGTC 
R:CCTATGTCCACACCAAATTCC
320bp (Tholpady et al. 
2003)
Collagen 
Type III
F: AGATGCTGGTGCTGAGAAG 
R:TGGAAAGAAGTCTGAGGAAGG
134bp (Tholpady et al. 
2003)
MSX-2 FiCCGCCTCGGTCAAGTCGGAAA
RiAGGGCTCATATGTCTTGGCGG
92bp (Tsuruoka et al. 
2007)
Sox-9 F :CCCTTCAACCTCCCACACTACAGC 
R:TGTGTAGACGGGTTGTTCCCAGTG
249bp (Schumacher et al. 
2008)
PPARy F.GGAAAGACAACAGACAAATCAC 
R: G AACTT C AC AGC A A ACT C A A AC
408bp (Tholpady et al. 
2003)
p-Actin F :TGAAGATCAAGATCATTGCTCCTCC 
R: CT AG A AGC ATTTGCGGT GG ACG AT G
155bp (Gatto et al. 2008)
Table 3.1: A list of all primer sequences used in PCR reactions. A primer Blast search was run on 
each primer sequence in order to ensure specificity for the intended amplification targets. P-Actin was 
used as a housekeeping gene.
85
3.2.5 Visualisation of PCR Products
PCR products were visualised on ethidium bromide impregnated TBE 
agarose gels. 5x TBE buffer, used for both to make agarose gels and as a running 
buffer, contained 0.5M tris-base (Sigma Aldrich), 0.5M boric acid (Sigma Aldrich), 
0.03M EDTA (Sigma Aldrich) and had a pH of 8.1. TBE buffer was diluted 10 times 
to a concentration of 0.5x prior to use.
3.2.5.1 Agarose Gel Preparation
lOOmL 1% agarose gels were prepared (Sigma Aldrich) using 0.5x TBE 
buffer. Agarose was dissolved into solution by heating in a microwave prior to the 
addition of 7pi of ethidium bromide (Promega). The agarose solution was 
immediately poured into a casting tray and left to cool.
3.2.5.2 Running Agarose Gels and Product Visualisation
lOpl of each PCR product were loaded into wells on the agarose gel. In 
addition each get also contained 7pi of a lOObp DNA ladder (Promega). The loaded 
gel was run in 0.5x TBE buffer at 125mA for 45 mins. Gels were removed from the 
casting tray and placed on a Gel Doc™ scanner (Bio-Rad, Hemel Hempstead, UK). 
Products were visualised using UV light and images captured using Quantity One 
image analysis software (BioRad).
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3.2.6 Protein Expression Profile of BMSCs Grown on Experimental Surfaces
In order to determine if mRNA expression led to the expression of bone 
matrix proteins by BMSCs, protein was extracted from cells grown on the 
experimental surfaces and plastic controls. Protein extracts were run on 4-12% Bis- 
tris gels and Western blots were used to investigate the expression of several non- 
collagenous proteins found in bone matrix.
3.2.6.1 Protein Extraction
Protein was extracted from BMSCs grown on the experimental surfaces and 
plastic controls at 5 day and 12 days post seeding, using a protein extraction buffer 
containing 4M GuCl, 0.03M EDTA and 0.05M Tris HC1. Immediately prior to use, 
one Complete™ protease inhibitor cocktail tablet (Roche, Hertfordshire, UK) was 
dissolved in the extraction buffer, per 50mL of extraction buffer as per 
manufacturers’ instructions. Discs were removed from their culture wells and placed 
into fresh 24 well plates and washed twice for 5 mins PBS. BMSCs grown on plastic 
as controls were simply washed twice for 5 mins with PBS. After the addition of 
lmL of extraction buffer to each well, samples were left at 4°C for 48 hrs with 
constant agitation. Extracts were collected and centrifuged at l,000g for 5 mins. The 
resulting supernatants were collected and desalted using Centriprep spin columns 
(Millipore, Billerica, USA) prior to freeze-drying overnight and resuspension in 
2mLs of distilled water. All samples were homogenized by sonification and stored at 
-20°C.
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3.2.6.2 Protein Quantification
Protein concentration in the samples was determined using a BCA protein 
assay kit (Pierce, Northumberland, UK). The addition of a BCA reagent containing 
bicinchoninic acid and cupric sulfate to a solution containing protein leads to the 
peptide bonds in the protein reducing copper ions in a manner proportional to the 
amount of protein in the sample, which are in turn chelated by the bicinchoninic acid. 
This leads to the formation of a purple product which can be measured by 
absorbance, indicating the relative protein concentration in a given sample.
For each assay, a standard curve was generated by adding 25pi of known 
BSA standards in a range of concentrations from 20pg/ml to 2,000pg/ml to triplicate 
wells of a 96 well plate. 25pi of each protein extract was placed into triplicate wells 
of the same plate. The BCA reagent was prepared combining ‘Reagent A’, a sodium 
bicinchonihate solution with ‘Reagent B’, a cupric sulphate solution in a 50:1 ratio. 
200pl of the combined sodium bicinchoninate/cupric sulphate solution was added to 
each well containing either sample or standard and incubated at 37°C for 30 mins. 
Absorbance at 570nm was read using on a Microplate™ reader (BioTek Instruments 
Limited). A best fit line through the standard curve generated by the absorbance 
values of the BSA standards allowed the concentration of the protein samples to be
determined. The linearity of the best fit line through the standard curve was assessed
0 • • • • *using regression analysis and it was found to have R >0.9, indicating linearity
(Instant Package, Graph Pad Software, San Diego, USA). Protein samples were 
diluted to an equal concentration of 30pg/mL.
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3.2.6.3 Protein Separation Using Bis-Tris Gels
30pg/mL protein samples were diluted 1:1 with a protein sample buffer 
containing 26% (v/v) 0.5M Tris HC1, 21% (v/v) glycerol, 42% (v/v) of 10% (w/v) 
SDS in distilled water, 10 %(v/v) of 2-p-mercaptoethanol and 1% (v/v) of 0.5% 
(w/v) bromophenol blue in distilled water (final protein concentration 15pg/mL). 
Samples were boiled for 10 mins prior to loading into pre-cast NuPAGE® 4-12% 
Bis-Tris gels (Invitrogen). Gels were run in NuPAGE® running buffer (Invitrogen) 
diluted 1:20, as per manufacturers’ instructions. 500pl of Nupage® antioxidant 
reagent (Invitrogen) was also added to the gel tank. Gels were run for 35 mins at 
120mA.
3.2.6.4 Protein Electroblot
Proteins were transferred to a Hydrobond P 0.45pm blotting membrane 
(Amersham), prepared by soaking in methanol for 5 mins and subsequently for 5 
mins in protein transfer buffer, containing 0.03M Tris base, 0.2M glycine, 10% (v/v) 
of methanol and 1% (v/v) of 20% (w/v) SDS in distilled water. The NuPAGE® 
blotting module (Invitrogen) was used for the electroblot. Three sponges were 
soaked in the protein transfer buffer and placed into the blotting module. Two pieces 
of Whatman number 1 filter paper (GE Healthcare) soaked in transfer buffer were 
placed atop the sponges followed by the bis-tris gel containing the separated protein 
samples, the prepared Hydrobond P blotting membrane, and two further pieces of 
soaked filter paper. Finally two more sponges soaked in protein transfer buffer were 
placed atop the filter paper, completing the transfer ‘sandwich’. Proteins were 
transferred for 1 hr at 160mA in protein transfer buffer prior to the recovery of the 
blotting membrane.
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3.2.6.5 Protein Detection
The blotting membrane was placed in a 50mL falcon tube and blocked in a 
5% w/v milk (Sainsbury’s) in TBS solution for 1 hr. Primary antibodies (Table 3.2) 
were diluted ratio with 5% w/v milk in TBS and incubated with the membrane 
overnight at 4°C with agitation and subsequently washed in TBS 3 times for 5 mins. 
Appropriate secondary antibodies (Table 3.2) conjugated with horse radish 
peroxidise (HRP) were diluted in a 5% w/v milk solution and incubated with the 
membrane for 1 hr at room temperature with agitation and washed in TBS 3 times for 
5 mins. Finally, an ECL Plus substrate reagent (GE Healthcare) was added to the 
membrane for 3 mins. Chemoluminescence was detected by exposing the membrane 
to Hyperfilm (Amersham) and developed using a Curix 60 auto-developer (AGFA, 
Mortsel, Belgium) which passed exposed film through a developer (AGFA), a 
fixative (AGFA) and a wash in distilled water. Blocking peptides for the antibodies 
used to detect osteonectin and osteopontin were used to produce negative controls, 
and are also listed in Table 3.2. Primary antibodies were incubated at 37°C for 
30mins with a lOx excess of blocking peptide prior to use in the detection protocol. 
Blocking peptides for the antibody used to detect BSP were not available. All 
Western blots were replicated once.
/
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Primary
antibody
Antibody source 1° isotype and 
dilution used
HRP 2° 
and dilution used
Anti-rat Bone 
Sialoprotein
Larry Fisher IgG; Rabbit 
polyclonal; 1:50
Goat anti-rabbit 
IgG; 1:5,000 
(Santa Cruz)
Anti-rat
Osteopontin
(P-18)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Goat 
polyclonal; 1:30
Rabbit anti-goat 
IgG 
1:5,000 (Santa 
Cruz)
Anti-rat
Osteonectin
(H-14)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Goat 
polyclonal; 1:30
Rabbit anti-goat 
IgG 
1:5,000 (Santa 
Cruz)
Osteopontin 
Blocking Peptide 
(P-18)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
n/a n/a
Osteonectin 
Blocking Peptide 
(H-14)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
n/a n/a
Table 3.2: Antibodies used in Western Blot and Their Dilutions. A lso listed are the blocking peptides 
used as negative controls.
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Figure 3.1: Typical SEM images o f  machined discs after BM SC seeding and culture for 7 days. 
Cells appear to be covered by a thin layer o f  m atrix material. Exam ples o f  cells are indicated by 
arrows. Inset on the upper image is an SEM image o f  a surface with no cells seeded.
Figure 3.2; Typical SEM images o f  grit-blast/acid etched discs after BMSC seeding and culture 
for 7 days. Above, the topographical low points (or ‘valleys’) appear to be partially filled in with 
matrix material. Inset is an SEM image o f  a surface with no cells seeded. Below, a cell partially 
encased in this material, which is indicated by an arrow.
Figure 3.3: Typical SEM images o f  BM SCs seeded onto TCP coated discs and cultured for 7 
days. A lthough no cells are clearly visible at the surface, matrix material is visible around the 
topographical features. Exam ples o f  this m atrix are indicated by arrows. Inset on the upper 
image is an SEM  image o f  a surface with no cells seeded.
3.3.2 Recovery of Cells from Experimental Surfaces
Figure 3.4 shows a graph of the percentage of cells recovered from the 
different surfaces across five post-seeding time points. Generally the initial number 
of cells recovered after 1 hr was very low compared to the number seeded, although 
this proportion increased over time on all surfaces. At all time points, the highest 
proportion of cells was recovered from the machined surface. There were generally 
not large differences between the other three experimental surfaces in terms of the 
proportion of cells recovered, although the initial recovery of cells 1 hr seeding was 
lower from the TCP coated surface relative to the other surfaces.
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Figure 3.4: A graph showing the percentage o f  cells recovered at different post-seeding tim e 
points from each experim ental surface. The percentage o f  cells recovered was based on the total 
number o f  cells seeded. The graph represents the averaged results o f  triplicate cultures in 2 
experimental replicates. Error bars represent standard error o f  the mean.
3.3.3 BMSC mRNA Expression
The mRNA expression profiles at 5, 7 and 12 days post-seeding for osteoblast 
markers of BMSCs cultured on the experimental surfaces are shown in Figures 3.5 
and 3.6. All osteoblast markers investigated were found to be strongly expressed by 
BMSCs on all surfaces and at all three post-seeding time points. BMSC expression 
of the chondrocyte markers Sox9 and Col II and the adipocyte marker ppary across 
the experimental surfaces is shown in Figures 3.7 and 3.8. Bands for ppary appeared 
across all surfaces at all time points, although generally they were faint. An 
exception to this was the band from the TCP coated surface at 5 days post-seeding 
which was noticeably stronger. Bands for ppary were visibly stronger on plastic at all 
time points, with a particularly strong band at 12 days post-seeding. There is also a 
second faint band for ppary present at all three time points on the plastic surface 
which does not correspond to an expected product size. This may be an artefact due 
to PCR machine failure, as the heating blocks were not maintaining consistent 
temperatures around the time the reactions from the plastic surfaces were carried out. 
No bands for Col II were seen from any surface at any time point. Faint bands for 
Sox9 were also visible across all titanium surfaces at all time points. Tables 3.3a-c 
and Tables 3.4a-c summarise the RT-PCR results, with *++’ indicating clear strong 
bands, *+’ indicating clear bands, ‘faint’ indicating barely visible bands and 
denoting negative. Neither water controls nor RT negative controls showed any 
product formation, except for small bands of less than 50bp, which are likely primer- 
dimer.
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F igure  3.6: RT-PC R results show ing the m RNA  expression profile o f  BM SCs cultured on TCP 
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Table 3.3a Table 3.3b
Product M G T P
OP + + + + + + + +
OC + + + + + + + +
ON + + + + + + + +
BSP + + + + + + + +
AP + + + + + + + +
Coll + + + + + + + +
Runx2 + + + + + + + +
MSX2 - - - faint
Col III + + + + + + + +
Product M G T P
OP + + + + + + + +
OC + + + + + + + +
ON -H- + + + + + +
BSP + + + + + + + +
AP + + + + + + + +
Coll + + + + + + + +
Runx2 + + + + + + . + +
MSX2 - - - -
Col III ++ + + + + + +
Table 3.3c
Product M G T P
OP + + + + + + + +
OC + + + + + + -H-
ON + + + + + + + +
BSP + + + + + + + +
AP + + + + + + + +
Coll + + -H- + + -H-
Runx2 + + + + + + + +
MSX2 faint faint faint -
Col III + + + + + + + +
Tables 3.3a. 3.3b and 3.3c: Tables summarising the RT-PCR results presented at day 5 (3.3a) 
day 7 (3.3b) and day 12 (3.3c) post-seeding time points. M-machined, G-grit blasted/acid etched, 
T-TCP coated, P-Plastic, OP-osteopontin, OC-osteocalcin, ON-osteonectin, BSP-bone 
sialoprotein, AP-alkaline phosphatase, Col I-type I collagen, Col Ill-type III collagen. *++* 
indicates clear strong bands, *+* indicates clear bands, ‘faint’ indicates barely visible bands and 
denotes no band.
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Figure 3.8: RT-PC R results showing an mRNA expression profile o f  BM SCs cultured on the 
TCP coated and plastic surfaces at different post-seeding tim e points. (3 actin was used as a house 
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Table 3.4a Table 3.4b
Product M G T P
Ppary + + + + + +
C o l l i - - - -
Sox9 faint faint faint -
Product M G T P
Ppary + + + + +
C o l l i - - - -
Sox9 faint faint faint -
Table 3.4c
Product M G T P
Ppary faint faint faint + +
C o l l i - - - -
Sox9 faint faint faint +
Tables 3 .4a. 3 .4b  and 3.4c: Tables summarising the RT-PCR results presented at day 5 (3.4a) 
day 7 (3.4b) and day 12 (3.4c) post-seeding time points. M -machined, G-grit blasted/acid etched, 
T-TCP coated, P-Plastic, Col II-type II collagen. *++* indicates clear strong bands, *+* indicates 
clear bands, ‘faint’ indicates barely visible bands and denotes no band.
3.3.4 Protein Expression Profiles of BMSCs
Western blots showing the protein expression profile of BMSCs cultured on 
the experimental surfaces for 5 and 12 days post-seeding are shown in Figures 3.9 
and 3.10. In Figure 3.9, bands indicating the expression of BSP were seen across all 
surfaces at both time points with the exception of the plastic surface at 5 days post 
seeding. Figure 3.9 also shows that OP was expressed on the machined and plastic 
surfaces at 12 days post-seeding and to a lesser extent on grit-blasted/acid etched 
surface at the same time point. There are a large number of OP degradation products 
visible. ON, shown in Figure 3.10 had a similar expression pattern, with the 
machined and plastic surfaces having a relatively high level of expression at 12 days 
post-seeding, with a much lower level of expression seen on the grit blasted/acid 
etched surface at the same time point. Figure 3.11 shows the negative control blots, 
where the primary antibody was pre-incubated with a blocking peptide. No immuno- 
reactivity was detected in either negative control.
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F igure  3.9: W estern blot results sh o w in g  the expression o f  bone sialoprotein and osteopontin by 
BM SCs grown on different surfaces at 5 and 12 day post-seeding tim e points.
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Figure 3.10: W estern blot results show ing the expression o f  osteonectin by BM SCs grown on 
different surfaces at 5 and 12 day post-seeding tim e points.
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Figure 3.11: Negative controls for W estern blots, in which the prim ary antibody was incubated 
with a blocking peptide prior to use in the blot. O P-osteopontin, ON-osteonectin.
3.4 Discussion
The results of this chapter have shown that cultured BMSCs attach to all 
experimental surfaces. It is also interesting to note that the mRNA expression 
profiles of cells across all surfaces were highly similar, suggesting that the cellular 
activity at the transcriptional level remained largely unchanged regardless of the 
surface the cells were cultured on. Titanium, regardless of the surface treatment, also 
appeared to promote osteoblast over adipocyte differentiation by suppressing the 
expression of ppary mRNA compared to a plastic control. At the level of protein 
secretion, surface treatment did appear to have an influence on cellular activity, as 
BMSCs cultured on the TCP coating showed variations in the matrix, which may 
influence the osseointegrative potential of this surface treatment. The patterns of 
matrix deposition may have been influenced by the surface topography, with the 
rougher grit blast/acid etched and TCP coated surfaces producing a thicker layer in 
apposition to the matrix than the machined surface. This could result in better 
mechanical interlocking and is therefore of critical important when considering the 
osseointegrative potential of a surface.
From the cell recovery at 1 hr post-seeding, it is a possibility that the 
machined surface had the highest rate of initial cell attachment. In contrast, the TCP 
coated surface, which was also the roughest of the experimental surfaces, had the 
lowest rate of initial attachment, which may have significant consequences for the 
osseointegrative potential of this surface treatment. The proportion of cells recovered 
from all experimental surfaces generally increased over time, demonstrating that all 
of the experimental surfaces were capable of supporting adherent BMSC 
populations. Interestingly however, the highest proportion of cells was recovered 
from the machined surface at all post-seeding time points, indicating that it may be 
this surface which most favours cell expansion over time. BMSCs cultured on the 
rougher grit blasted/acid etched and TCP coated surfaces, along with the plastic 
control, had a lower proportional recovery over time. This trend may indicate that 
smoother titanium surfaces are more favourable to the attachment of osteoblast 
progenitor cells, which has been widely reported in the literature (Bachle and Kohal
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2004; Kieswetter et al. 1996b; Kim et al. 2006; Mustafa et al. 2001). Alternately, 
cells could simply be more difficult to recover from the rougher surfaces, as cells 
adherent within the topographical features would be less accessible to the Accutase. 
Further, cells on these surfaces, having encased themselves in matrix, may have 
undergone apoptosis. It is therefore difficult to interpret these results in terms of the 
functional osseointegrative potential of each surface, as they are simply a measure of 
how many cells were available for recovery from each surface over time as opposed 
to an assessment of their ability to induce and sustain matrix production.
The desire to assess the functional ability of each experimental surface to 
support the production of osteoid matrix, and therefore the process of 
osseointegration, was the primary motivation for carrying out mRNA expression 
profiles for BMSCs grown on them. Interestingly, the expression profiles of BMSCs 
from all experimental surfaces had a very high degree of similarity. It is clear from 
the results that all surfaces are capable of supporting a population of cells which 
express mRNA for a wide range of osteoblast markers. This is well supported in the 
literature, with a range of modified titanium surfaces having been shown to support 
osteoblast differentiation (Balloni et al. 2009; Marinucci et al. 2006; Masaki et al. 
2005; Ponader et al. 2008; Qu et al. 2007; Schneider et al. 2003; Tsukimura et al. 
2008). As RT-PCR is at best a semi-quantitative method, it is impossible to comment 
directly on the absolute levels of mRNA expression between the different titanium 
surfaces, however the results do show that osteoblast markers are clearly expressed 
by BMSCs cultured on all of the surfaces, while chondrocyte and adipocyte markers 
generally had low levels of expression. Using quantitative PCR to directly measure 
the differences in the levels of mRNA expression between cells cultured on the 
different experimental surfaces would have allowed more subtle differences in cell 
activity that could not be defected using the methods employed here to be clarified. 
The drawback to such methodology is the cost and time involved; rarely is it possible 
to examine a broad range of markers using quantitative PCR. Rather it would be 
useful to examine several key indicators of osseointegrative activity and examine 
them in more detail using this technique
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BMSCs cultured on all surfaces were also found to weakly express ppary and 
Sox 9, which may be the result of residual mRNA copies for these markers initially 
present in cells, despite the BMSCs apparently being primarily switched to an 
osteoblast cell type. The noticeably stronger expression of ppary by BMSCs cultured 
on the plastic surface is noteworthy, as it may indicate that titanium surfaces, no 
matter their surface treatment, promote differentiation down the osteoblast lineage, 
as opposed to the adipocyte lineage. In fact, at 12 days post-seeding, there are only 
strong, clear ppary product bands from the plastic surface, which may indicate that 
osteoblast differentiation is better supported by the titanium surfaces compared to the 
plastic control over time. These results would have no doubt been strengthened by 
the addition of a positive control, such RNA from an chondrocyte cell line, which 
could have confirmed any negative findings, for example in the case of Sox 9.
There are conflicting accounts in the literature regarding the influence of 
surface characteristics on osteoblast gene expression. Using quantitative PCR, 
Ponader et al (2008) found no differences in the expression of OC, BSP, AP or Col I 
by human osteoblasts grown on a smooth machined surface and a number of surfaces 
highly roughened by electron beam. This is in contrast to other groups using 
quantitative PCR, which have found alterations in the expression of osteoblast 
markers in cells grown on variously modified titanium surfaces (Masaki et al. 2005; 
Schneider et al. 2003). Similarly, there have been many reports of osteoblast marker 
expression being influenced by the modification of titanium surfaces using semi- 
quantitative comparison of RT-PCR product band intensities (Balloni et al. 2009; 
Marinucci et al. 2006; Qu et al. 2007; Tsukimura et al. 2008). On the whole, the 
results presented in this chapter would tend to support the position that alterations in 
the titanium surface do not substantially influence the mRNA expression of BMSCs.
Based on the Western blot results presented, it is apparent that there are some 
differences in the composition of the matrix produced by cells cultured on the 
experimental surfaces, despite BMSCs cultured on these surfaces having a broadly 
similar mRNA expression profiles. The cells on the TCP coated surface appeared to 
express only BSP, demonstrating that cells cultured on this surface produce the least 
‘complete’ matrix after 12 days. It appears that cells grown on the experimental
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titanium surfaces are influenced in terms of the secretion of non-collagenous matrix 
proteins. This finding may indicate that the TCP coated surface is the least 
favourable for osseointegration. Equally, the weaker expression of ON and OP on the 
grit blast/acid etched surface compared to the machined and plastic surfaces may 
indicate a reduced osseointegrative potential. It has, however, been reported in the 
literature that there are different possible compositions of bone, each containing a 
unique mix of non collagenous proteins. Trabecular bone for example, has been 
found to contain substantially higher levels of osteonectin than cortical bone, while 
cortical bone contains a higher proportion of osteocalcin (Ninomiya et al. 1990). The 
precise functions of these non-collagenous matrix proteins are poorly understood, 
especially in terms of their relative contribution to the mechanical function of bone 
(Gorski 1998; Ninomiya et al. 1990). Therefore, while it could be assumed that an 
ideal bone matrix would contain all of the non-collagenous matrix proteins, it is 
somewhat difficult to speculate as to what an optimal ratio for their occurrence 
would be or to categorically state that the matrix produced by BMSCs grown on the 
TCP coated surface is inferior.
Differences in the structure of the matrix depositions by BMSCs cultured on 
the different experimental surfaces are obvious from the SEM images. On the 
machined surface, the BMSCs appear to have distributed themselves evenly over the 
surface prior to synthesizing a thin sheet of matrix material. In contrast, BMSCs 
cultured on the grit blasted/acid etched and TCP surfaces appear to have migrated 
into the ‘valleys’ created by the alterations to surface topography and filled them 
with matrix material, resulting in a thicker layer of matrix material in apposition to 
the titanium surface. It has been widely reported in the literature that implants with 
rougher surfaces have higher rates of osseointegration in vivo (Al-Nawas et al. 2008; 
Buser et al. 2004; Buser et al. 1991; Franchi et al. 2007; Gotfredsen et al. 1995). This 
may be attributed to surface roughening creating a greater surface area in opposition 
to bone, which in turn causes higher bone matrix apposition to the surface (Cooper 
2000; Le Guehennec et al. 2007). Based on the observed patterns of matrix 
deposition, it is a possibility that the thin later of matrix in direct apposition to the 
machined titanium surface would show a lesser degree of mechanical interlocking 
with surrounding bone compared that allowed by the in-filling of topographical
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features on the grit blasted/acid etched surface and the TCP coated surface. This 
higher potential for mechanical interlocking may result in better osseointegrative 
potential in vivo for the roughened surfaces, despite the observed similarity in 
influence the experimental surface treatments had on BMSC activity in vitro.
An intriguing possibility raised by this work is that surface treatments may 
exert an influence over osseointegration by their mechanical interaction with bone as 
a tissue, rather than influencing osteoblast differentiation directly on a cellular level. 
Due to the complexities inherent in the process of bone formation and the diverse 
factors which can influence this process however, it is likely that in vivo 
investigations, described in Chapters 5 and 6, will be of use in further understanding 
the ways in which titanium surface treatments affect the process of osseointegration.
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Chapter 4: The Effects of Modified Titanium Surfaces on the
Expression of Inflammatory Cytokines and Control of Bone
Resorption
4.1 Introduction
The process of inflammation, and the cytokines which mediate it, play an 
important role in the osseointegration of titanium dental implants. Placement of a 
titanium implant results in an initial trauma and local tissue damage, leading directly 
to the release of a cascade of pro-inflammatory cytokines (Davies 2003; Hughes et 
al. 2006; Le Guehennec et al. 2007). In particular, the inflammatory cytokines 
interleukin 1-p (IL-ip), tumour necrosis factor a (TNFa) and interleukin 6 (IL-6) are 
well known to influence the process of bone formation (Bellido et al. 1997; Boyce et 
al. 1989; Erices et al. 2002; Gowen et al. 1988; Hanazawa et al. 1986; Hughes et al. 
2006; Nanes 2003). These inflammatory mediators function synergistically to 
influence the process of osseointegration at different levels, from mediating 
osteoblast differentiation and bone matrix production, to controlling bone 
remodelling through the modulation of osteoclast function. Similarly, a variety of 
growth factors are also heavily involved in the regulation of osteoblast differentiation 
and function, an important example being TGFpi (Centrella et al. 1994; Hughes et 
al. 2006; Robey et al. 1987). It is therefore relevant to examine the potential 
influence of variously modified titanium surfaces on the production and activity of 
these factors, as surfaces which minimize the expression of inflammatory mediators 
while maximizing the expression of pro-osteogenic factors would be favourable for 
osseointegration.
The inflammatory response in the context of treatment with dental implants is 
complex and at times apparently contradictory. On one hand, acute phase 
inflammation in response to the initial placement of an implant is not only 
unavoidable, but is also necessary for the stimulation of the bone repair process 
(Davies 2003; Hughes et al. 2006; Le Guehennec et al. 2007). Conversely, if
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expression of inflammatory cytokines persists around the implant site it causes a 
number of deleterious effects, leading to a general delay in the healing process, 
increasing the risk of fibrous encapsulation and, ultimately, stimulation of bone 
resorption by osteoclasts (Boyle et al. 2003; Davies 2003; Hughes et al. 2006; Le 
Guehennec et al. 2007). While the initial inflammatory response is a crucial step in 
the process of bone repair, a prolonged one is highly deleterious to it. Inflammation 
is a complex and many aspects of it, particularly the processes by which it is 
regulated, are poorly understood. It is clear however, that a delicate and tightly 
controlled balance is required for rapid and complete bone healing and therefore 
optimal osseointegration of titanium implants.
The cytokines involved in the inflammatory response are multifunctional and 
have a variety of roles depending on the context of their expression. Specifically, 
their roles in and effects on the healing process are dependant on when in this 
processes they are expressed, and also on the concurrent expression of other 
cytokines. For example, IL-1 has been variously shown to inhibit osteoblast 
production of bone matrix (Stashenko et al. 1987), increase osteoblast progenitor 
proliferation and differentiation (Lange et al. 2009) and to increase bone 
mineralization (Ding et al. 2009). TNFa, in contrast, has a broadly suppressive effect 
on osteoblast proliferation, differentiation and production of matrix components 
(Abbas et al. 2003; Gowen et al. 1988; Rosenquist et al. 1996). Relatively little is 
known about the functions of IL-6, although it is thought to inhibit osteoblast 
proliferation, whilst stimulating differentiation in the presence of its soluble receptor 
(Bellido et al. 1997; Erices et al. 2002; Iwasaki et al. 2008). The regulation of these 
cytokines is equally complex. IL-lp, for example, is a key regulator of the 
inflammatory process and is known to modulate osteoblast production of TNFa and 
IL-6 (Hughes et al. 2006;, Ishimi et al. 1990; Wei et al. 2005). Inflammatory 
cytokines present around an implant site may not only exert direct effects on the 
surrounding tissues, but also influence the process of bone repair indirectly through 
the modulation of other cytokines, adding to the overall complexity of the situation.
Another crucial way in which inflammatory cytokines exert control over the 
process of osseointegration is through the control of osteoclast activity, and therefore
102
bone resorption. IL-ip, TNFa and IL-6 can all upregulate osteoblast expression of 
RANKL, leading to a potent stimulation of bone resorption through RANKL/RANK 
mediated osteoclast activation (Boyle et al. 2003; Hsu et al. 1999; Lemer 2004; 
O'Brien et al. 2000; Teitelbaum 2000). IL-1 p and TNFa also influence the negative 
feedback control of osteoclast activation by stimulating osteoblast production of 
OPG, which competitively binds to RANKL, preventing it from activating RANK 
(Brandstrom et al. 1998; Vidal et al. 1998). These inflammatory cytokines are 
intimately involved in the maintenance of a RANKL/OPG ratio which directly 
regulates bone resorption. As the control of bone resorption has obvious implications 
to the osseointegration of dental implants, it is critical that any investigation into the 
influence of surface modification on osteoblast activity considers its impact on the 
expression of both the inflammatory mediators and signalling molecules involved.
As bone healing progresses, the initial inflammation around the implant site 
is resolved and the process of bone repair commences under the direction of a variety 
of growth factors. One such growth factor, TGFpl, is a crucial component of a 
complex regulatory cascade which is involved in the initial recruitment of osteoblast 
progenitor cells (Centrella et al. 1994; Hughes et al. 2006; Janssens et al. 2005). The 
specific activity of TGFpi is contextual and may vary based on its ratio of 
expression with other growth factors, but it has been found to specifically drive the 
early phases of the osteoblast differentiation pathway, particularly in terms of driving 
the proliferation of osteoblast progenitor cells (Centrella et al. 1994). Additionally, 
TGFpl enhances OPG expression, making it an inhibitor of osteoclast activation and 
therefore bone resorption (Boyle et al. 2003). TGFpl has also been reported to 
suppress the TNFa potentiated production of IFNy by dendritic precursor cells 
(Koutoulaki et al. 2010), suggesting that it may have anti-inflammatory properties, 
although IFNy may also suppress the formation of osteoclasts, complicating the issue 
(Xu et al. 2010). The effects of surface modifications on the production of TGFpl by 
osteoblasts is therefore of interest in investigating favourable conditions for the 
osseointegration of dental implants.
It is clearly important to consider the influence of surface modification on the 
inflammatory process, due to the wide ranging impact it has on osteoblast
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differentiation and activity and its direct mediation of bone resorption. In this chapter 
therefore, the same in vitro model used in the previous chapter, to investigate BMSC 
expression of osteoblast markers on the different experimental surfaces, will be 
employed to investigate the expression of several inflammatory cytokines at both the 
mRNA and protein level. Additionally, due to the involvement of osteoblasts in the 
regulation of osteoclast activity and the obvious relevance of this to the process of 
osseointegration, the expression of RANKL and OPG mRNA will be considered. 
TGFpi mRNA expression will also be investigated, due to its central role in the 
regulation of the osteoblast differentiation pathway, its role in the inhibition of 
osteoclast activation and its possible anti-inflammatory properties. Investigating the 
expression of these elements by osteoblasts cultured on the experimental surfaces 
aims to give a clearer understanding of how these surface modifications may affect 
the process of osseointegration.
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4.2 Materials and Methods
4.2.1 Bone Marrow Stromal Cell (BMSC) Isolation and Culture on Titanium 
Surfaces
BMSCs were extracted from rat femurs and cultured on the experimental 
surfaces as described in section 3.2.1.1.
4.2.2 BMSC mRNA Expression Profiles on Experimental Surfaces
The mRNA expression of the inflammatory cytokines IL-ip, TNFa, and IL-6, 
the osteoclast regulatory elements OPG and RankL and the growth factor TGFpi by 
BMSCs grown on the experimental titanium surfaces and plastic controls were 
investigated using RT-PCR. mRNA was extracted at 5, 7 and 12 days post-seeding as 
described in section 3.2.4.1. Quantification of mRNA and RT-PCR reactions were 
carried out as described in sections 3.2.4.2, 3.2.4.3 and 3.2.4.4 respectively. 
Information about the primers used in the PCR reactions is given in Table 4.1.
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Primer Seauences 5*-3’ Product
Size
Reference
IL-lp F :GACAGAACATAAGCCAACAAG 
RiGTCAACTATGTCCCGACCATT
335bp (Wheeler et 
al. 2000)
TNFa FrTACTGAACTTCGGGGTGATTGGTCC
R:CAGCCTTGTCCCTTGAAGAGAACC
295bp (Nadeau et 
al. 1995)
IL-6 F :CAAGAGACTTCCAGCCAGTTGC 
R:TTGCCGAGT AGACCTC AT AGT GACC
614bp (Nadeau et 
al. 1995)
OPG F :TGGC AC ACGAGT GAT GAAT GCG 
R: GCT GG AAAGTTT GCT CTT GCG
538bp (Myers et al. 
1999)
RankL F: ACGC AGATTT GC AGG ACTCG AC 
R:TTCGTGCTCCCTCCTTTCATC
493bp (Myers et al. 
1999)
TGFpl FiAAGAAGTCACCCGCGTGCTA
R:GGCACTGCTTCCCGAATG
118bp (Gurantz et 
al. 2005)
P-Actin F :TGAAGATCAAGATCATTGCTCCTCC 
RiCTAGAAGCATTTGCGGTGGACGATG
155bp (Gatto et al. 
2008)
T ab le  4.1: A list o f  all prim er sequences used in PC R  reactions. A  p rim er B last search was run on 
each prim er sequence in order to  ensure specificity for the intended am plification  targets B -A ctin was 
used as a  housekeeping gene.
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4.2.3 Visualisation of PCR Products
PCR products were visualised by running on ethidium bromide impregnated 
agarose gels as described in section 3.2.5.1. Gel images were captured as described 
in section 3.2.5.2.
4.2.4 Detection of BMSC Expression of IL-1B and TNFa by ELISA
The level of IL-lp and TNFa synthesis was measured by enzyme-linked 
immunosorbent assay (ELISA). Media supernatants were collected from cultures of 
BMSCs grown on the experimental surfaces for 5, 7, and 12 days after seeding. 
Commercial ELISA Development Kits (Peprotech, NJ, USA) were used. These kits 
contain capture antibodies specific to the protein being investigated, biotinylated 
detection antibodies, avidin-HRP, and standards which are comprised of a fixed 
amount of the protein of interest.
4.2.4.1 Collection of Culture Supernatants
Culture supernatants were collected by pipette from the BMSC cultures on 
the experimental titanium surfaces and plastic controls at 5, 7 and 12 days post- 
seeding. Collected supernatants were frozen at -20°C until required.
4.2.4.2 ELISA Plate Preparation
96-well plates (Fisher Scientific) were coated with the appropriate capture 
antibody diluted to 2pg/mL with a diluent buffer containing 0.05% v/v Tween-20 
and 0.01% w/v BSA in TBS and incubated overnight at room temperature. Wells 
were then washed 4x with wash buffer (0.05% v/v Tween-20 in TBS). In order to
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minimize non specific binding, plates were blocked for 1 hr with blocking buffer 
(1% w/v BSA in TBS). Plates were once again washed 4x in wash buffer.
4.2.4.3 ELISA Standard Preparation
Standards for ELISAs were prepared by diluting the appropriate supplied 
protein standards in a range from 3ng/mL to 0.05ng/mL using 2 fold dilutions with 
diluent buffer. lOOpl of each standard concentration were added in triplicate to each 
coated ELISA plate. Triplicate wells containing only diluent buffer were used as a 
zero.
4.2.4.4 ELISA
lOOpl of each collected supernatant sample were added in triplicate to coated 
plates and incubated for 2 hrs at room temperature. Plates were then washed 4x with 
wash buffer, before lOOpl of biotinylated detection antibody diluted to 0.5pg/mL in 
diluent buffer were added to each well. Plates were incubated for 2 hrs at room 
temperature before 4 further washes in wash buffer. 100 pi of avidin-HRP diluted 
1:2,000 with diluent buffer was added to each well and incubated for 30 mins at 
room temperature, prior to a final 4 washes in wash buffer. SureBlue™ TMB 
(Insight Biotechnology, Wembley, UK) was used as a peroxidase substrate and 50pl 
was added to each well prior to a 30 min incubation at room temperature. The 
peroxidase reaction was stopped using 50 pi TMB stop solution (Insight 
Biotechnology). Experiments were performed in duplicate.
4.2.4.5 ELISA Signal Detection and Quantification
ELISA plate absorbance was read at 405nm on a Microplate™ reader 
(BioTek Instruments Limited). A best fit line through the standard curve generated 
by the absorbance values of the standards allowed the concentration of IL-lp or 
TNFa in the collected supernatant samples to be determined.
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4.3 Results
4.3.1 BMSC mRNA Expression
The mRNA expression profile at 5, 7 and 12 days post-seeding of BMSCs 
cultured on the experimental surfaces is shown in Figure 4.1. RANKL was only 
found to be faintly expressed by cells cultured on the grit blasted/ acid etched surface 
at the 12 day post-seeding time point. Faint OPG bands were seen from all titanium 
surfaces at 5 days-post seeding, while the band from the plastic surface at this time 
point was much stronger. Strong bands for OPG were visible from all surfaces at 7 
and 12 days post-seeding. IL-lp appeared to be expressed only by BMSCs cultured 
on the plastic surface. Bands indicating TNFa expression were seen from cells 
cultured on all surfaces, although were faint from the titanium surfaces at 5 days-post 
seeding, in contrast to the strong band seen from the plastic surface, which remains at 
days 7 and 12 post-seeding. BMSCs cultured on the machined and grit blasted/acid 
etched surface showed increasing expression of TNFa over days 7 and 12 post- 
seeding, while BMSCS on the TCP coated surface showed a uniformly weak 
expression over these time points. Very faint bands for IL-6 were visible from 
BMSCs cultured on all surfaces at all time points, except for the TCP coated surface 
from which no bands are seen.TGFpl expression was seen from BMSCs cultured on 
every surface at every time point. Tables 4.2a-c summarise the RT-PCR results, with 
*++’ indicating clear strong bands, *+’ indicating clear bands, ‘faint’ indicating 
barely visible bands and denoting negative. Neither water controls nor RT 
negative controls showed any product formation, except for small bands of less than 
50bp, which are likely primer-dimer.
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F igure 4.1; RT-PCR results showing an mRNA expression profile o f  BM SCs cultured on the 
machined and grit blasted/acid etched surfaces at the different post-seeding tim e points. (3 actin 
was used as a house keeping gene. RANKL - Rank ligand, OPG - Osteoprotegerin, IL - ip  - 
Interleukin 1J3, TN Fa -  Tumour Necrosis Factor a, IL-6 - Interleukin 6, T G F b l- Transform ing 
Growth Factor p i. Product band sizes are estimated based on their relative position to a lOOkb 
DNA ladder.
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Figu re  4.2; RT-PCR results showing an mRNA expression profile o f  BM SCs cultured on the 
TCP coated and plastic surfaces at the different post-seeding time points, p actin was used as a 
house keeping gene. RANKL - Rank ligand, OPG - Osteoprotegerin, IL -ip  - Interleukin ip , 
TN Fa -  Tumour Necrosis Factor a, IL-6 - Interleukin 6, T G F b l- Transforming Growth Factor 
p i. Product band sizes are estimated based on their relative position to a lOOkb DNA ladder.
Table 4.2a Table 4.2b
Product M G T P
RANKL - - - -
OPG + + + + +
IL-lp faint faint - + +
TNFa faint faint faint + +
IL-6 faint faint - +
TGFpl + + + + + + + +
Product M G T P
RANKL - - . - -
OPG + + + + + + + +
IL-ip - - - + +
TNFa + + faint +
IL-6 faint faint - faint
TGFpl + + + + + + + +
Table 4.2c
Product M G T P
RANKL - faint - -
OPG + + + + + + + +
IL-lp - - - + +
TNFa + + + + faint +
IL-6 + + - -
TGFpl + + + + + + + +
Tables 4.2a. 4.2b and 4.2c: Tables summarising the RT-PCR results presented at day 5 (4.2a) 
day 7 (4.2b) and day 12 (4.2c) post-seeding time points. M-machined, G-grit blasted/acid etched, 
T-TCP coated, P-Plastic, RANKL - Rank ligand, OPG - Osteoprotegerin, IL-lp - Interleukin ip, 
TNFa -  Tumour Necrosis Factor a, IL-6 - Interleukin 6, TGFpl- Transforming Growth Factor 
pi. *++' indicates clear strong bands, *+* indicates clear bands, ‘faint’ indicates barely visible 
bands and denotes no band.
4.3.2 TNFa and IL-1B ELISAs
Graphs showing the standard curves generated from both the TNFa and IL-lp 
ELISAs are shown in Figure 4.4. No detectable levels of either protein were found in 
the culture supernatants of BMSCs cultured on any of the experimental surfaces at 
any time point. The standard curves, however, show that there was immunoreactivity 
in the ELISAs, as the absorbance increased with increasing concentrations of the 
standards.
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F igure 4.4: Standard curves generated by the IL -lp  and T N Fa ELISAs. Neither protein was 
detected in the culture supernatant, but the standard curves show imm unoreactivity with the 
standards.
4.4 Discussion
In this chapter, the data presented have shown that there are differences in the 
IL-lp mRNA expression profiles of BMSCs grown on titanium surfaces versus 
plastic controls, which may indicate potential differences in the inflammatory 
response of BMSCs to different surfaces. A reduction was also observed in the 
expression of TNFa mRNA by BMSCs cultured on the TCP coated surface, which 
would likely be favourable to bone formation. Interestingly however, neither IL-lp 
nor TNFa appeared to be released by BMSCs cultured on any surface. BMSCs from 
all surfaces appeared to generate osteogenic signals through the expression of OPG 
and TGFpi mRNA.
One of the key findings presented in this chapter is that all of the titanium 
surfaces appeared to suppress the expression IL-lp mRNA compared to the plastic 
control surface at all time points investigated and that this phenomena was 
independent of surface treatment. This is significant due to the complex role that this 
cytokine plays in the process of osteoblast differentiation and function; there have 
been contradictory reports over the effect of IL-ip on osteoblast differentiation and 
function. It was initially reported that IL-lp inhibits the production and secretion of 
bone matrix proteins by osteoblasts in vitro, particularly after sustained exposure 
(Canalis 1986; Stashenko et al. 1987). Conversely, it has been also been shown that 
IL-lp increases the differentiation and proliferation of pre-osteoblasts in vitro (Lange 
et al. 2009), and promotes mineralisation while decreasing Runx2 expression in vitro 
(Ding et al. 2009). In vivo, an initial inflammatory response involving IL-lp may be 
necessary to initiate the healing process by stimulating osteoblast progenitor cell 
proliferation, but this response would need to be quickly suppressed to allow the 
formation of new bone. Although the overall influence of IL-ip on the process of 
osseointegration is not fully understood, it is clearly a key regulatory element in the 
early osteoblast differentiation pathway. Therefore, the observed suppression of IL- 
1 p mRNA expression by titanium surfaces, particularly at the later post-seeding time 
points, may enhance the osseointegrative potential of surfaces and thereby serve to 
enhance bone formation in vivo. Alternatively, the increase in IL-ip expression by
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BMSCs cultured on plastic surfaces may have been caused by an increase in 
macrophage adherence to these surfaces, as these cells are a primary source of IL-lp 
in vivo.
Overall, TNFa has a deleterious effect on bone formation and has been 
shown to broadly inhibit the production of bone matrix components by osteoblasts 
and also to inhibit osteoblast proliferation (Gowen et al. 1988; Rosenquist et al. 
1996) and differentiation via the suppression of Runx2 (Abbas et al. 2003; Gilbert et 
al. 2002). The expression profile of TNFa mRNA by BMSCs varied somewhat 
across the different surfaces, with stronger bands for the machined and grit 
blasted/acid etched surfaces at each subsequent time point, while the band strength 
decreased for the plastic surface over time. In contrast, the TCP coated surfaces had 
minimal TNFa expression at all time points. An increased expression of TNFa 
mRNA over time by BMSCs cultured on the machined and grit blasted/acid etched 
surfaces is therefore somewhat surprising, given the apparent suppression of IL-lp 
by these surfaces. This however, did not appear to affect their ability to produce bone 
matrix material, as was shown in Chapter 3. Likewise, the lower expression of TNFa 
by BMSCs cultured on the TCP coated surface did not appear to confer any 
particular advantages to the formation of bone matrix. It is therefore difficult to 
gauge the important of this finding. All bands for IL-6 mRNA were consistently 
faint, which is somewhat surprising as TNFa has been shown to increase osteoblast 
production of IL-6 (Dai et al. 2006). Therefore, it might be expected that those 
surfaces which caused an increased expression of TNFa may have caused a 
corresponding increase in IL-6 expression by BMSCs cultured on them.
The direct regulation of osteoclast activity by osteoblasts through the 
RANKL/OPG pathway has been previously characterized (Boyle et al. 2003). OPG 
mean product band intensity from the titanium surfaces increased over time, while 
the mean band intensity from the plastic surface remained relatively constant at all 
post-seeding time points. RANKL mRNA, in contrast, was only faintly expressed by 
BMSCs cultured one surface at a single post-seeding time point. In vivo, the ratio of 
RANKL expression versus OPG expression directly regulates the level of osteoclast 
activation and therefore the process of bone resorption (Boyle et al. 2003). In
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BMSCs cultured on the experimental surfaces, this ratio was found to be highly in 
favour of OPG expression, suggesting that the adherent BMSCs are suppressing 
osteoclast activity and therefore bone resorption. It is peculiar that RANKL is not 
widely expressed in conjunction with OPG, and there is no doubt that appropriate 
positive controls, for example RT-PCR reactions using RNA from an osteoblast cell 
line, would have served to clarify this issue.
TGFpi mRNA was found to be expressed by BMSCs cultured on all of the 
experimental surfaces at all time points. This is indicative of both the osteoblast 
phenotype and of bone matrix production, as TGFpl is produced along with the bone 
matrix proteins and is sequestered in the bone matrix (Hughes et al. 2006). 
Therefore, this result confirms the fact that all of the experimental surfaces were 
capable of supporting populations of osteoblast progenitor cells and the production of 
matrix.
A surprising finding presented in the chapter was the lack of either IL-lp or 
TNFa in the culture supernatants despite the presence of both cytokines at the 
transcriptional level. Although BMSCs cultured on the plastic surface had IL-ip 
mRNA copies present at all time points, they apparently did not secrete it at 
detectible levels. This would indicate that cells either did not move from 
transcription to translation of IL-lp or that the protein remained in intracellular 
storage as a pro-peptide, perhaps due to a lack of a stimulus for release (Ferrari et al. 
2006). Similarly, TNFa mRNA was detected yet the cytokine itself was not found in 
any culture supernatants, possibly due to a lack of translation or because the cytokine 
was stored in an inactive form by BMSCs. Unfortunately, further speculation is 
beyond the scope of the investigations carried out here.
The most notable difference observed between the mRNA expression profiles 
of BMSCs cultured on the experimental surfaces was the apparent suppression of IL- 
1P by titanium as opposed to plastic. With the exception of the reduced expression of 
TNFa mRNA in BMSCs cultured on the TCP coated surface, none of the 
experimental titanium surfaces showed any outstanding effects on cells which would 
indicate a higher osseointegrative potential. On the contrary, cells from all surfaces
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showed mRNA expression of OPG and TGFpi, suggesting a suppression of bone 
resorption and the presence of a population of active osteoblast-like cells, both of 
which would be favourable to osseointegration.
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Chapter 5: The Osseointegration of Titanium Dental Implants in an
In Vivo Rat Model of Type II Diabetes Mellitus
5.1 Introduction
Titanium dental implants have a high clinical success rate in healthy 
individuals where there is ample good quality bone around the implant site. There are 
many individuals however, with conditions which prevent them from being able to 
benefit from treatment with dental implants. A prime example of such a condition is 
diabetes mellitus (DM). DM is a metabolic disorder, which is characterised by 
chronic hyperglycaemia, and has two types, type I and type II. Type I DM, or insulin 
dependent diabetes, is caused by the destruction of insulin producing beta cells in the 
pancreas by an auto-immune response, thus eliminating the ability to produce insulin. 
Approximately 5 to 10 percent of individuals with DM have type I, making it the 
minority variant (Graves et al. 2006). Type II DM, or non-insulin decedent diabetes, 
is caused by a desensitisation of the tissues to insulin, which is brought on by 
sustained hyperglycaemia. This type of DM is by far the most prevalent, with the 
remaining 90 to 95 percent of cases consisting of type II diabetes (Graves et al. 
2006). It is estimated that more than 150 million individuals worldwide have type II 
DM (Zimmet et al. 2003).
The placement of dental implants in diabetic individuals has proven to be 
controversial. Although there are reports of implants being well tolerated in diabetic 
patients (Klokkevold and Han 2007; Morris et al. 2000), diabetes is often held to be a 
contraindication for treatment, with higher failure rates reported in diabetic 
individuals (Fiorellini et al. 2000; Morris et al. 2000; Valero et al. 2007). This may 
be explained by the fact that diabetes has been repeatedly shown to impair the 
process of bone formation and thereby significantly delay the process of 
osseointegration (Hasegawa et al. 2008; He et al. 2004; Kwon et al. 2005; Liu et al. 
2007b; Shyng et al. 2006; Siqueira et al. 2003). Although the specific cause for this
i
delay in healing remains to be fully elucidated, it is thought that a slower attachment
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of tissue to the implant surface allows opportunities for bacterial invasion, leading to 
infection and sustained inflammation, resulting in an impairment of bone formation 
in diabetic individuals (Graves et al. 2006; Valero et al. 2007). For example, it has 
been demonstrated that monocytes harvested from individuals with type I DM have 
increased levels of TNF-a and IL-lp in response to bacterial LPS (Salvi et al. 1997a; 
Salvi et al. 1997b), which would lead to increased inflammatory tissue damage and 
therefore impaired healing in diabetic individuals. It is possible that certain 
aberrations exist in the activity of osteoblast cells in DM, leading to altered function 
and therefore have an impact on the process of bone repair around an implant site.
In order to investigate possible mechanisms behind the delay in healing 
around implants in diabetic individuals and how different titanium surfaces could 
affect it, an in vivo rat model has been developed in conjunction with Osaka Dental 
University in Japan (Sakai et al. 2008). This model involves the removal of an 
incisor and subsequent placement of titanium dental implants with a machined 
surface into the resulting socket. The progression of mandibular bone healing 
following the placement of a titanium implant allows bone healing to be observed at 
a series of post-operative time points, and osteogenic activity around an actual 
implant site can be assessed by the presence of various cellular markers. A model of 
type II DM, the Goto-Kakizaki (GK) rat (Goto et al. 1975), which exhibits 
spontaneous hyperglycaemia leading to impaired insulin sensitivity, allows the 
process of osseointegration to be studied in the context of this disease state. This 
model has previously been used to investigate the removal torques of implant placed 
in GK rats compared to normal controls. Interestingly, these were found to be 
significantly higher in diabetic animals, despite the fact that a small decrease in bone 
formation around the diabetic implant site was observed histologically (Sakai et al. 
2008).
There have been a number of in vivo models which suggest that both type I 
and type II DM decrease the level of osseointegration of titanium implants in both 
rats and mice (Fiorellini et al. 1999; Hasegawa et al. 2008; Kwon et al. 2005; 
McCracken et al. 2000; McCracken et al. 2006; Nevins et al. 1998; Shyng et al. 
2006; Siqueira et al. 2003).' Many of these studies have been carried out in models
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where implants were inserted into the tibia or femurs of animals, presumably due to 
the ease of access, with the aim of modelling the progression of osseointegration of a 
dental implant. Although this clearly provides useful information about the effects of 
bone repair around titanium implants, it is entirely possible that there are regional 
differences in the way the bone repair process is affected by DM. Furthermore, in the 
tibia, the environment in which bone healing takes place is entirely different from the 
oral cavity. For example, exposure to the oral flora no doubt has a substantial impact 
on the inflammatory process, as does the constant exposure of the oral cavity to the 
external environment. As an altered response to various infectious agents is thought 
to be a major factor in the delayed healing seen around dental implants in DM (He et 
al. 2004; Valero et al. 2007), taking these factors into account when considering the 
clinical situation in humans is of critical importance. In addition, the cell populations 
involved in the bone repair process would almost certainly be different between the 
tibia and the oral cavity. Using an in vivo model which involves the direct insertion 
of implants into the mandible can therefore only give a clearer representation of the 
clinical situation than insertion of implants into a more peripheral site.
Within the present study, basic haematoxylin and eosin (H&E) staining was 
used to gauge the level of bone healing around the implant site in both normal and 
diabetic animals at 1, 3, 9 and 12 week post-operative time points. Staining with 
alizarin red served to detect tissue mineralisation. Several biomarkers specific to 
different stages in the osteoblast differentiation process were also selected for 
immunolocalisation in order to track the progression of osteoblast progenitor cells 
through this process around the implant sites in both the normal and disease states. 
Stro-1 is a cell surface marker associated with mesenchymal stem cells and 
osteoblast progenitor cells early in their differentiation, indicating the presence of 
progenitor cells recently migrated from the bone marrow and the remnants of the 
PDL (Stewart et al. 1999; van den Dolder and Jansen 2007; Walsh et al. 2000). The 
cell proliferation marker proliferating cell nuclear antigen (PCNA) was used to 
identify the presence of mitotic cells. Cellular proliferation around the implant site 
indicates a healing response involving the proliferation of a variety of cell types, 
including osteoblast progenitor cells. Osteopontin (OP), an early osteoblast marker 
which serves a role in cellular adhesion and osteocalcin (OC), a later osteoblast
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marker known to be an inducer of mineralization (Hughes et al. 2006), were chosen 
to label mature osteoblasts. Finally, the presence of transforming growth factor pi 
(TGF pi), a powerful stimulator of early osteoblast proliferation and a critical factor 
in matrix synthesis (Centrella et al. 1992; Janssens et al. 2005) was also examined.
Due to the trauma involved in the initial placement of the implant, cytokines 
such as IL-ip and TNFa would normally be secreted around the implant site by 
activated macrophages. The presence of these potent inflammatory mediators, which 
are known to inhibit bone formation and are involved in bone resorption (Bertolini et 
al. 1986; Boyce et al. 1989; Ellies and Aubin 1990; Hughes et al. 2006; Nanes 2003), 
normally wanes as the healing process advances. These cytokines were therefore 
immunolocalised along with the pan specific macrophage marker F4/80 around the 
implant sites in both normal and diabetic animals in order to examine their 
expression during the healing process in both the normal and disease state. Sustained 
expression of these cytokines and the presence of the cells which are critical 
modulators of them may be a key mechanism behind the delayed bone healing 
observed in DM. The development of a model of implant osseointegration in DM 
permits the study of the effects of DM on the process of bone healing at the cellular 
level, serving to elucidate differences in cell behaviour which contribute to delays in 
bone healing, and thereby worsen clinical outcomes in implant treatment
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5.2 Materials and Methods
5.2.1 Preparation of Mandibles
Implant procedures were performed by Diago Sakai and Joji Okazaki at the 
Dental University of Osaka Japan on both 10 week old male Wistar and Goto and 
Kakizaki (GK) rats, as described in Sakai et al (2008). All experimental protocols 
involving these animals were reviewed and approved by the Animal Committee of 
Osaka Dental University (approval number 08-03009), and conformed with the 
procedures described in the ‘Guiding Principles for the Use of Laboratory Animals’ 
handbook at the Laboratory Animal Facilities in the Institute of Osaka Dental 
Research, Osaka Dental University. The continuously erupting incisors of the rats 
were trimmed at 14,11, 7 and 4 days prior to extraction in order to stimulate eruption 
(Figure 5.1a). This served to loosen the incisors, facilitating an extraction which 
minimally disrupted surrounding tissues. Pre-treatment trimming procedures were 
carried out under infiltration anaesthesia with isoflurane (Isoflurane Rhodia™, 
Nissan Chemical Industries Ltd., Tokyo, Japan). Tooth extraction was carried out 
under the general anaesthetic sodium pentobarbital (Nembutal®, Dainippon 
Pharmaceutical Co., Ltd. Osaka, Japan) delivered by intra peritoneal injection 
(Figure 5.1b). Blood samples were collected immediately after tooth extraction and 
blood glucose levels measured using the Acensia Contour™ glucose monitoring 
system (Bayer Medical Co. Ltd., Tokyo, Japan). Blood glucose levels in the GK rats 
were found to be significantly higher than in control animals. The implant sockets 
were then curetted to remove debris and the majority of the periodontal ligament. 
Machined titanium alloy (Ti-6A1-4V) implants with a length of 17.0mm and a 
1.2mm diameter (SNK Screwpost Ti-tan®, Dentsply-Sankin K.K. Tokyo, Japan). 
Implants were immediately placed in the socket (Figure 5.1c). Rats were then 
sacrificed by intra peritoneal injection of sodium pentobarbital (Nembutal®, 
Dainippon Pharmaceutical Co) at post-operative time points of 1, 3, 9 and 12 weeks. 
Animals were finally fixed by perfusion with 10% neutral-buffered formalin, 
extracted and sent to the Cardiff in formalin for processing.
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Figure 5.1: Schematic of implant placement and histological processing. Pre-treatment trimming 
of mandibles in shown in (a), followed by incisor extraction (b) and placement of implants (c). 
In (d) a radiograph of an implant in a mandible is shown, along with an example an of a tissue 
section, which were taken such that they were perpendicular to the implant socket. All sections 
shown come from a 2mm section near the middle of the mandible, between the two lines shown 
in (d).
5.2.2 Processing of Mandibles
Implants were removed from the mandibles by carefully unscrewing them out 
of the socket. After removal of the ramus and condyle, the mandibles were then cut 
into approximately 2mm thick sections running perpendicular to the implant socket 
using a bone saw (Figure 5.Id) and placed in 10% formic acid with agitation for 72 
hs to demineralise the tissue sections. The tissue sections were then placed in biopsy 
cassettes and processed using a processing machine (Shandon Pathcentre), which 
passed them through a series of 70, 90, and 100% graded alcohol soaks which served 
to dehydrate them, cleared them with a xylene rinse and finally impregnated them 
with molten paraffin wax (Raymond Lamb, UK). Tissue sections were then removed 
from the processing machine and embedded in paraffin wax (Raymond Lamb). 5pm 
sections were cut on a rotary microtome (Leica) and mounted on poly-L-lysine 
coated glass slides (Sigma Aldrich) before being placed in an oven at 65°C overnight 
in order to improve tissue adhesion and sections were stored at room temperature in 
closed boxes until required.
5.2.3 Haematoxylin and Eosin Staining
Sections were stained with haematoxylin and eosin (H&E) using an 
automated staining machine, in order to visualize the area around the implant site. 
Firstly, the automated staining system passed the slide mounted sections through a 
heater to dry them. Tissue sections were then passed through a series of xylene, 
graded alcohol and water rinses in order to remove all paraffin and rehydrate them. 
The sections were then immersed in haematoxylin which stains the nucleus of cells 
blue, washed and blued in Scott’s tap water, and differentiated in 1% acid alcohol. 
After a further rinse in tap "water, sections were stained with eosin which stains 
cytoplasmic components red. Finally, the sections were rinsed in tap water, 
dehydrated in alcohol and immersed in xylene. Cover slips were mounted onto the 
sections using DPX mounting medium (Raymond Lamb). Images were captured 
using an Olympus AX70 microscope incorporating a Nikon DXM 1200 digital 
camera and ACT-1 software.
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5.2.4 Alizarin Red Staining
In order to assess the level of mineralization in the tissues around the implant 
sites, sections were stained with alizarin red, which stains areas rich in calcium ions 
bright red, indicating a degree of mineralization. Although sections had undergone 
demineralization, there was still enough residual calcium remaining in the tissue 
sections to stain with alizarin red. Sections were deparaffinized with xylene for 10 
mins, rinsed with industrial methylated spirit (IMS) for 5 mins and washed in tap 
water for 5 mins. Sections were circled using a paraffin pen (Sigma Aldrich). 0.1% 
w/v alizarin red, adjusted to pH 5.5 with ammonium hydroxide, was applied to each 
slide for approximately 5 mins. Slides were then rinsed with tap water, washed with 
IMS for 5 mins and cleared with xylene for 5 mins. Cover slips were applied to slides 
using DPX glue, and images taken using an Olympus AX70 microscope 
incorporating a Nikon DXM 1200 digital camera and ACT-1 software.
5.2.5 Immunohistochemistrv
5.2.5.1 Preparation of Sections
Sections were deparaffinized with xylene for 10 mins, rinsed with industrial 
methylated spirit (IMS) for 5 mins and washed in tap water for 5 mins. Sections were 
circled with a paraffin pen. For the immunolocalisation of TGFpl, IL-ip, TNFa and 
F4/80, antigen retrieval was performed by treating the tissue sections with 24pg/mL 
protinase K (Sigma Aldrich) for 10 mins at 37°C. After this step the sections were 
washes three times in TBS for 5 min. Finally in order to quench endogenous 
peroxidase activity, sections were incubated at room temperature in 3% hydrogen 
peroxide for 10 mins. This was followed by three further 5 min washes with TBS.
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5.2.5.2 Immunolocalisation
Immunodetection of PCNA, osteopontin, osteocalcin, TGFpl, IL-ip, TNFa 
and F4/80 was carried out using a Vectastain Universal IgG Kit (Vector 
Laboratories) and a DAB perioxidase kit (Vector Laboratories). Non specific binding 
of antibodies was blocked by incubating with 1% w/v normal horse serum, diluted in 
tris buffered solution (TBS), for 1 hr at room temperature. After blocking, sections 
were incubated with the appropriate IgG primary antibody (Table 1) at the 
appropriate dilution in 1% w/v horse serum in TBS at 4°C overnight. As a negative 
control for each experiment, a non-immunogenic IgGi control antibody (Sigma 
Aldrich) was substituted for the primary within the protocol or the primary was 
excluded altogether and was with blocking serum. Sections were washed three times 
for 5 min with TBS, and the universal secondary antibody (Vector Laboratories) 
diluted with lOOpl of normal blocking serum (Vector Laboratories) in TBS was 
applied for 30 mins. Appropriate dilutions for both primary and secondary antibodies 
were determined experimentally and are given in Table 1. Following incubation with 
the secondary antibody, sections were again washed three x5 min with TBS and 
incubated with the ‘ABC’ reagent (Vector Laboratories) for 30 mins. The ‘ABC’ 
reagent, which is an avidin-biotin complex which acts as a signal amplifier, was 
prepared by adding two drops of ‘reagent A’, containing avidin, and two drops of 
‘reagent B’, containing biotin, into 5mL of TBS. Sections were washed three x5 min 
for a final time and incubated with a 3, 3’diaminobenzidine (DAB) peroxidase made 
up using a DAB substrate kit (Vector Laboratories) for approximately 2 mins. The 
substrate solution was made up by adding the following kit contents to 5ml of 
distilled water as per the manufacturer’s instructions: 100pi Buffer Stock Solution, 
200pl DAB stock Solution, lOOpl Hydrogen Peroxide Solution and lOOpl Nickel 
Solution. Finally, slides were rinsed in tap water, counterstained with 0.1% w/v 
methyl green for approximately 1 min, rinsed in industrial methylated spirit for 5 
mins and cleared with xylene for 5 mins. Cover slips were applied to sections using 
DPX glue, and images taken using an Olympus AX70 microscope incorporating a 
Nikon DXM 1200 digital camera and ACT-1 software. All immunolocalisations 
were performed in duplicate.
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5.2.5.3 Stro-1 Localization
The primary antibody to Stro-1 is an IgM class antibody and therefore the 
Vectastain Kit was not appropriate for use. Instead, sections were blocked with 5% 
goat serum (Sigma Aldrich) for 20 mins and incubated with the IgM primary 
antibody or negative controls overnight (Table 1 for dilution details). After washing 
two x5 min with TBS sections were incubated with the secondary antibody, a 
biotinylated goat anti-mouse IgM antibody (Vector Laboratories) for 30 mins. 
Sections were then treated with the ABC reagent from the Vecastain universal kit 
and immuno-reactivity detected using the DAB peroxidase substrate as described in 
the previous section.
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Primary
antibody
Antibody source 1° isotype and 
dilution used
Biotinylated 2° 
and dilution used
Anti-human
Stro-1
National Hybridoma 
Bank
IgM; Mouse 
polyclonal; 1:25
Goat anti-mouse 
IgM; 1:600
Anti-rat PCNA 
(PC 10)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Mouse 
monoclonal; 1:25
Vectastain 
Universal IgG; 
1:100
Osteopontin 
(recombinant 
OPN human 
origin; FMb-14)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Mouse 
monoclonal; 1:50
Vectastain 
Universal IgG; 
1:100
Osteocalcin 
(amino acid 1-95 
mouse OCN; FL- 
95)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Rabbit 
polyclonal; 1:50
Vectastain 
Universal IgG; 
1:100
IL-1B (Anti rat 
B122)
eBioscience, CA, USA IgG; Armenia 
Hamster 
polyclonal; 1:50
Vectastain 
Universal IgG; 
1:100
TNFa (N- 
terminus mouse 
origin; L-19)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Goat 
polyclonal; 1:50
Vectastain 
Universal IgG; 
1:100
TGFB 1 
(c-terminus 
human origin; v)
Santa Cruz 
Biotechnology, Inc., 
CA, USA
IgG; Rabbit 
polyclonal; 1:50
Vectastain 
Universal IgG; 
1:100
F4/80 (Anti-Rat 
Pan macrophage 
marker ab 15637)
Abeam, MA, USA
V.
IgG; Mouse 
monoclonal; 1:40
Vectastain 
Universal IgG; 
1:100
T ab le  5.1: A list o f  prim ary antibodies, along w ith dilutions o f  prim ary and secondary antibodies 
used.
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5.2.5.4 Semi-Quantification of Immunohistochemical Results
Positively stained cells were counted using the Image Pro-Plus version 
6.0.0.260 image analysis software (Media Cybernetics Inc. Bethesda, MD). This 
software allows colors to be manually selected from an image and continuous 
objects, which are these colors, are designated as ‘positive’. From each section, 
images were taken from five random fields of view around the implant socket. On 
each of these 5 images, positive cells in 5 100pm2 areas around the implant site were 
counted and averaged, giving a semi-quantitative value for the number of average 
positive cells per 100pm in 5 random fields of view. Overall average cell counts 
from the 5 random fields of view were calculated alongside the standard error of the 
mean.
i
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5.3 Results
5.3.1 Haematoxylin & Eosin Histology
Figures 5.2-5.5 show that bone healing appeared to be delayed in the diabetic 
animal, especially at the earlier time points. In Figure 5.2, a cell rich granulation 
tissue (GT) is visible around the implant socket in both normal and diabetic animals 
at one week post-operation. No bone formation appeared to have occurred at this 
stage in either animal. By three weeks post-operation (Figure 5.3) however, although 
a substantial amount of the granulation tissue was still visible in the sections from 
both animals, there was evidence of new bone growth around the implant socket in 
the normal animal. This is in stark contrast to the diabetic animal, which had 
granulation tissue around the implant site at this time point. At nine weeks post­
operation (Figure 5.4), bone healing had advanced considerably around the normal 
implant socket, with only a small amount of granulation tissue evident. In the area 
around the diabetic implant socket, some newly formed bone was visible, although 
less than that in the normal animal. In both the normal and diabetic animals at twelve 
weeks post-operation (Figure 5.5), a substantial amount of bone formation had taken 
place, with little difference visible between the two animals.
126
iOOum
Figure 5.2: H&E stained sections obtained from a normal (a) and diabetic (b) rat at one week 
post-operation. MB indicates mandibular bone, IS indicates the implant socket and G T the 
granulation tissue.
Figure 5.3: H&E stained sections obtained from a normal (c) and diabetic (d) rat at three weeks 
post-operation. MB indicates mandibular bone, IS indicates the implant socket and GT the 
granulation tissue. Newly formed bone is indicated by arrows.
Figure 5.4: H&E stained sections obtained from a normal (a) and diabetic (b) rat at nine week 
post-operation. MB indicates mandibular bone, IS indicates the implant socket and GT the 
granulation tissue. Newly formed bone is indicated by arrows.
Figure 5.5: H&E stained sections obtained from a normal (c) and diabetic (d) rat at twelve 
weeks post-operation. MB indicates mandibular bone, IS indicates the implant socket and GT the 
granulation tissue. Newly formed bone is indicated by arrows.
5.3.2 Alizarin Red Staining
Images obtained following the staining of mineral residue with alizarin red 
are shown in Figures 5.6-5.9. The results concur with those from H&E staining. At 
one week post operation (Figure 5.6), no bright red staining was visible on sections 
from either the normal or diabetic animal, which indicated that no mineralisation has 
taken place around either implant site at this time point. By three week post­
operation however (Figure 5.7), areas of bright red staining were visible around the 
normal implant site, indicating the deposition of mineral at these locations. This is in 
contrast to the diabetic implant site, around which there was no evidence of 
mineralisation at this time point. In the sections from nine weeks post-operation 
however (Figure 5.8), areas of bright red staining were visible around the edges of 
newly formed bone in both normal and diabetic animals, although there were 
noticeably fewer of these in the diabetic animal. There was a similar situation at 
twelve weeks post-operation (Figure 5.9), with bright red staining appearing at the 
edges of newly formed bone around implant sites in both animals.
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Figure 5.6: Alizarin red stained sections from a normal (a) and diabetic (b) rat at one week post­
operation. The implant site is indicated by IS, granulation tissue by GT and m andibular bone by 
MB.
Figure 5.7: Alizarin red stained sections a normal (c) and diabetic (d) rat at three weeks post­
operation. Around the normal implant socket (IS) bright red staining is visible (indicated by 
arrows) and is evidence o f  mineralisation. Granulation tissue is indicated by GT and m andibular 
bone by MB.
Figure 5.8: Alizarin red stained section from a normal (a) and diabetic (b) rat at nine weeks 
post-operation. The implant site is indicated by IS, granulation tissue by GT and m andibular 
bone by MB. Areas o f  bright red staining are indicated by arrows.
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Figure 5.9: Alizarin red stained sections from a normal (c) and diabetic (d) rat at twelve weeks 
post-operation. Around the normal implant socket (IS) bright red staining is visible (indicated by 
arrows) and is evidence o f  mineralisation. Granulation tissue is indicated by GT and m andibular 
bone by MB.
5.3.3 Immunolocalisation of Stro-1
Images obtained from the immunolocalisation of mesenchymal progenitor 
cells are shown in Figures 5.10-5.12. Stro-1 expression is indicated by brown cellular 
staining. There were not any substantial differences between normal and diabetic 
animals in the number of these cells present around the implant sites at any time 
point. At one week post-operation, Stro-1 was found to be present around the implant 
sites of both diabetic and normal rats (Figure 5.10). Expression of Stro-1 at three 
weeks post-operation (Figure 5.11) was much reduced in both animals, with only a 
very few positive cells seen around the implant sites. At nine weeks post-operation 
(Figure 5.12), there was no population of Stro-1 positive cells which could be 
identified around the implant site in either normal or diabetic animals. Figure 5.13 
shows a graph of the average number of Stro-1 positive cells per 100pm in tissue 
sections from both animals over one, three and nine weeks post-operation. Images of 
immunolocalisation of Stro-1 at twelve weeks post-operation are not shown due to 
the lack of Stro-1 expression in either animal at twelve weeks post-operation.
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Figure 5.10: Immunolocalisation o f  Stro-1 in tissue sections from a normal (a) and diabetic (b) 
rat at one week post-operation. Positive cells are indicated by arrows. W here visible, the implant 
socket is indicated by IS. Inset into both images are a magnified areas o f  the images.
Figure 5.11: Immunolocalisation o f  Stro-1 in tissue sections from a normal (c) and a diabetic (d) 
rat at three weeks post-operation. Positive cells are indicated by arrows. The implant socket, 
where visible is indicated by IS.
Figure 5.12: Immunolocalisation o f  Stro-1 in tissue sections from a normal (a) and a diabetic (b) 
rat at nine weeks post-operation. The implant socket, where visible is indicated by IS.
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Figure 5.13: Graph o f  the average num ber o f  Stro-1 positive cells per 100pm2 in five random
fields o f  view over one, three and nine weeks post operation.
5.3.4 Immunolocalisation of PCNA
Images resulting from the immunolocalisation of proliferating cell nuclear 
antigen (PCNA) are shown in Figures 5.14-5.17. PCNA positivity is indicated by 
brown cellular staining. In the diabetic condition, there was a prolonged expression 
of PCNA compared to normal controls. PCNA was not highly expressed in sections 
from either normal or diabetic animals at one week post-operation, although higher 
levels were observed in the normal animal (Figure 5.14). This is in contrast to three 
weeks post-operation (Figure 5.15), when a high degree of PCNA positivity was seen 
around both normal and diabetic implant sites. At nine weeks post-operation (Figure 
5.16) however, PCNA was not widely expressed around the normal implant site, but 
was expressed at a higher level around the diabetic implant site. At twelve weeks 
post-operation (Figure 5.17), PCNA did not appear to be expressed around the 
implant site in sections from either normal or diabetic animals. Figure 5.18 shows a 
graph of the average number of PCNA positive cells per 100pm2 in tissue sections 
from both animals over all four time points.
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Figure 5.14: Immunolocalisation o f  PCNA in tissue sections from a normal (a) and a diabetic 
(b) rat at one week post-operation. The implant socket is indicated by IS.
Figure 5.15: Immunolocalisation o f PCNA in tissue sections from a normal (c) and a diabetic 
(d) rat at three weeks post-operation. Positive cells are indicated by arrows. The implant socket, 
where visible, is indicated by IS.
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Figure 5.16: Immunolocalisation o f  PCNA in tissue sections from both a normal (a) and a 
diabetic (b) rat at nine weeks post-operation. Examples o f  positive cells are indicated by arrows. 
Where visible, the implant socket is indicated by IS. Inset into image b is a magnified area o f  the 
image.
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Figure 5.17: Immunolocalisation o f PCNA in tissue sections from both a normal (above) and a
diabetic (below) rat at twelve weeks post-operation. The implant socket, where visible, is
indicated by IS.
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Figure 5.18: Graph o f  the average num ber o f  PCNA positive cells per 100pm2 in five random
fields o f view over one, three, nine and twelve weeks post operation.
5.3.5 Immunolocalisation of Osteopontin
Images obtained from the immunolocalisation of osteopontin are shown in 
Figures 5.19-5.22. Osteopontin expression is indicated by brown cellular staining and 
followed approximately the same pattern as PCNA expression, with a prolonged 
expression in the diabetic condition. At one week post-operation osteopontin was 
present in a relatively low level around the implant sites of both normal and diabetic 
animals (Figure 5.19). By three weeks post-operation (Figure 5.20), osteopontin was 
expressed at high levels around the implant site in both normal and diabetic animals, 
1 with much lower levels of expression in the normal animal by nine weeks post­
operation. In contrast, the expression of osteopontin in the diabetic animal at this 
time point was higher, being comparable to the three week post-operative level 
(Figure 5.21). Finally, at twelve weeks post-operation (Figure 5.22), there was very 
little osteopontin expression around the implant site in either animal. Figure 5.23 
shows a graph of the average number of osteopontin positive cells per 100pm in 
tissue sections from both animals over all four time points.
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Figure 5.19: Immunolocalisation o f  osteopontin in tissue sections from both a normal (a) and a 
diabetic (b) rat at one week post-operation. The implant socket, where visible, is indicated by IS.
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Figure 5.20: Immunolocalisation o f  osteopontin in tissue sections from both a normal (c) and a 
diabetic (d) rat at three weeks post-operation. Positive cells are indicated by arrows. The im plant 
socket, where visible, is indicated by IS.
Figure 5.21; Immunolocalisation o f osteopontin in tissue sections from both a normal (a) and a 
diabetic (b) rat at nine weeks post-operation. Examples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS.
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Figure 5.22; Immunolocalisation o f osteopontin in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve weeks post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.23: Graph o f  the average num ber o f  osteopontin positive cells per 100pm2 in five
random fields o f  view over one, three, nine and tw elve weeks post operation.
5.3.6 Immunolocalisation of Osteocalcin
Images obtained from the immunolocalisation of osteocalcin are shown in 
Figures 5.24-5.27. Osteocalcin expression is indicated by brown cellular staining. 
Overall, expression of osteocalcin appeared to take place earlier in the normal 
animals compared to their diabetic counterparts. No expression of osteocalcin was 
observed at one week post-operation in either animal (Figure 5.24). At three weeks 
post-operation (Figure 5.25), there was a significantly higher level of expression 
around the implant site in the normal animal compared to the diabetic animal. The 
opposite situation exists at nine weeks post-operation (Figure 5.26), where there was 
minimal expression around the implant site in the normal animal, while there was a 
higher degree of expression around the diabetic implant site. By twelve weeks post 
operation (Figure 5.27), there was not a substantial expression of osteocalcin around 
the implant sites in either animal, although the level of expression in the normal 
animal was slightly higher. Figure 5.28 shows a graph of the average number of 
osteocalcin positive cells per 100pm2 in tissue sections from both animals over all 
four time points.
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Figure 5.24; Im m unolocalisation o f  osteocalcin in tissue sections from both a normal (a) and a 
diabetic (b) rat at one week post-operation. The im plant socket is indicated by IS.
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Figure 5.25: Im m unolocalisation o f  osteocalcin in tissue sections from a norm al (c) and a 
diabetic (d) rat at th ree  w eeks post-operation. Exam ples o f  positive cells are given by arrows. 
The im plant socket, w here visible, is indicated by IS. Inset into image c is a m agnified area o f  
the image.
Figure 5.26; Immunolocalisation o f osteocalcin in tissue sections from both a normal (a) and a 
diabetic (b) rat at nine weeks post-operation. The implant socket is indicated by IS. Inset into 
image b is a m agnified area o f  the image.
Figure 5.27: Immunolocalisation o f  osteocalcin in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve weeks post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.28: Graph o f the average num ber o f  osteocalcin positive cells per 100pm2 in five 
random fields o f  view over one, three, nine and twelve weeks post operation.
5.3.7 Immunolocalisation of TGFB1
Images obtained from the immunolocalisation of TGFpi are shown in 
Figures 5.29-5.32. TGFpl expression is indicated by brown cellular staining. 
Expression o f TGFpl appeared to be delayed in the diabetic condition, as opposed to 
an early peak of expression in the normal animals. TGFpi expression was higher at 
week 1 post-operation in the normal animal compared to its diabetic counter-part at 
(Figure 5.29). At 3 weeks post operation however, similar levels of TGFpi 
expression were observed around both the normal and the diabetic implant site 
(Figure 5.30). TGFpl was seen around both implant sites at 9 weeks post operation, 
^ although at a lower level in the normal animal (Figure 5.31). Finally, at the 12 week 
time point, expression was higher in the normal animal (Figure 5.32). Figure 5.33 
shows a graph of the average number of TGFpl positive cells per 100pm2 in tissue 
sections from both animals over all four time points.
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Figure 5 .2 9 :  Immunolocalisation o f  TGFf31 in tissue sections from both a norm al (a) and a 
diabetic (b) ra t at one week post-operation. Exam ples o f  positive cells are indicated by arrows. 
The im p la n t  socket is indicated by IS. Inset into image a is a m agnified area o f  the image.
Figure 5 .3 0 :  Immunolocalisation o f  TGFJ31 in tissue sections from both a norm al (c) and a 
d iabetic (d) ra t at three weeks post-operation. Exam ple o f  positive cells are indicated by arrows. 
The im p la n t  socket, where visible, is indicated by IS. Inset into both im ages are a m agnified 
areas o f  t h e  im ages.
Figure 5.31: Immunolocalisation o f  T G F pi in tissue sections from both a norm al (a) and a 
diabetic (b) rat at nine weeks post-operation. Exam ples o f  positive cells are indicated by arrows. 
The implant socket, where visible is indicated by IS. Inset into both images are a m agnified areas 
o f  the images.
Figure 5.32: Immunolocalisation o f  TGF01 in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve weeks post-operation. Exam ple o f  positive cells are indicated by 
arrows. The implant socket, where visible, is indicated by IS. Inset into image c is a m agnified 
area o f  the image.
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Figure 5.33; Graph o f  the average number o f  TGF01 positive cells per 100pm2 in five random  
fields o f  view over one, three, nine and twelve weeks post operation.
5.3.8 Immunolocalisation of IL-1B
Images obtained from the immunolocalisation of IL-ip are shown in Figures 
5.34-5.37. IL-lp positivity is indicated by brown cellular staining. IL-ip expression 
appeared to be delayed in the diabetic healing process, with an early expression 
around the normal implant site which was not seen around the diabetic. At one-week 
post operation, expression of IL-ip was evident around the normal implant site but 
was absent from the diabetic (Figure 5.34). At three weeks post-operation, IL-lp was 
expressed around the implant site in both normal and diabetic animals, although 
expression was higher in the normal animal (Figure 5.35). At both the 9 (Figure 5.36) 
and 12 (Figure 5.37) week time points, no expression was seen in either animal. 
Figure 5.38 shows a graph of the average number of IL-lp positive cells per 100pm2 
in tissue sections from both animals over all four time points.
133
Figure 5.34: Immunolocalisation o f  IL -ip  in tissue sections from both a normal (a) and a 
diabetic (b) rat at one week post-operation. Exam ples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into image a is a magnified area o f  
the image.
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Figure 5.35; Immunolocalisation o f  IL -lp  in tissue sections from both a normal (c) and a 
diabetic (d) rat at three week post-operation. Examples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into both images are a m agnified 
areas o f  the images.
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Figure 5.36; Immunolocalisation o f IL -lp  in tissue sections from both a norm al (a) and a 
diabetic (b) rat at nine week post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.37; Immunolocalisation o f  IL -ip  in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve week post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.38: Graph o f  the average num ber o f  IL1-0 positive cells per lOOpm2 in five random  
fields o f  view over one, three, nine and twelve weeks post operation.
5.3.9 Immunolocalisation of TNFa
Images obtained from the immunolocalisation of TNFa are shown in Figures 
5.39-5.42. TNFa positivity is indicated by brown cellular staining. TNFa was only 
seen to be expressed in the diabetic animal at the 3 week post operative time point 
and expression levels were relatively low (Figure 5.40). Figure 5.43 shows a graph of 
the average number of TNFa positive cells per 100pm2 in tissue sections from both 
animals over all four time points.
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F igure 5.39; Immunolocalisation o f  TN Fa in tissue sections from both a norm al (a ) and a 
diabetic (b) rat at one week post-operation. The implant socket, where visible, is indicated by IS.
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F igure 5.40; Immunolocalisation o f  TN Fa in tissue sections from both a norm al (c) and a 
diabetic (d) rat at three weeks post-operation. Examples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into image d is a m agnified area o f  
the image.
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Figure 5.41: Immunolocalisation o f  TN Fa in tissue sections from both a normal (a) and a 
diabetic (b) rat at nine weeks post-operation. The implant socket, where visible, is indicated by 
IS.
F igure 5.42; Immunolocalisation o f  TN Fa in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve weeks post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.43; Graph o f  the average number o f  T N Fa positive cells per 100pm2 in five random  
fields o f  view over one, three, nine and twelve weeks post operation.
5.3.10 Immunolocalisation of F4/80
Images obtained from the immunolocalisation of F4/80 are shown in Figures 
5.44-5.47. F4/80 positivity is indicated by brown cellular staining. Cells positive for 
the pan specific macrophage marker F4/80 were apparent in the healing tissue around 
the normal implant site at one week post-operation, in contrast to the diabetic implant 
site at this time point, around which no expression was seen (Figure 5.44). 
Conversely, at 3 weeks post operation, no F4/80 expression appeared around the 
normal implant site, while there was expression around the diabetic implant site 
(Figure 5.45). Figure 5.46 shows that there is even higher expression of F4/80 around 
$ the diabetic implant site at 9 weeks post-operation, while there is no expression 
around the normal implant site. At 12 weeks post operation, there does not appear to 
be any staining around either normal or diabetic implant sites (Figure 5.47). Figure 
5.48 shows a graph of the average number of F4/80 positive cells per 100pm in 
tissue sections from both animals over all four time points.
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Figure 5.44; Immunolocalisation o f  F4/80 in tissue sections from both a normal (a) and a 
diabetic (b) rat at one week post-operation. Examples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into image a is a m agnified area o f  
the image.
Figure 5.45: Immunolocalisation o f  F4/80 in tissue sections from both a normal (c) and a 
diabetic (d) rat at three weeks post-operation. Exam ples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into image b is a m agnified area o f  
the image.
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Figure 5.46: Immunolocalisation o f  F4/80 in tissue sections from both a normal (a) and a 
diabetic (b) rat at nine weeks post-operation. Exam ples o f  positive cells are indicated by arrows. 
The implant socket, where visible, is indicated by IS. Inset into image b is a m agnified area o f  
the image.
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Figure 5.47; Immunolocalisation o f  F4/80 in tissue sections from both a normal (c) and a 
diabetic (d) rat at twelve weeks post-operation. The implant socket, where visible, is indicated by 
IS.
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Figure 5.48: Graph o f  the average num ber o f  F4/80 positive cells per 100pm2 in five random  
fields o f  view over one, three, nine and tw elve weeks post operation.
5.3.11 Negative Controls
Typical examples of both non-immunogenic IgG (IgM for Stro-1) and 
primary excluded negative controls for all immunolocalisations performed are shown 
in Figure 5.49. Both of these negative controls were performed for all tissue sections 
at all time points and none showed any positive staining.
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Figure 5.49: Typical examples o f  negative controls which had the primary antibody ex c lu d ed  
(left) and a negative control in which a non-immunogenic IgG antibody (non-im munogenic Ig M  
in the case o f  Stro-1) was used in place o f  the primary IgG (or IgM for Stro-1) antibody (r ig h t). 
These controls were perform ed for every tim e point and condition and did not dem onstrate a n y  
positive staining.
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5.3.12 Summary of Immunohistochemistrv Results
A flow chart summarising the temporal appearance of the markers examined 
by immunohistochemistry in both normal and diabetic mandibles is shown in Figure 
5.50.
i
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Figure 5.50: A flow chart summarising the immunohistochemistry results at the different tim e 
points around the normal and the diabetic implant sites.
5.4 Discussion
The results presented in this chapter show the effectiveness of the in vivo 
model of osseointegration as a means to contrast progression of healing around 
titanium dental implants in both a normal and a clinically relevant disease state, type 
II DM. Although bone healing occurred around the implant site in both normal and 
diabetic animals, diabetic bone healing was shown to be delayed compared to the 
normal animal, and there were substantial differences in the temporal expression of 
bone markers, inflammatory cytokines, the growth factor TGFpi and the presence of 
it macrophages around the implant site. These results, which indicate behavioural 
differences between cells around normal and diabetic implant sites, may serve to 
partially elucidate the cellular basis of the delay in healing observed in diabetic bone.
It is widely reported that there is a delay in bone healing associated with DM 
(Hasegawa et al. 2008; Kwon et al. 2005; Liu et al. 2007b; McCracken et al. 2000; 
Shyng et al. 2006; Siqueira et al. 2003), which is in agreement with the histology 
results presented in this chapter. Although both animals appear to have developed 
granulation tissue around the implant site by one week post-operation, delayed 
formation of new bone and deposition of calcium were apparent in the GK rats 
compared to normal controls. This was particularly evident at 3 weeks post­
operation, at which time new bone and tissue mineralisation were seen adjacent to 
the implant site in the normal animal, while there was no indication of these bone 
healing responses in the diabetic animal. Healing was again seen to be delayed in the 
diabetic animal at 9 weeks post-operation, while by 12 weeks post-operation, the 
diabetic animal had an almost identical amount of bone around the implant socket 
compared to its normal counterpart, suggesting that osseointegration was occurring 
in the diabetic animal, but at a substantially slower rate than in the normal animal. 
The time frame observed for delayed healing in diabetic bone corresponds with much 
of the literature, although few have investigated diabetic bone healing at a time point 
as late as 12 weeks (Hasegawa et al. 2008; Kwon et al. 2005; McCracken et al. 2000; 
Shyng et al. 2006; Siqueira et al. 2003).
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One finding presented herein, that is of particular interest, is that the observed 
delay in bone healing in the diabetic animals did not appear to be the result of the 
failure of mesenchymal stem cells (MSCs) to arrive at the site of the injury. The 
expression pattern of Stro-1, a marker for these cells, was the same for both normal 
and diabetic animals at all time points investigated. This would suggest that MSCs, 
present in their niche in bone marrow adjacent to the implant site, responded to the 
extraction of the incisor and placement of the implant, migrated to the site of the 
injury and infiltrated the granulation tissue and thus were present in both the normal 
and diabetic animal at 1 week post-operation. Thus it does not appear that either a 
lack of response from these cells, or an impairment of their ability to migrate to the 
, site of injury were responsible for the observed delayed healing response in diabetes. 
It is possible, therefore, that this delay arises from alterations in the behaviour of the 
cells present.
The cell proliferation marker PCNA appeared around the normal implant site 
at one week post-operation at low levels yet was not expressed around the diabetic 
implant site until 3 weeks post-operation. It has been previously reported that PCNA 
expression is delayed in an obese rat model of type II DM bone healing compared to 
normal controls 2 weeks after an injury to tibia bone (Liu et al. 2007b). Similarly, it 
has been reported that PCNA is reduced in rat models of type I diabetic bone healing 
7 days after controlled femoral fractures (Gebauer et al. 2002; Tyndall et al. 2003). 
Not only do the results presented in this chapter correspond with the reported delay 
in the expression of PCNA during the early phase of the diabetic bone healing 
process, but additionally demonstrate the persistence of PCNA expression around the 
diabetic implant site at 9 weeks post-operation, in contrast to the corresponding 
normal implant site. This could suggest that the proliferative response of cells to 
injury was delayed in the diabetic condition, perhaps contributing to the observed 
delay in diabetic bone healing. Furthermore, the sustained proliferative response 
observed around the diabetic implant site could indicate a sustained inflammatory 
response, with the proliferation of immune cells such as macrophages, or a delay in 
the differentiation of proliferating MSCs into post-mitotic osteoblast progenitor cells 
around the implant site, both of which would likely lead to a delay in bone formation. 
Certainly, positive staining for F4/80, indicating the presence or macrophages,
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corresponds with the persistence of cell proliferation around the diabetic implant site 
at 9 weeks post-operation.
Also of interest are the differences in the expression of the osteoblast markers 
osteopontin (OP) and osteocalcin (OC) between normal and diabetic animals. OP, 
which is expressed early in the process of osteoblast differentiation, has a wide array 
of functions including playing a role in the attachment of cells, including 
differentiating osteoblasts, to matrices (Sodek et al. 2000). The differences in the 
expression of OP around the diabetic and normal implant sites followed a similar 
pattern to the differences in PCNA expression, in that OP was present around both 
^mplant sites at 3 weeks post-operation, yet persisted around the diabetic implant site 
at 9 weeks post-operation, by which point it had ceased around the normal. 
Continued expression of OP around the diabetic implant site could indicate a delay in 
the progression of osteoblast differentiation, as it is typically expressed in the early 
stages of this process (Hughes et al. 2006; Sodek et al. 2000). OP also has a number 
of other complex functions in wound healing however, including a chemo-attractant 
and anti-apoptotic signal for macrophages, neutrophils, T-cells, fibroblasts and 
endothelial cells as well as osteoblast progenitor cells via CD 44 interaction (Ashkar 
et al. 2000; Denhardt et al. 2001; O'Regan et al. 1999; Wang and Denhardt; Weber et 
al. 1996). Interestingly, macrophage numbers, as indicated by F4/80 positivity, were 
much higher around the diabetic implant site at 9 weeks post-operation, which 
corresponded to the observed persistence of OP and may indicate that OP is playing 
a role in the continued recruitment of macrophages and possibly other immune cells. 
This would lead to an extended inflammatory response, which would certainly 
contribute to a delay in the bone healing process.
OC expression, in contrast to that of OP, is seen to be delayed around theV. 1
diabetic implant site. While there were high levels of expression around the normal 
implant site at 3 weeks post-operation, similar levels were not seen in the diabetic 
animal until 9 weeks post-operation. OC is an osteoblast specific protein which is 
considered to be an indicator of a mature osteoblast phenotype, and has been 
proposed to halt the process of bone formation and begin the process of bone 
remodelling, thus participating the final stage of bone maturation (Boskey et al.
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1998; Ducy et al. 1996). Therefore, a temporal delay in the expression of OC, such as 
was observed in the diabetic animal, would indicate that the osteoblast differentiation 
pathway is somehow disrupted in type II DM, leading to a delay in process of bone 
healing.
TGFpi is known to be involved in the early phases of the osteoblast 
differentiation pathway, where it is suggested to be responsible for driving the 
expansion of osteoblast progenitor cells (Centrella et al. 1994; Hughes et al. 2006). 
Conversely TGFpi has been shown to suppress terminal osteoblast differentiation 
and the process of mineralisation (Maeda et al. 2004). The expression of TGFpi 
* around the normal implant site was at its highest level at 1 week post-operation, with 
a subsequent decrease to much lower levels at each subsequent time point. These 
novel findings would indicate that TGFpl may be functioning to create a pool of 
osteoblast progenitor cells at the outset of the healing response, which would then 
undergo differentiation into more mature osteoblasts as expression decreased. In 
contrast, around the diabetic implant site, expression of TGFpl was not seen until 3 
weeks post-operation and was maintained until 9 weeks post-operation. This fits with 
the delay and prolongation of cell proliferation, continued expression of OP and the 
delay in OC expression observed in the diabetic animals. If TGFpl expression was 
delayed around the implant site in the diabetic animal, it could cause a delay and 
subsequent elongation of the initial proliferative phase of osteoblast progenitor cells, 
which would impair the process of osteoblast differentiation causing the observed 
alterations in OP and OC expression, in this way contributing to the observed delay 
in the process of bone formation.
The study presented in this chapter also demonstrated some differences in the 
expression of inflammatory. cytokines between normal and diabetic animals. 
Differences in the temporal expression of IL-lp and TNFa between normal and 
diabetic animals may play a role in the observed delay in diabetic bone healing. IL- 
lp is an inflammatory cytokine with a vast number of complex functions attributed 
to it. In the context of bone, it has been reported to both inhibit osteoblast 
proliferation and increase bone formation (Hanazawa et al. 1986; Ohmori et al. 1988) 
and conversely it may increase osteoblast proliferation while inhibiting
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differentiation and thus bone formation, particularly at lower concentrations (Canalis 
1986; Ellies and Aubin 1990; Rickard et al. 1993). In the context of the results 
presented here, IL-lp expression was seen around the normal implant site at 1 and 3 
weeks post-operation, as opposed to only at 3 weeks post-operation around the 
diabetic implant site. It may be that the early expression of IL-lp is the result of a 
normal early inflammatory response, concomitant with the presence of macrophages 
around the normal implant site at 1 week post-operation, which served to stimulate 
the process of osteoblast progenitor cells proliferation, before resolving and enabling 
the process of osteoblast differentiation and thus bone formation to continue. The 
delay in IL-lp expression seen around the diabetic implant site may indicate a 
*§ disruption in the normal process of inflammation and stimulation of bone healing.
TNFa expression, by contrast, was only seen at 3 weeks post-operation in the 
diabetic animal, and then at a relatively low level. Generally, TNFa is known as 
inflammatory cytokine which has deleterious effects on the process of bone healing, 
inhibiting both osteoblast proliferation and differentiation (Bertolini et al. 1986; 
Gowen et al. 1988) and stimulating bone resorption (Nanes 2003). It is difficult to 
interpret what the impact of TNFa expression on the process of diabetic bone healing 
may be, as it is only expressed at a relatively low level at a single post-operative time 
point. TNFa expression would however, indicate an inflammatory response around 
the implant site, which would almost certainly impair bone healing, leading to the 
delay observed in the diabetic animals.
It is an unfortunate fact that only a single animal from each experimental 
group was available for study at each time point, meaning that there was an N of 1. 
This work would have been considerably strengthened by the addition of replicate 
animals; limitations were enfprced however, by the sheer distance involved in the 
collaboration that produced this work. Initially, replicate animals were sought and 
some replicate mandibles were delivered. Upon inspection of these mandibles 
however, it was apparent that a large number of implants had not undergone 
osseointegration, and histological examination revealed evidence of fibrous 
encapsulation, possibly resulting from infections and incomplete healing. These
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replicates were therefore judged to be unusable. Unfortunately time and budgetary 
constraints did not allow further animals to be obtained from Japan.
In summary, the data presented in this chapter have shown that there is a 
delay in bone'healing around a dental implant site in a rat model of type II DM. 
Possible causes for the observed delay appear to include a prolongation of cell 
proliferation and OP expression around the implant site, leading to a delay in 
progression of the osteoblast differentiation pathway as evidenced by the delay in the 
expression of OC. Differences in the expression of TGFpi around the implant site 
may contribute to this delay, particularly as the onset of expression is delayed in the 
*1 diabetic animal. It is also possible that an altered inflammatory response, seen in the 
variations of the presence of macrophages and expression of IL-lp and TNFa around 
the implant site, is either partially responsible or a result of the other differences 
observed between the normal and diabetic implant sites and almost certainly is 
involved in the observed delay in diabetic bone healing. It is difficult to speculate 
further from the data presented here however as to possible mechanisms for the 
observed findings, however these results will hopefully contribute to a greater 
understanding of the delayed healing which has been widely observed in DM, 
particularly in relation to titanium dental implants. If the mechanisms by which 
osseointegration of dental implants is delayed in DM were to be better understood, it 
is possible that this information could be translated into therapies which would 
improve outcomes for diabetic individuals, thus broadening their access to treatment.
/
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Chapter 6; The Osseointegration of Modified Titanium Surfaces in
Rat Mandibles
6.1 Introduction
As discussed in detail within the introduction of this thesis, the bone repair 
process which takes place around the site of a titanium dental implant has several key 
phases. Fibrin clot formation, the activation and resolution of the inflammatory 
response, the initiation of bone formation and the bone remodelling process all 
interact in order to bring about the final osseointegration of the implant (Davies 
2003; Hughes et al. 2006). The regulation of the progression of these phases is highly 
complex, and it is nearly impossible to consider all aspects of it when attempting to 
accurately model this process in vitro. An in vitro model involving osteoblast-like 
cells being cultured on titanium surfaces under mineralising conditions has been 
described this thesis, and examples of many similar model systems can be found in 
the literature (Deligianni et al. 2001; Qu et al. 2007; Salido et al. 2007; Schneider et 
al. 2003; Tsukimura et al. 2008; Zhao et al. 2005). These models are useful as they 
serve to simplify a highly complex process, thereby allowing the direct impact of 
surface modification on osteoblast activity to be investigated and interpreted. As a 
result of this simplification however, these models disregard important aspects of 
osseointegration, making it difficult to define the influence that alterations in surface 
parameters such as topography and chemistry have on this process in a clinical 
situation, when these implants are placed in patients. The use of an in vivo model of 
osseointegration, which can model all aspects of the process of osseointegration, is 
therefore a key component in determining potential clinical benefits of surface 
modification.
An in vivo rat model of dental implant osseointegration, developed in 
conjunction with Osaka Dental University in Japan (Sakai et al. 2008), has been 
described in this thesis and was used to investigate the effects of DM on the 
osseointegration of implants with machined surfaces. In this chapter however, the 
same model system was used, to investigate the osseointegration of titanium dental
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implants with modified titanium surfaces. These surfaces were modified in the same 
way as the titanium discs used in the in vitro investigations described in this thesis. 
This provides a direct link between observations made regarding the behaviour of 
osteoblast progenitor cells attached to each of the experimental surfaces and the 
impact of these surfaces on the process of bone healing upon their insertion into a rat 
mandible. It has been previously reported in the literature that a variety of modified 
surfaces have enhanced osseointegration in vivo (Buser et al. 2004; Cho and Park 
2003; Cochran et al. 1998; Franchi et al. 2007; Schwarz et al. 2007; Sul et al. 2005; 
Sul et al. 2001; Wennerberg et al. 1998). It may be the case that, due to the 
complexities of the bone repair process, osteoblast progenitor cells behave similarly 
i  on two differently modified surfaces in vitro, while these surface modifications have 
implications for the osseointegrative potential of an implant in vivo. This possibility 
therefore renders the use of this model critical to the investigation of the impact of 
titanium surface modification on osseointegrative potential.
The work described in Chapter 3 questioned whether the modification of 
titanium surfaces caused accelerated bone formation or improved mechanical 
interlocking with bone matrix, resulting in better bone attachment. The use of in vivo 
model of the osseointegration of modified titanium surfaces will serve to further 
clarify this issue. In this model, improved osseointegration response to a given 
surface would be indicated by an accelerated formation of bone in apposition to that 
surface. H&E and alizarin red staining were therefore used to histologically assess 
the progression of bone healing at 1, 3, 9 and 12 week post-operative time points 
around sites where implants with machined, grit blasted/acid etched and TCP coated 
surfaces were placed. This served to detect any influences these surface 
modifications might have had on implant osseointegration over time. It is also a 
possibility that, in addition to altering bone formation, surface modifications may 
lead to changes in osteoblast progenitor cell recruitment, proliferation and 
differentiation around implant sites. Therefore, immunolocalisations were carried out 
for Stro-1, PCNA, OP and OC in order to detect changes in cell activity brought 
about by implant surface modification.
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The use of an in vivo model of osseointegration of titanium implants in a rat 
mandible in this chapter represents a close approximation of the clinical situation and 
is perhaps one of the closest available. Ultimately, it is the bone healing response to a 
surface in an in vivo situation which determines its suitability for use clinically, 
irrespective of its effects on attached osteoblast progenitor cells in vitro. Therefore 
using this model to investigate the osseointegrative potential of each experimental 
surface is the logical extension of the other investigations described in this thesis and 
will generate useful data which is directly relevant to determining the effects of 
modified titanium surfaces on the process of osseointegration.
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6.2 Materials and Methods
6.2.1 Preparation of Mandibles
All implant procedures were carried out at the Dental University of Osaka 
Japan on 24 10-week old male Wistar rats, as described in Sakai et al (2008). All 
experimental protocols involving these animals were reviewed and approved by the 
Animal Committee of Osaka Dental University (approval number 08-03009), and 
conformed with the procedures described in the ‘Guiding Principles for the Use of 
* Laboratory Animals’ handbook at the Laboratory Animal Facilities in the Institute of 
Osaka Dental Research, Osaka Dental University. Incisors were trimmed prior to 
extraction as described in section 5.2.1, in order to stimulate eruption. Anaesthetic 
was applied and tooth extraction followed by curette was carried out as described in 
section 5.2.1. Implants were produced and prepared by Osteo-Ti (Guernsey) and 
included a machined, grit blasted/acid etched surface and a TCP coated surface. 
These surface treatments were carried out as for the titanium discs, described in 
section 2.2.1. Animals were sacrificed at post-operative time points of 1, 3, 6, 9 and 
12 weeks, fixed and mandibles extracted as described in section 5.2.1.
6.2.2 Processing of Mandibles
Implants were removed from mandibles, cut into approximately 2mm thick 
sections running perpendicular to the implant socket using a bone saw and 
demineralised as described in section 5.2.2. Demineralised tissue sections were 
placed in biopsy cassettes pnd processed by machined as described in section 5.2.2. 
Processing of mandibles was carried out as described in section. 5.2.2. The processed 
tissue sections were embedded in paraffin wax and 5 pm sections were cut as 
described in section 5.2.2. Sections were then mounted on poly-L-lysine coated glass 
slides (Sigma Aldrich) before being placed in an oven at 65°C overnight.
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6.2.3 Haematoxvlin and Eosin Staining
Sections were stained with haematoxylin and eosin (H&E) using an 
automated staining machine, in order to assess the level of bone healing around the 
implant site (described in section 5.2.3). Images were captured using an Olympus 
AX70 microscope incorporating a Nikon DXM 1200 digital camera and ACT-1 
software.
6.2.4 Alizarin Red Staining
In order to assess the level of mineralization in the tissues around the implant 
sites, sections were stained with alizarin red as described in section 5.2.4.
6.2.5 Immunohistochemistrv
6.2.5.1 Preparation of Sections
Mounted sections were deparaffinized and endogenous peroxidase activity 
quenched with 3% hydrogen peroxide as described in section 5.2.5.1. For the 
immunolocalisation of TGFpi, IL-lp, TNFa and F4/80, antigen retrieval was 
performed using 24pg/mL protinase K (Sigma Aldrich) as described in section
5.2.5.1.
v. 1
6.2.5.2 Immunolocalisation
Immunodetection of PCNA, osteopontin, osteocalcin, TGFpl, IL-ip, TNFa 
and F4/80 was carried out using a Vectastain Universal IgG Kit (Vector 
Laboratories) and a DAB peroxidase kit (Vector Laboratories) as described in section
5.2.5.2. As a negative control for each experiment, a non-immunogenic IgGi control
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antibody (Sigma Aldrich) was substituted for the primary within the protocol or the 
primary was excluded altogether and was with blocking serum. Cover slips were 
applied to sections using DPX glue, and images taken using an Olympus AX70 
microscope incorporating a Nikon DXM 1200 digital camera and ACT-1 software. 
All immunolocalisations were performed in duplicate. Details of all antibodies used 
are given in Table 5.1
6.2.5.3 Stro-1 Localization
Immunodetection of Stro-1 was carried out as described in section 5.2.5.3, 
without the Vectastain Kit, as the primary antibody to Stro-1 is an IgM class 
antibody. Details of the Stro-1 antibody are given in Table 5.1.
6.2.5.4 Semi-Quantification of Immunohistochemical Results
The results of the immunolocalisation experiments were semi-quantified as 
described in section 5.2.5.4. In order to statistically compare the number of positive 
cells per 100pm2 present around the sites of the different implants, a Kruskal-Wallis 
test was used, as there were three treatment groups to be compared at each time point 
(Instant Package, Graph Pad Software). A Dunn post test was used to compare the 
three groups to each other. Non-parametric statistical tests were performed as the n 
numbers were too small to assume normality or equal variance. P values below .05 at 
a 95% confidence interval were held to be statistically significant.
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6.3 Results
6.3.1 Haematoxvlin & Eosin Histology
Figures 6.1-6.4 show that bone healing-appeared to progress at approximately 
the same rate around the implant sites for all three treated implant implants. Further, 
there was no difference between the three surfaces or the amount of contact versus 
distance osteogenesis at any time point. In Figure 6.1, a cell rich granulation tissue 
(GT) is visible around the implant sockets of all three surface treatments at one week 
** post-operation. By three weeks post-operation (Figure 6.2) however, there was 
evidence of new bone growth around all three implant sockets. At nine weeks post­
operation (Figure 6.3), bone healing had advanced considerably around all of the 
implant sockets. Figure 6.4 shows that bone healing was nearly complete around the 
machined and grit blasted/acid etched implant sites at twelve weeks post-operation, 
while a large amount of granulation tissue was seen around the TCP coated implant 
site, with very little evidence of bone healing. This was replicated in both 
experimental animals.
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F igure 6.1: H&E stained sections obtained from rat mandibles with machined (a) grit
blasted/acid etched (b) and TCP (c) coated  implants one week post-operation. MB indicates 
m andibular bone, IS indicates the im plant socket and GT the granulation tissue.
500um
F igure 6.2: H&E stained sections ob ta ined  from rat mandibles with machined (d) grit 
blasted/acid etched (e) and TCP coated (f) im plants three weeks post-operation. MB indicates 
m andibular bone, IS indicates the im plan t socket and GT the granulation tissue. New bone is 
indicated by arrows.
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F igu re  6.3; H&E stained sections obtained from rats with m achined (a) grit blasted/acid etched 
(b) and TCP (c) coated implants nine weeks post-operation. MB indicates m andibular bone and 
IS indicates the implant socket. New bone is indicated by arrows.
F ig u re  6.4: H&E stained sections obtained from rat mandibles with m achined (d) grit 
blasted/acid etched (e) and TCP coated (f) im plants tw elve weeks post-operation. MB indicates 
m andibular bone and IS indicates the im plant socket. New bone is indicated by arrows.
6.3.2 Alizarin Red Staining
Images obtained following the staining of mineral residue with alizarin red 
are shown in Figures 6.5-6.8. The results concur with those from H&E staining. At 
one week post operation (Figure 6.5), no newly formed mineralised bone was visible 
around any of implant sites. At three and nine weeks post-operation (Figure 6.6-6.7), 
areas of bright red staining were visible, particularly at the edges of newly formed 
bone tissue, indicating tissue mineralisation. In the sections from twelve weeks post­
operation (Figure 6.8), areas of bright red staining were visible at the edges of newly 
* formed bone around the machined and grit blasted/acid etched implant sites due to 
the small amount of bone formation around the TCP coated implant site at this time 
point, little staining was seen.
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Figure 6.5: Alizarin red stained sections obtained from rat mandibles with machined (a) grit 
blasted/acid etched (b) and TCP (c) coated implants one week post-operation. MB indicates 
mandibular bone, IS indicates the implant socket and GT the granulation tissue.
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Figure 6.6; Alizarin red stained sections obtained from rat mandibles with machined (d) grit 
blasted/acid etched (e) and TCP coated (f) implants three weeks post-operation. MB indicates 
mandibular bone, IS indicates the implant socket and GT the granulation tissue. Areas o f  positive 
staining are indicated by arrows.
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Figure 6.7: Alizarin red stained sections obtained from rat mandibles with machined (a) grit 
blasted/acid etched (b) and TCP (c) coated implants nine weeks post-operation. MB indicates 
mandibular bone and IS indicates the implant socket. Areas o f  positive staining are indicated by 
arrows.
100um
MB
F igure 6.8; Alizarin red stained sections obtained from rat mandibles with machined (d) grit 
blasted/acid etched (e) and TCP coated (f) implants twelve weeks post-operation. MB indicates 
mandibular bone and IS indicates the implant socket. Areas o f  positive staining are indicated by 
arrows.
6.3.3 Immimolocalisation of Stro-1
Stro-1 positive cells were not found around any implant sites at any time 
point. Images resulting from the immunolocalisation of Stro-1 around the implant 
site of all three experimental implants at one week post operation are shown in 
Figure 6.9. Images from three, nine, and twelve weeks are not shown.
i
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F igure 6 .9 : Im m unolocalisation o f  Stro-1 in sections obtained from rat m andibles with
m achined (a )  grit blasted/acid etched (b) and TC P (c) coated implants one week post-operation. 
IS indicates the im plant socket.
6.3.4 Immunolocalisation of PCNA
Images resulting from the immunolocalisation of proliferating cell nuclear 
antigen (PCNA) are shown in Figures 6.10-6.11. Positive staining for PCNA is 
indicated by brown cellular staining. The temporal expression pattern of PCNA was 
the same around the three surface treated implant sites, with positive cells only seen 
at one week post-operation (Figure 6.10). The levels of PCNA expression were not 
found to be significantly different around the three implant sites at this time point. 
Figure 6.11 shows no positive staining around any of the three implant sites at three 
weeks post-operation. There was no staining around any implant sites at either nine 
or twelve weeks post-operation and the images are not shown. Figure 6.12 shows a 
graph of the average number of PCNA positive cells per 100pm2 in tissue sections 
around all implant sites over the four time points. The graph represents the average 
number of positive cells per 100pm around the implant sites of two animals per 
surface treatment per time point. P values shown in a table indicate that there is no 
significant difference in the level of expression around any of the experimental 
implant sites at one week post operation. As there was no positive staining at three, 
nine or twelve weeks post-operation no statistical tests were performed for these time 
points.
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F igure 6.10: Immunolocalisation o f  PCNA in sections obtained from rat m andibles w ith
machined (a) grit blasted/acid etched (b) and TCP (c) coated implants one week post-operation. 
IS indicates the implant socket. Examples o f  positive cells are indicated by arrows.
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F igure 6.11: Immunolocalisation o f  PCNA in sections obtained from rat m andibles with 
machined (d) grit blasted/acid etched (e) and TCP coated (f) implants three weeks post­
operation. IS indicates the implant socket.
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Figure 6.12: G raph o f  the average num ber o f  PCNA positive cells per lOOpm2 in five random  
fields o f  view over one, three, nine and 12 weeks post-operation. P values resulting from a 
Kruskal-W allis test are given in  a table.
6.3.5 Immunolocalisation of Osteopontin
Images obtained from the immunolocalisation of osteopontin are shown in 
Figures 6.13-6.14. Osteopontin expression is indicated by brown cellular staining. 
The temporal expression pattern of OP was the same around the three surface treated 
implant sites, with positive cells only seen at three weeks post-operation (Figure 
6.13). The levels of OP expression were not found to be significantly different 
around the three implant sites at this time point. At nine weeks post-operation, no 
staining is seen around any of the experimental implants (Figure 6.14). No staining 
was seen around any implant site at one or twelve weeks post-operation and images 
are not shown. Figure 6.15 shows a graph of the average number of osteopontin 
positive cells per 100pm in tissue sections from all implant sites over the four time
  9
points. The graph represents the average number of positive cells per 100pm around 
the implant sites of two animals per surface treatment per time point. P values shown 
in a table indicate that there is no significant difference in the level of expression 
around any of the experimental implant sites at three weeks post operation. As there 
was no positive staining at one, nine or twelve weeks post-operation' no statistical 
tests were performed for these time points.
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Figure 6.13: Im munolocalisation o f  OP in sections obtained from rat mandibles with m achined 
(a) grit blasted/acid etched (b) and TCP (c) coated implants three weeks post-operation. IS 
indicates the implant socket. Exam ples o f  positive cells are indicated by arrows.
ri ' f  100um  IS
Figure 6.14; Immunolocalisation o f  OP in sections obtained from rat mandibles with m achined 
(d) grit blasted/acid etched (e) and TCP coated (f) implants nine weeks post-operation. MB 
indicates m andibular bone and IS indicates the implant socket.
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Figure 6.15: G raph o f  the average num ber o f  OP positive cells per lOOpm2 in five random  fields 
o f  view over one, three, nine and tw elve w eeks post operation. P values resulting from  a 
K ruskal-W allis test are given in a table.
6.3.6 Immunolocalisation of Osteocalcin
Images obtained from the immunolocalisation of osteocalcin are shown in 
Figures 6.16-6.18. Cells positive for osteocalcin are stained brown. The temporal 
expression pattern of OC was similar around the three surface treated implant sites 
with positive cells seen primarily at nine and twelve weeks post-operation (Figures 
6.17-6.18), while staining was minimal at three weeks post-operation (Figure 6.16). 
The levels o f  OC expression were not found to be significantly different around the 
three implant sites at any time point. No staining was seen at one week post­
operation around any of the implant sites and the images are not shown. Figure 6.19 
shows a graph of the average number of osteocalcin positive cells per 100pm2 in 
tissue sections from all implant sites over the four time points. The graph represents 
the average number of positive cells per 100pm2 around the implant sites of two 
animals per surface treatment per time point. P values shown in tables indicate that 
there is no significant difference in the level of expression around any of the 
experimental implant sites at three, nine or twelve weeks post operation. As there 
was no positive staining at one week post-operation no statistical tests were 
performed for this time point.
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Figure 6.16; Immunolocalisation o f  OC in sections obtained from rat m andibles with m achined 
(a) grit blasted/acid etched (b) and TCP (c) coated implants three w eeks post-operation. IS 
indicates the implant socket.
IS
100um
100um  ^
Figure 6.17: Im m unolocalisation o f  OC in sections obtained from rat m andibles with m achined 
(d) grit blasted/acid etched (e) and TCP coated (f) implants nine w eeks post-operation. IS 
indicates the im plant socket. Exam ples o f  positive cells are indicated by arrows. Inset into all 
images are m agnified areas o f  the images.
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Figure 6.18: Im m unolocalisation o f  OC in sections obtained from rat m andibles w ith m achined 
(a) grit blasted/acid etched (b) and TC P (c) coated im plants tw elve w eeks post-operation. IS 
indicates the im plant socket. Exam ples o f  positive cells are indicated by arrows. Inset into all 
images are m agnified areas o f  the im ages.
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Figure 6.19: G raph o f  the average num ber o f  OC positive cells per 100 pm 2 in five random  fields 
o f  view over one, three, nine and tw elve w eeks post operation. P values resulting from  a 
Kruskal-W allis test are given in a table.
6.3.7 Negative Controls
Typical examples of both non-immunogenic IgG and primary excluded 
negative controls for all immunolocalisations performed are shown in Figure 6.20. 
Both of these negative controls were performed for all tissue sections at all time 
points and none showed any positive staining.
*1
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Figure 6.20: T ypical exam ples o f  negative controls w hich had the prim ary antibody excluded 
(left) and a negative  control in w hich a non-im m unogenic IgG antibody (non-im m unogenic IgM  
in the case o f  S tro -1 ) w as used in place o f  the prim ary IgG antibody (or IgM for S tro-1) (right). 
T hese con tro ls  w ere  perform ed for every tim e point and im plant group and did not dem onstrate 
any positive sta in ing .
6.4 Discussion
The use of the in vivo model of the osseointegration of modified titanium 
dental implants described in this chapter has allowed the experimental surface 
treatments to be tested in conditions which consider all aspects of the complex 
process o f  bone formation. Interestingly, it appears from the results presented that 
there were no temporal differences in the amount of bone healing which took place 
around the sites of implants with different experimental surface treatments. 
Furthermore, both cell proliferation and osteoblast markers showed the same 
temporal pattern of expression around implant sites across all three of the 
experimental groups. Therefore, it appears that none of the experimental surface 
i  treatments had an advantage in promoting the formation of bone in apposition to 
implants in vivo.
From the H&E results presented in this chapter, it is apparent that bone 
healing occurred at approximately the same rate over time around the implant sites of 
the machined, grit blasted/acid etched and TCP coated implants. Further, the rate of 
bone formation was similar to that of the normal animals in Chapter 5. Bone 
formation also appeared to follow the same pattern over time around all of the 
experimental implant sites; no differences in the amount of distance or contact 
osteogenesis were observed. Alizarin red staining showed that mineralisation of the 
newly formed bone occurred at approximately the same rate around all of the 
experimental implant sites over time. The rate of bone formation therefore appeared 
to be neither substantially enhanced nor impaired around any of the experimental 
implant surfaces, indicating that surface modification had no effect on the rate of 
osseointegration in this model.
It must be noted that the histological results from around the TCP coated 
implants at 12 weeks post-operation are likely to be anomalous, as healing appeared 
to have progressed normally in all animals with TCP coated implants at three and 
nine weeks post-operation. It is possible that this is the result of an infection around 
the implant site in these animals, as a large amount of un-mineralised connective
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tissue is evident around the implant sites, indicative of fibrous encapsulation. Both 
animals with TCP coated implants at this time point were affected.
In the literature, accounts differ as to the impact of modifying titanium 
surfaces on the osseointegration of titanium implants. It has been reported that 
implant surfaces roughened by acid etching results in a greater the amount of bone 
formation J n  apposition to implant surfaces in canine mandibles (Cochran et al. 
1998). Acid etching of implants has also been shown to increase the removal torque 
values of implants placed into rabbit tibiae (Cho and Park 2003), as has the oxidation 
of implant surfaces (Sul et al. 2005). Franchi and colleagues have reported that grit 
blasting with zinc particles results in more rapid peri-implant bone formation in 
sheep tibiae (2007). Likewise, blasting with alumni grit has been shown to enhance 
bone implant contact in rabbit tibiae (Wennerberg et al. 1998). Conversely, it has 
also been reported that modifying titanium implants in terms of their topography and 
surface chemistry does not dramatically influence the process of osseointegration in 
vivo. Grit blasting surfaces has been reported to have no effect on the rate of bone 
formation in apposition to implants in either mini-pig (Bemd et al. 2008) or canine 
(Kawahara et al. 2006) mandibles. Based on the evidence in the literature, it seems 
clear that surface treatments rarely have an adverse affect on osseointegration as it is 
frequently noted that all surfaces are successfully osseointegrated. It is the speed at 
which bone is formed in apposition to implants which directly determines an 
improved surface. It is a possibility that some surface modifications may result in 
more rapid bone healing around implant surfaces, given the large range of 
modifications (Bagno and Di Bello 2004). In terms of the results presented here 
however, no such increase in the rate of bone healing was seen around any of the 
experimental implant surfaces.
The quality and strength of bone produced in apposition to the implant 
surfaces was assessed via implant removal torque in Japan at both three and nine 
weeks post-operation. These results were used in a student thesis in Japan and are 
therefore only described in the discussion herein. From this data, it appears that 
removal torque values were similar between the machined and grit blasted/acid 
etched implants but much higher for TCP coated implants at both time points. It is a
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possibility is that the TCP coating, being more porous than titanium, allowed 
collagen fibres present in the soft tissue to crosslink with pores present on the surface 
of the coating, leading to increased removal torque values. It is difficult to interpret 
these findings due to the histological similarities in the progression of bone 
formation around the sites of implants with the experimental surfaces. Further studies 
into the mechanical properties of the bone formed around each of the experimental 
surfaces over time would possibly help to clarify this issue.
Expression of PCNA, OP and OC followed the same temporal pattern around 
the sites of all of the experimental implants and the level of their expression did not 
vary significantly between the experimental groups. This suggests that the surface 
modifications investigated in this thesis had no influence on the activity or 
proliferation of cells around implant sites in vivo. Stro-1 was not expressed around 
any of the experimental surfaces at one week post-operation, which suggests that 
surface modification did not affect the recruitment of osteoblast progenitor cells to 
the implant site. The one week post-operative time point may have been outside the 
window of Stro-1 expression, which is known to be brief and to occur very early in 
osteoblast differentiation (Simmons and Torok-Storb 1991). The similar temporal 
expression of these markers reflects the fact that the experimental surface 
modifications did not appear to alter the rate of bone healing, as it is certain that any 
such alterations would be reflected in the pattern of their expression.
It has been reported previously in this thesis that the experimental surface 
treatments, despite generating a surface with unique characteristics, did not have a 
great deal of influence on the behaviour of BMSCs in vitro, although the protein 
expression profile of cells cultured on the TCP coated surface was altered. It was 
therefore possible that this experimental surface would influence the process of 
osseointegration in vivo. The results presented in this chapter however suggest that 
the experimental surfaces treatments did not increase the rate of bone formation in 
apposition to implant surfaces. Neither did they alter the proliferative activity of cells 
surrounding the implant site or the differentiation of adjacent osteoblasts, both key 
indicators of osseointegration. Broadly speaking, the aim of any surface modification 
is to increase the speed at which bone is formed apposition to an implant surface, not
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only reducing the chances of infection and peri-implantitis, but also the amount of 
clinical time required for treatment. Based on the in vivo results presented here 
however, it does not appear that any of the experimental surfaces treatments is more 
advantageous than an y  other from this standpoint. This chapter generally confirms 
the results of the previously described in vitro experiments using a more complex 
model of the process o f  bone healing around titanium dental implants.
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Chapter 7: General Discussion
This thesis set out to identify ways in which the modification of titanium 
surfaces influences the osseointegration of titanium dental implants. To this end, 
three commercially available treatments were applied to titanium surfaces. These 
surfaces were then characterised and their effects on the process of osseointegration 
investigated using both an in vitro and in vivo model systems. The use of an in vitro 
model allowed cell morphology, attachment, and the mRNA and protein expression 
profiles of osteoblasts cultured on the experimental surfaces to be examined in 
isolation, while the in vivo model allowed the process of bone formation and cell 
activity around titanium implants implanted into mandibular bone containing a 
variety of tissue type to be assessed. Additionally, the in vivo model was used to 
model the process of implant osseointegration in type II DM, a common clinical 
condition with direct implications for treatment with dental implants. A better 
understanding of the effects of type II DM on the osseointegration of dental implants 
may suggest ways in which surfaces could be modified to negate the effects of the 
disease and thereby secure a better clinical outcome for diabetic individuals.
The systematic characterisation of the experimental surfaces was central to 
the goal of investigating the ways in which surface modifications influence the 
process of osseointegration. Variations in the topography, surface chemistry and 
hydrophobicity are all generally thought to be highly influential on both osteoblast 
activity and on the formation of bone in apposition to implant surfaces (Le 
Guehennec et al. 2007; Zhao et al. 2005). Machining, grit blasting/acid etching and 
TCP coating were each shown to produce different topographies, with TCP coating 
producing the roughest surface of the three modifications, followed by grit 
blasting/acid etching and finally by machining. The experimental surface 
modifications each produced a distinct surface with respect to topography and 
elemental content. In contrast, hydrophobicity values were similar for all surfaces 
and showed that all surfaces were slightly hydrophilic.
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Culturing rat bone marrow stromal cells on the experimental surfaces 
modelled effects of surface modifications directly on osteoblast activity. Some 
differences were observed in the morphology of cells adherent to the different 
experimental surfaces, with the machined surface having cells with a rounded 
morphology and cells on the grit blasted/acid etched and TCP coated surface having 
a more elongated one. Additionally, cells seemed to attach preferentially to the 
smoother machined surface than the other two rougher experimental titanium 
surfaces or even plastic controls. This was in agreement with the convention that 
smoother surfaces promote cell attachment and proliferation (Bachle and Kohal 
* 2004; Kieswetter et al. 1996a; Kim et al. 2006; Le Guehennec et al. 2007; Mustafa et
al. 2001). Interestingly, the patterns of matrix deposition were seen to be different 
across the three experimental surfaces, with cells on the machined surface producing 
matrix in a thin sheet rather than the thick depositions seen to fill the ‘valleys’ 
generated by roughening on the grit blasted/acid etched and TCP coated surfaces. 
Such variations in the matrix deposition raised the possibility that roughened surface 
topographies may achieve due higher levels of mechanical interlocking between 
implant surfaces and surrounding bone and may therefore osseointegrate more 
securely.
Despite differences in cell morphology and the visual appearance of matrix 
deposition, there was a high degree of similarity in the mRNA expression profiles of 
cells cultured on the different experimental surfaces. This indicated that cellular 
activity was broadly the same across all of the modified surfaces and that surface 
modification did not greatly influence the expression of osteoblast cell marker 
mRNA. Adherent cells appeared to behave as osteoblasts independently of the 
surface they were cultured on. This is in contrast with much of the literature which 
reports that surface modification can influence the expression of osteoblast marker 
mRNA using both RT-PCR (Balloni et al. 2009; Marinucci et al. 2006; Qu et al. 
2007; Tsukimura et al. 2008) and quantitative PCR (Masaki et al. 2005; Schneider et 
al. 2003). One novel finding from this model was the apparently suppressive effect of 
titanium on the expression of ppary compared to plastic, suggestive of an osteogenic
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property of titanium as a material. This suppressive effect did not appear to be 
influenced by the titanium surface characteristics however.
It is a possibility that the observed similarities in cell behaviour are due to the 
nature of the model system used. Cells were cultured under mineralising conditions, 
which would have served to drive them down the osteoblast lineage. Therefore, it 
may be that the observed similarity in cellular mRNA expression across the different 
experimental surfaces is unsurprising. Despite this possibility however, cells were 
influenced by the culture conditions in the same way across all the surfaces, which 
could equally indicate that surface characteristics had less influence on cellular 
differentiation than did the osteogenic culture media.
Overall, the mRNA expression of inflammatory cytokines and the growth 
factor TGFpl appeared to be broadly similar, with the exception of a decrease in the 
expression of TNFa mRNA in cells cultured on the TCP coated surface. Similarly 
cells cultured on all surfaces consistently expressed OPG mRNA, but did not express 
RANKL, suggesting a net suppression of osteoclast activity. Additionally, all of the 
titanium surfaces appeared to have a suppressive effect on the production of IL-lp 
compared to plastic surfaces. Although this possible anti-inflammatory property of 
titanium confirms its utility as a material to use in dental implants, it did not appear 
to be affected by surface modification. Neither IL-lp nor TNFa were shown to be 
released into the supernatants of cultures from any surfaces, although this may be 
due to the fact that the proteins were stored internally as pro-peptides awaiting the 
appropriate stimulus for release. Further studies using this model to investigate 
differences in release of these cytokines from cells cultured on modified surfaces 
after stimulation with LPS or other pro-inflammatory agents would perhaps serve to 
clarify this issue.
The composition of the protein matrix produced by adherent cells was shown 
to be different on the TCP coated surface. It was found to consist of BSP but not ON 
or OP, despite cultured BMSCs expressing mRNA for these markers. It is difficult to 
determine if this is relevant to the structural properties of the matrix produce from 
the use of an in vitro model alone, although it is clear evidence of surface
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modification affecting the secretion of matrix proteins. There may have been 
variations in the expression of other bone matrix proteins, and further investigation 
of those proteins actually produced and secreted by cells may have been revealing, as 
opposed to investigating their expression at the level of mRNA.
The in vitro model showed that bone marrow stromal cells cultured on 
modified titanium surfaces under mineralising conditions behave in a similar manner 
in terms of their expression of mRNA for osteoblast markers, osteogenic factors and 
inflammatory cytokines despite some differences in initial adhesion, morphology, the 
pattern of matrix deposition and the composition of the matrix deposited. The results 
* presented in this thesis seem to suggest therefore, that the basis for modifying 
surfaces, improved rates of osseointegration, may be strongly related to an improved 
the level of mechanical interlocking by variable topography lending itself to 
increased implant-matrix contact, as opposed to modified surfaces directly 
influencing the behaviour of individual osteoblasts and accelerating the rate at which 
bone is deposited. While the data presented suggests that there may be some value in 
micro-roughening titanium surfaces, in terms of improving mechanical interlocking, 
there was no strong indication that any of the modifications provided a surface which 
was optimal for osseointegration. While the observed improvement in mechanical 
interlocking was most likely the direct result of a roughened topography, it is 
difficult to separate the influence of surface topography from that of surface 
chemistry, which may also have played a role. In terms of implant design and 
manufacture, it may be the case that many commercially available surface 
modifications do not substantially enhance osteogenic activity by osteoblasts and 
therefore do not appreciably improve the process of osseointegration.
In order to model the complex nature of osseointegration of titanium dental 
implants into bone tissue, an in vivo model was used. In this way, the limitations of 
considering the effects of surface modification on osteoblasts as isolated cells were 
overcome by inserting surface modified implants into bone tissue containing a 
variety of cell types, an immune response, a blood supply and a healing response. 
Interestingly, no differences in either the rate of bone healing or in the expression of 
cell proliferative or osteoblast specific markers were observed around the sites of any
164
of the modified implants, indicating that surface modification has no effect on the 
rate of bone formation in apposition to implants. This seems to confirm the general 
conclusions from the in vitro model. It follows that osteoblasts displaying similar 
cellular behaviour across the modified surfaces would, by extension, indicate that the 
in vivo progression of bone formation around those surfaces would be similar. The 
literature is somewhat conflicting in terms of the impact of surface modification on 
in vivo model of osseointegration, with reports that it both improves (Cho and Park 
2003; Cochran et al. 1998; Sul et al. 2005) and does not affect it (Bemd et al. 2008; 
Kawahara et al. 2006). It must be noted that all surfaces did appear to undergo 
successful osseointegration; the speed at which this was accomplished however 
seemed to be independent of the differences in both surface chemistry and 
topography between the experimental surfaces.
The data generated by both model systems, coupled with the astronomically 
high clinical success rates of routine dental implant treatment, suggest that current 
attempts to develop implant surfaces with higher osseointegrative potentials for 
routine clinical use through surface roughening and calcium phosphate coating may 
be largely irrelevant. Research time and resources invested in this area may be better 
employed elsewhere, for instance investigating implant modifications for use in 
difficult clinical situations, where patients are not ideal candidates for treatment. For 
example, it has recently been reported that using surgical techniques which increase 
the amount of bone fragments around the implant site may be beneficial, as these 
fragment may stimulate implant osseointegration (Tabassum et al. 2010). Implants 
with roughened surfaces may similarly serve to increase the number of bone upon 
implant placement, possibly increasing the rate of osseointegration, particularly in 
individuals with a compromised bone healing response (Tabassum et al. 2009). 
Biomimetic coatings containing growth factors such as BMPs, TGFp, and VEGF or 
other osteogenic agents could be tailed to specifically improve aspects of various 
conditions which impair osseointegration such as DM and osteoporosis (Ellingsen et 
al. 2006; Le Guehennec et al. 2007; Liu et al. 2007a; Valero et al. 2007). Such 
advances would not only serve to improve the current understanding of the 
mechanisms by which these diseases affect bone tissue, but would also increase the 
access to treatment with implants to patients for whom it is currently contraindicated.
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It is often this group from which the greatest clinical need arises, yet it is often not 
possible for them to receive treatment which would significantly enhance their 
quality of life.
To this end, the in vivo model allowed implant osseointegration to be studied 
in the context of a clinically relevant disease state, type II DM. Within this thesis, it 
was found that there was a substantial delay in the rate of bone healing around 
implants in diabetic animals, and that this delay was underpinned by a variety of 
alterations in the activity of cells present around the implant site, and the use of this 
model allowed these to be identified. Foremost among these possible mechanisms 
was a general delay in differentiation of osteoblasts around the diabetic implant site, 
but interestingly, not in the appearance of Stro-1 positive mesenchymal progenitor 
cells, suggesting that migration of these cells to the implant site was unaffected by 
type II DM. The delay in TGFpl expression around the diabetic implant site 
indicates a delay in the initiation of osteoblast differentiation, as this growth factor is 
known to be a key mediator of this process, particularly its early phases (Centrella et 
al. 1994; Janssens et al. 2005). The delayed expression of IL-lp expression in 
diabetic animals has implications which are less clear. Although it is an 
inflammatory mediator and is known to inhibit the formation of bone and increase 
bone resorption (Nguyen et al. 1991), it has been suggested that IL-lp may also have 
an initial stimulatory effect on osteoblast progenitor cell proliferation and 
differentiation (Canalis 1986; Hughes et al. 2006), and the observed delay in 
diabetics may play a role in delaying the process of osteoblast differentiation. 
Diabetic animals also showed a possibly sustained inflammatory response around 
their implant sites, as evidenced by elevated TNFa expression and the prolonged 
presence of macrophages. Delays in diabetic bone healing are well documented in 
the literature (Hasegawa et &1. 2008; Liu et al. 2007b; McCracken et al. 2006; Shyng 
et al. 2006; Siqueira et al. 2003), and the results presented in this thesis add to this 
understanding by describing the underlying cellular events associated with this 
delayed healing.
This in vivo model may prove to be useful in further investigating surface 
modifications which would be useful in treating individuals with a compromised
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bone healing response. Herein, it has been used to elucidate possible cellular 
mechanisms involved in effects of DM on bone repair and could easily be used to 
investigate the utility of surface modifications for reversing this delay in bone 
healing. Due to the range of parameters which can be examined in the model using 
immunohistochemistry, surface modifications could target specific cellular 
mechanisms disrupted in the disease state. For example, implants with TGFpl 
impregnated coatings may help to compensate for the delayed expression of this 
growth factor in DM, reducing the delay in bone formation. The experimental 
surface modifications presented in this thesis could also be investigated in the model; 
while they did not appear to have any beneficial effects under normal conditions, it is 
a possibility that they may improve osseointegration in DM. Furthermore, very little 
is currently known about the characteristics of diabetic osteoblasts. Diabetic Bone 
marrow stromal cells could be extracted from the diabetic rats used in this model for 
study in vitro, allowing the basic biology of the diabetic osteoblast to be investigated, 
specifically regarding their responsiveness to a variety of osteogenic growth factors 
and inflammatory cytokines, or their behaviour under mineralising conditions. This 
model is also amenable to the investigation of other conditions which impair bone 
healing, and has been used to study the osseointegration of implants in 
ovariectomized osteoporotic rats (Kusunoki et al. 2006). It could therefore be used to 
investigate a wide range of implant modifications in a variety of adverse clinical 
conditions, with the aim of negating specific aspects of their pathologies.
Over the course of this thesis the osseointegrative potential of three modified 
titanium surfaces has been compared using both in vitro and in vivo model systems. 
Overall, it appears that surface modifications investigated had little impact on the 
differentiation and activity of osteoblasts or on the rate of bone formation around 
titanium implants, apart" from possibly improved bone-implant mechanical 
interlocking for the rougher surfaces. It is therefore difficult to identify one of the 
experimental surfaces as having a higher osseointegrative potential. The nearly 
infinite range of implant modifications available however, means that it is entirely 
possible that surfaces with different modifications may have performed differently in 
the models used here. This diversity is cited as one of the key difficulties in defining 
surface characteristics which are optimal for osseointegration (Bagno and Di Bello
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2004). From a clinical perspective, the central tenet of the surface modification of 
titanium dental implant surfaces is that they should improve patient outcomes. The 
current clinical value derived from the modification of titanium dental implant in 
routine cases is unclear, as dental implant treatment seems to have an impressively 
high success rate regardless of the surface modification. A systematic review of 
sixteen clinical trials found little evidence to indicate that surface modification 
improved patient outcome (Esposito et al. 2007). It may be the case, from the 
standpoint of implant design, that surface modifications do not necessarily lead to 
more rapid osseointegration; rather the rate of osseointegration in the clinical may 
depend on factors directly relating to the patient, for example the individual bone 
f  healing response and the management of inflammation. Expensive surface treatments 
carried out to enhance the rate of osseointegration may therefore be of limited value 
for patients who are good candidates for treatment. The future of surface 
modification of dental implants may lie with attempting to improve treatment success 
rates in non-routine more difficult clinical cases, for example individuals who have 
systemic diseases which affect the process of osseointegration.
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